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Acute leukemia is associated with a wide spectrum of gross chromosomal 
rearrangements.  These acquired mutations include balanced and unbalanced 
chromosomal translocations. The analysis of chromosomal translocations has 
provided much insight into understanding the biology of hematologic malignancies, 
leading to improved diagnosis and classification, as well as identification of novel 
therapeutic targets. The rare but recurring chromosomal translocation 
[t(10;11)(p13;q21)] results in a CALM-AF10 fusion that occurs in patients with both 
acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).   CALM-
AF10 transgenic mice developed AML with lymphoid features and had Hoxa gene 
cluster upregulation.   In this model, mice developed leukemia after a long latency 
period with incomplete penetrance.   These findings suggest that additional genetic 
  
events are needed to complement CALM-AF10 mediated leukemic transformation.  
Retroviral insertional mutagenesis was used to identify complementary genetic events 
that might collaborate with CALM-AF10 during leukemic transformation.  A cohort 
of CALM-AF10 mice was infected with the Mol4070LTR retrovirus; by 5.5 months 
of age, 50% of the transgenic mice developed AML, a clear acceleration of disease 
onset compared to either wild type littermates injected with the retrovirus or CALM-
AF10 mice not injected with the retrovirus.  The tumors assayed by Southern blotting 
for viral integration showed clonal to oligoclonal expansion.  Ligation-mediated PCR 
and sequence analysis of DNA derived from leukemic cells was used to identify 
potential collaborating genes at the retroviral insertion sites including Evi1, Nf1, kRas, 
Zeb2, and Mnl.  Identification of these genes as a potential collaborating gene with 
CALM-AF10 supports the  emerging paradigm in leukemia biology that predicts that 
most, if not all leukemic cells must undergo at least two collaborative events to 
produce a fully transformed cell.  One of these events typically leads to impaired 
differentiation and enhanced renewal of stem cells, whereas the second event leads to 
increased proliferation and/or decreased apoptosis.  It has been shown here that 
retroviral infection accelerates the onset of acute leukemia, and identified genes that 
potentially collaborate with the CALM-AF10 fusion gene in the leukemic 
transformation process.  This transgenic murine model serves as a model system for 
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Saint Augustine once wrote “Men go forth to wonder at the heights of mountains, the 
huge waves of the sea, the broad flow of the rivers, the vast compass of the ocean, the 
courses of the stars; and they pass by themselves without wondering”.  As I reflect 
upon my medical education, I am deeply honored and humbled by the opportunity to 
observe the intricacies of the human body each day.  These observations occurred on 
many levels and presented their own challenges.  Yet, through it all, each challenge 
brought reward.  Many times it was difficult to appreciate the benefit, and the path to 
discovery was often clouded by fear and unrealistic expectations.  However, there 
was a constant source of inner strength that continuously fueled the call of purpose, 
perseverance, and service.  These elements take their roots beginning with values 
instilled into me as a child.  They were further enforced through my formal education 
at Virginia Tech that echoed the motto “Ut prosium”.  Finally, they were called into 
practice by the Benedictine brothers at Conception Monastery who challenged my 
imagination, independent will, purpose, and daily contemplation.  I am forever 
indebted to those individuals who remained behind the walls of Conception.  They 
faithfully watched as I chose secular over monastic life; sought purpose in a different 
direction; and continued to serve humanity.  I am forever committed to public service 
and discerning my purpose in this life.  The pages that follow reflect the work of 















by William Ernest Henley; 1849-1903 
 
Out of the night that covers me, 
Black as the Pit from pole to pole, 
I thank whatever gods may be 
For my unconquerable soul. 
 
In the fell clutch of circumstance 
I have not winced nor cried aloud. 
Under the bludgeonings of chance 
My head is bloody, but unbowed. 
 
Beyond this place of wrath and tears 
Looms but the horror of the shade, 
And yet the menace of the years 
Finds, and shall find me, unafraid. 
 
It matters not how strait the gate, 
How charged with punishments the scroll, 
I am the master of my fate; 
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Cancer is a disease of the genome that results, in large part, from mutations in proto-
oncogenes or tumor suppressor genes that yield a dominant gain or recessive loss of 
function respectively (Hanahan and Weinberg 2000).   Although the incidence of 
cancer appears to be decreasing in the US population, it still accounted for 26% of all 
deaths compared to 18% of deaths related to cardiovascular disease in patients less 
than 65 years of age in 2005 (Ries, Melbert D et al. 2008). The most frequent tumors 
that occur in men involve the prostate, lung, colon/rectum; in woman, the most 
common tumors include breast, lung and colon/rectum.  Cancers involving these body 
systems make up about 50% of all cancer diagnoses compared to 3% of leukemic 
diagnoses.   However, leukemias make up a much larger percentage of cancers in 
children, and as a group, are the most common malignancy resulting in dramatic loss 
of productive life years (Ries, Melbert D et al. 2008). Leukemias are seen in both 
pediatric and adult patients; of the childhood cancers, acute leukemias are the most 
common malignancies with a median age at diagnosis being 13 for ALL and the 
median age at diagnosis being 67 for AML (Ries, Melbert D et al. 2008).  According 
to the NCI Surveillance Epidemiology and End Results (SEER), the age-adjusted 
death rate for leukemia in 2004 was 7.2 per 100,000 per year for men and women. In 
2004 there were 21, 472 deaths associated with leukemia in the United States; this is 
in contrast to 553,800 total deaths due to cancer; 40,954 in women  with breast 
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cancer; 29,002 case in men with cancer that involved prostate; and 158,000 cases of 
lung cancer (Ries, Melbert D et al. 2008). 
Clinical and molecular basis of leukemia 
The hematopoietic system is the source of erythrocytes, leukocytes, and platelets that 
function in oxygen exchange, immune surveillance, and coagulation respectively.  
This system is reviewed in Figure 1.1.  Leukemia refers to a disease characterized by 
a predominance of immature hematopoietic or lymphoid precursor cells (acute 
leukemia) or an expansion of mature marrow elements (chronic leukemia) (Niemeyer 
and Sallen 1998).  Historically, leukemia and lymphoma have been classified using 
the French-American-British system which defined tumors based on their 
morphology (Harris, Jaffe et al. 2001; Gilliland and Tallman 2002).  This included the 
following four categories:  acute lymphocytic leukemia (ALL), chronic lymphocytic 
leukemia (CLL), acute myelogenous leukemia (AML), or chronic myelogenous 
leukemia (CML).  The more recent WHO classification scheme stratifies 
hematopoietic neoplasms according to lineage, but also extends the classification to 
incorporate immunophenotype, genetic features, and clinical syndromes (Harris, Jaffe 
et al. 2001).  Signs and symptoms associated with acute leukemia are attributed to 
leukemic infiltration into either bone marrow or parenchymal organs (Lowenberg, 
Downing et al. 1999).  Symptoms related to bone marrow infiltration lead to bone 
marrow failure and are reflected by lethargy and listlessness due to anemia, bleeding 
disorders due to thrombocytopenia, and secondary infections because of leukopenias 
(Figure 1.2).  The clinical presentation seen with organ infiltration varies with the 
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type of organ involved and the degree of infiltration. If left untreated, acute leukemia 




Figure 1.1. Hematopoietic and progenitor cell lineages. HSCs can be divided into 
LT-HSCs, highly self-renewing cells that reconstitute an animal for its entire life 
span, or ST-HSCs, which reconstitute the animal for a limited period. ST-HSCs 
differentiate into MPPs, which do not or briefly self-renew, and have the ability to 
differentiate into oligolineage-restricted progenitors that ultimately give rise to 
differentiated progeny through functionally irreversible maturation steps. The CLPs 
give rise to T lymphocytes, B lymphocytes, and natural killer (NK) cells. The CMPs 
give rise to GMPs, which then differentiate into monocytes/macrophages and 
granulocytes, and to megakaryotic/erythroid progenitors (MEP), which produce 
megakaryocytes/platelets and erythrocytes. Both CMPs and CLPs can give rise to 
dendritic cells. All of these stem and progenitor populations are separable as pure 
populations by using cell surface markers. ((Passegue, Jamieson et al. 2003) Used 











Figure 1.2.  Outcome of leukemia   
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Acute leukemia results as a consequence of multiple acquired mutations that 
accumulate in hematopoietic precursor cells.  These mutations can be grouped into 
three general categories:  point mutations, gross chromosomal rearrangements, and 
epigenetic changes (Lin and Aplan 2004).  The analysis of theses altered genetic 
events  has proven to be especially useful in understanding the biology of 
hematopoietic malignancies, leading to improved diagnosis and classification, as well 
as identification of novel targets for therapy (Rowley 1999).   
 
Acquired point mutations in genes that encode hematopoietic transcription factors 
play a significant role in leukemogenesis.  First, gain of function point mutations have 
been identified in several genes that resulted in acute leukemia.  For example, internal 
tandem duplications or missense point mutations have been observed in patients in 
the FMS-like tyrosine kinase (FLT3) gene (Renneville, 2008).  Mutations in FLT3 
confer a proliferative advantage to myeloid blasts cells through constitutive 
phosphorylation of FLT3-ligand and downstream activation of PI3/AKT, Ras/MAPK, 
and JAK/STAT pathways (Rannevile, 2008).  Secondly, point mutations that involve 
the proto-oncogene KIT have been observed in less than two per cent of AML 
patients (Bacher, Kern et al. 2005), KIT, a tyrosine kinase, binds to Stem Cell Factor 
(SCF) and results in the activation of several downstream pathways including 
proliferation.  Mutations in either exon 8 that involves the extracellular receptor 
domain or codon 816 of the catalytic domain activation loop are seen in AML 
patients with t(8;21) or inv(16)/t(16;16) (Frohling, Scholl et al. 2005).  Detection of 
KIT mutations offer a prognostic indicator in patients and help guide therapy.  Third, 
 7 
 
in contrast to patients with either FLT3 or cKIT mutations that lead to activation of a 
transcription factor, point mutations that involve base substitutions, deletions, or 
insertions in GATA1 result in gene inactivation (Wechsler, Greene et al. 2002).  
GATA1 plays a critical role as a transcription factor in erythroid and megakaryocytic 
cell differentiation (Shimizu, Engel et al. 2008).  Point mutation in GATA1 can result 
in an amino-terminus truncated protein that has been observed in Down’s syndrome 
patients with acute megakaryoblastic leukemia (Wechsler, Greene et al. 2002) and 
transient myeloproliferative disorder (TMD) (Greene, Mundschau et al. 2003).  
 
Numerous gross chromosomal rearrangements (GCR) have been observed in 
leukemia biology.  These mutations include balanced and unbalanced chromosomal 
translocations, as well as chromosomal inversions, deletions, and 
amplifications(Rabbitts 1991; Cline 1994; Rabbitts 1994; Thandla and Aplan 1997). 
Of these GCRs, chromosomal translocations (CTs) have been observed in many cases 
of acute and/or chronic leukemia (Solomon, Borrow et al. 1991; Raimondi 1993).  
Research into the molecular pathogenesis  has revealed at least four important  
concepts about these mutations (Lin and Aplan 2004).  First, specific CTs are 
typically associated with a particular leukemic phenotype.  For example, the t(15:17) 
is associated only with promyelocytic leukemia that gives rise to a PML-RARα 
fusion seen in patients with M3 AML.  Secondly, at least two outcomes are associated 
with CTs:  either they produce a novel chimeric protein as in the case of BCR-ABL; 
or they lead to unscheduled expression of proto-oncogenes such as MYC-IGH.  Third, 
CTs often are involved in genes that encode for either transcription factors or proteins 
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associated with signal transduction pathways (Aplan 2006).  Finally, genes affected 
by CTs can also be associated with point mutations.  For example, the t(8;21) which 
produces an AML1-ETO fusion has been associated with point mutations (Rhoades, 
Hetherington et al. 1996). 
 
The pathogenesis of AML is a multistep process.   The current paradigm in leukemic 
biology proposes collaboration between two categories of mutations.  Class I 
mutations lead to enhanced cell proliferation as well as impaired apoptosis.  The 
mutations affect signal transduction or tyrosine kinase pathways and involve genes 
including RAS, cKIT, FLT3, or BCR/ABL.  Class II mutations result in mutant DNA 
binding transcription factors, these include PML/RARα, AML/ETO, and MLL fusions.  
These novel fusions lead to impaired hematological precursor cell differentiation 
(Kelly and Gilliland 2002). 
Techniques for studying collaborative pathways  
Earlier it was discussed that AML results from mutations that affect at least two 
different yet collaborative cellular pathways.  Until recently, potential cancer-causing 
genes and their associated pathways have been difficult to study.  The use of carefully 
designed genetically engineered mice (GEMs) for has provided much insight into the 
molecular biology of hematopoietic malignancy.   One of the major limitations of 
these model systems has been compartmentalization or limited expression of altered 
genetic events.  The observation that certain inbred strains of mice develop 
spontaneous leukemia as a result of retroviral integration, and the cloning of these 
specific  retroviral integrations has led to the discovery of important cancer genes. 
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Numerous high throughput techniques have been used to identify these genes in mice.  
For example, the combined strategy of generating subgenomic lamda libraries and 
Southern blotting with retroviral specific probes identified proviral DNA junctions in 
tumors from mice.  Another system relied upon cloning of proviral insertion sites near 
CpG islands using PCR to identify proviral insertion sites (Largaespada 2000).  More 
recent advances have been developed using a combination of high-throughput PCR-
based cloning techniques coupled with the use of an annotated mouse genome to 
identify cancer genes (Li, Shen et al. 1999; Mikkers, Allen et al. 2002).  High 
throughput application of this technology applied to the “sensitized” GEMs has lead 
to a better understanding of concepts in clonal expansion and multiple gene 
interactions in mouse model systems (Largaespada 2000; Touw and Erkeland 2007) 
 
In terms of clinical relevance, cloning of CTs has led to much insight with regards to 
prognosis and treatment of leukemia.  For example, cloning of the BCR-ABL fusion 
gene highlighted the role of tyrosine kinases in leukemic transformation and led to the 
subsequent development of imatinib, a tyrosine kinase inhibitor (Rowley 2001).  
Furthermore, chromosomal abnormalities are now routinely used to help classify 
leukemia patients for risk-directed therapy (Rubnitz, Behm et al. 1996).  
The t(10; 11) translocation  
The t(10; 11) translocation was first observed in a patient with diffuse histiocytic 
lymphoma (Sundstrom and Nilsson 1976);  the U937 cell line was established from 
this patient and has been used extensively as an in vitro model of monocyte 
differentiation (Harris and Ralph 1985). The presence of a reciprocal translocation 
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between chromosomes 10 and 11, a t(10; 11)(p13-14; q14-21) in the U937 cell line 
was confirmed and subsequently refined by cytogenetic analysis (Kobayashi, 
Thirman et al. 1995; Shipley, Williams et al. 1995).   Using positional cloning 
techniques to narrow the chromosome 10 breakpoint to a 3 cM region, AF10 was 
identified as a candidate gene on chromosome 10 potentially involved in this 
translocation.  Subsequent studies showed that the AF10 gene was indeed disrupted 
by the t(10;11) translocation, and identified CALM as the AF10 fusion partner in this 
recurrent translocation (Dreyling, Martinez-Climent et al. 1996).   
Structure and function of CALM 
CALM (for Clathrin Assembly Lymphoid Myeloid; also known as PICALM) is located 
on chromosome 11q23, ubiquitously expressed, and encodes a 652 aa protein with 
multiple domains involved in endocytosis (Figure 1.3)(Dreyling, Martinez-Climent et 
al. 1996). These domains include  the epsin N-terminal homology (ENTH) domain  
(Asp-Pro-Phe), a DPF (ASP-Pro-Phe) motif, an NPF (Asn-Pro-Phe) motif, and type I 
and type II clathrin-binding sequences (CBS I and II) (Tebar, Bohlander et al. 1999; 
Klebig, Wall et al. 2003; Meyerholz, Hinrichsen et al. 2005).  The predicted CALM 
protein is  similar to the neuronal specific monomeric clathrin assembly protein 
AP180, which was first identified in coated vesicles of bovine brain (Ahle and 
Ungewickell 1986; Takei, Mundigl et al. 1996). CALM homologues have been 
identified in rat, mouse and cow. 
 
Endocytosis is the active cellular process of removing proteins from the plasma 
membrane (Mukherjee, Ghosh et al. 1997).  The active formation of transport vesicles 
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that shuttle cytosolic cargo, such as transmembrane and luminal proteins from the 
plasma membrane and the trans-Golgi network (TGN) to endosomes requires 
participation of clathrin coated pits (Schmid 1997). Clathrin is composed of three 
major proteins; a 192 kDa heavy chain bound to two ~30 kDa light chains that forms 
a structure known as a triskelion (Schmid 1997).  In order for coat proteins to 
function properly in vesicle transport, they link to adaptor proteins (APs) (Robinson 
and Bonifacino 2001).  The role of APs is complex. First, studies suggest that AP-3 
likely functions as a clathrin adaptor protein and aids in signal mediated protein 
sorting events (Dell'Angelica, Klumperman et al. 1998).  Secondly, AP1 and AP2 
function to attach clathrin to the plasma membrane and help form complexes in the 
TGN (Robinson and Bonifacino 2001). AP180 homologues have been observed in 
yeast (Wendland and Emr 1998) and Drosophila (Zhang, Koh et al. 1998) where they 
were identified as participants in clathrin binding and endocytosis respectively. 
Likewise, AP180/CALM homologues identified in C. elegans presumably regulate 
endocyte vesicle size (Zhang, Koh et al. 1998).  Finally, point mutations in the CALM 
gene led to ineffective hematopoiesis, functional iron deficiency, and altered growth 
in mice, suggesting that CALM may play a role in endocytosis-mediated iron 
transport (Klebig, Wall et al. 2003). 
 
In addition to an established role in endocytosis, a recent study suggested that CALM 
may interact with nuclear proteins (Archangelo, Glasner et al. 2006).   In this study, 
the novel protein CATS (CALM interacting protein, expressed in thymus and spleen) 
was shown to interact with a region of the CALM protein that is retained in the 
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CALM-AF10 fusion protein and increased the nuclear localization of both CALM 
and a CALM-AF10 fusion protein.   This study further suggested that CATS may be 
important for malignant transformation mediated by CALM-AF10, through either 
mis-localization of the CALM-AF10 protein, or via transcriptional regulatory 
properties of the CATS protein (Archangelo, Glasner et al. 2006).  
 
A single case report described an MLL-CALM fusion in a 12-week-old Caucasian 
female who presented with rapidly progressive AML (Wechsler, Engstrom et al. 
2003).  In this study, the authors used panhandle PCR to determine that MLL was 
fused to CALM at 11q14-q21. By assaying RNA from the patient’s leukemic cells, 
fusion transcripts were identified. The breakpoints for this particular translocation 
were within MLL intron 7 (in the known MLL breakpoint cluster region) and CALM 
intron 7.  This finding is intriguing since, in this case, CALM sequences are present at 
the 3’ portion of the fusion gene, in contrast to CALM-AF10 fusions, where CALM 
sequences form the 5’ portion of the fusion gene. In addition the breakpoint lay 
within CALM intron 7, whereas the breakpoints for CALM-AF10 fusions typically 
occur within CALM introns 17-19.   
Structure and function of AF10 
The AF10 (also known as MLLT10) gene is located on chromosome 10p12 and 
encodes a 109-kDa protein containing 1,027 aa residues, and was initially cloned as 
an MLL partner gene in the recurrent t(10;11)(p13;q23) translocation (Chaplin, 
Bernard et al. 1995).  It is important to note that the reference sequence for human 
AF10 (NM_004641 or  U13948) is missing 124 nucleotides between exons 22 and 
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23; these 124 nucleotides are present in most human expressed sequence tags (ESTs) 
and a homologous 124 nucleotide sequence is present in the mouse reference 
sequence (NM_010804).   Insertion of these 124 nucleotides leads to a frameshift of 
the COOH terminal portion of the AF10 protein.  Studies in both humans and mice 
have demonstrated that AF10 expression is highest in the testis, and is also expressed 
in the thymus, ovary, colon, peripheral blood, brain, and kidney (Chaplin, Ayton et al. 
1995; Linder, Jones et al. 1998). AF10 is a member of a small highly conserved 
protein family that includes the AF17, BR140, and CEZF proteins (Chaplin, Ayton et 
al. 1995; Linder, Newman et al. 2000).  Although the precise function of AF10 is not 
known, both structural and functional data suggest that it functions as a transcription 
factor (Figure 1.3).  The AF10 protein contains PHD (Plant Homeo Domains) fingers, 
which are structurally conserved domains present in a number of known transcription 
factors that are involved in chromatin-mediated gene regulation, including the CBP, 
MLL, TRX, and Drosophila Polycomb group (PCL) proteins (Aasland, Gibson et al. 
1995).  In addition to the N-terminal PHD domain, AF10 contains an extended PHD 
domain also known as a leukemia-associated protein domain (LAP) that functions in 
homo-oligomerization and is conserved in several other proteins including MLL, 
AF17, and BR140 (Linder, Newman et al. 2000).  AF10 also contains an AT-hook 
motif,  a motif that was initially described in the high-mobility group of non-histone 
chromosomal proteins and other DNA-binding proteins,  and is thought to mediate 
protein binding to cruciform DNA (Aravind and Landsman 1998).  In addition to 
these domains, AF10 contains a bipartite nuclear localization signal (NLS) and a C-
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terminus glutamine-rich region.  However, due to alternative splicing the latter is not 
present in all isoforms (Linder, Newman et al. 2000; Debernardi, Bassini et al. 2002).   
 
 A role for AF10 in leukemic transformation was proposed as the gene was initially 
cloned as an MLL chromosomal translocation partner in 3 patients with AML-M5 and 
an MLL-AF10 fusion (Chaplin, Ayton et al. 1995).  An additional report presented 
two cases of pediatric AML-M5 in which there was paracentric inversion of the 11q 
region with chromosome 10p12 (Morerio, Rapella et al. 2005). Although pediatric 
acute megakaryoblastic leukemia (AML-M7) is considered rare, two independent 
case reports demonstrated fusions between MLL and AF10 in pediatric patients 
(Borkhardt, Haas et al. 1995; Morerio, Rapella et al. 2005).  Deletion analysis of the 
MLL-AF10 fusion protein has demonstrated that the leucine zipper (LZ) motif in the 
carboxy terminus of AF10 is essential for leukemogenesis (DiMartino, Ayton et al. 
2002), and the H3K79 methyltransferase hDOT1L has been shown to be involved in 
MLL-AF10 mediated leukemogenesis through interaction of hDOT1L and AF10 





Figure 1.3.  Structure of CALM, AF10 and CALM-AF10 fusions.  (A)  Schematic 
representation of the human CALM and AF10 genes based on the reference sequences 
NM_007166 and U13948 respectively. CALM exons 1-20 are indicated by striped 
rectangles.  The bracket spanning introns 18-19 indicate the genomic region where 
translocations are known to occur within CALM.  AF10 exons 1-24 are indicated by 
stippled rectangles.  The bracket spanning introns 3-9 indicate the genomic region 
where translocations are known to occur within AF10.  The black box immediately 
adjacent to exon 23 represents 124 bp of exon sequence this is present in most ESTs 
but missing from the reference sequence (U13948).  Centromere (C) and telomere (T) 
orientation is as indicated. (B) Schematic representation of the predicted protein 
structure for CALM, AF10 and the two chimeric proteins CALM-AF10 and AF10-
CALM.  Protein domains are indicated in each structure: ENTH (espin N-terminal 
homology; Asp-Pro-Phe), DPF (ASP-Pro-Phe) motif, NPF (Asn-Pro-Phe) motif, CBS 
I & II (clathrin binding sequence I & II), PHD (plant homology domain), LAP 
(leukemia-associated protein), NLS (nuclear localization signal), LZ (leucine zipper), 





Clinical features of leukemia with CALM-AF10 fusions 
Although the t(10;11)(p13:q14-21) translocation was initially observed in a patient 
with histiocytic lymphoma, Groupe Français de Cytogénétique Hématologique 
(GFCH) subsequently identified the t(10;11) translocation as a recurrent reciprocal 
translocation in patients with T-cell acute lymphoblastic leukemia (GFCH 1991). 
CALM-AF10 translocations appear to be most frequently associated with T-cell ALL, 
specifically T-cell ALL of either γ/δ or immature phenotypes. In the largest series of 
its kind, 20 cases of CALM-AF10 fusion leukemias were identified in a study of 144 
patients with T-ALL (Asnafi, Radford-Weiss et al. 2003). Patients with a CALM-
AF10 fusion ranged from 3-43 years of age (mean 20.7), and were more frequently 
male (M:F=2.8).  WBC at presentation ranged from 3.3-556 x 109/L, and 8 of 20 
patients had a mediastinal mass.  Although the numbers were small, patients with a 
CALM-AF10 fusion and an immature phenotype had a poor prognosis, as 10/12 
patients either did not respond to therapy or relapsed.  In contrast, 8/8 patients with a 
CALM-AF10 fusion and a TCR γ/δ phenotype were in complete remission at the time 
of the report.  In this series, CALM-AF10 fusions were present in 12/29 cases with an 
immature TCR γ/δ phenotype and 8/32 cases with a TCR γ/δ phenotype, but in 0/78 
α/β or IM β T-ALLs, demonstrating a marked bias toward T-cell ALL of the γ/δ 
lineage.   This study also suggested that the AF10 content of the CALM-AF10 fusion 
might correlate with the stage of maturation arrest.   All but the final four amino acid 
residues of the protein encoded by the CALM gene are retained in most CALM-AF10 
fusion transcripts (Figure 1.3) (Dreyling, Martinez-Climent et al. 1996; Asnafi, 
Radford-Weiss et al. 2003), although due to alternate splicing, 20, 35, or 55 amino 
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acid residues are excluded in some CALM-AF10 fusions.   At least four common 
AF10 fusion sites have been described (Asnafi, Radford-Weiss et al. 2003). The 
resultant CALM-AF10 fusion transcripts can be classified as either 5’ or 3’, depending 
on how much AF10 sequence is included in the fusion transcript.  5’ fusion 
transcripts, which retain almost all of the AF10 coding sequence, are associated with 
TCRγδ T-cells, whereas 3’ fusion transcripts, which contain less AF10 sequence, are 
associated with more immature T-cells that do not express a TCR on the cell surface 
(Asnafi, Radford-Weiss et al. 2003).    
 
CALM-AF10 fusions have also been observed in a variety of myeloid leukemias 
including AML-M0 ,M1, M2, M4, M5, and M7, as well as eosinophilic leukemia and 
granulocytic sarcoma (Table 1.1) (Kobayashi, Hosoda et al. 1997; Narita, Shimizu et 
al. 1999; Bohlander, Muschinsky et al. 2000; Salmon-Nguyen, Busson et al. 2000; 
Jones, Chaplin et al. 2001; Abdou, Jadayel et al. 2002; Nakamura, Maki et al. 2003; 
La Starza, Crescenzi et al. 2006; Abdelhaleem, Beimnet et al. 2007). Interestingly, 
most of the AML M0, M1, and M2 cases that have been analyzed show clonal IGH, 
TCRG, and/or TCRD gene rearrangements, suggesting that the target for malignant 
transformation may have been a multipotential hematopoietic precursor cell (Asnafi, 
Radford-Weiss et al. 2003; Deshpande, Cusan et al. 2006).  CALM-AF10 
translocations have been identified in both children and adults with AML; specific 
lesions include splenomegaly, hepatomegaly, mediastinal masses, and CNS leukemia 
(Kumon, Kobayashi et al. 1999).  Cytochemical and immunophenotypic data varies 
with the diagnosis but includes markers for lymphoid as well as myeloid antigens 
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(Kobayashi, Hosoda et al. 1997; Kumon, Kobayashi et al. 1999; Narita, Shimizu et al. 
1999; Bohlander, Muschinsky et al. 2000).   
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Patient Diagnosis CALM-AF10 Breakpoint(s) References
M/22 T-ALL CALM 2091; AF10 589 Bohlander 2000
F/16 pre T-ALL CALM 1926; AF10 883 Bohlander 2000
M/5 pre T-ALL CALM 2091; AF10 979 Bohlander 2000
1 ALL CALM 1926; AF10 980 Kumon 1999
2 ALL CALM 2091; AF10 883 Kumon 1999
3 ALL CALM 1926; AF10 589 Kumon 1999
F/10 ALL NR Kobayashi 1997
M/25 LBL NR Kobayashi 1997
F/17 T-ALL NR Salmon-Nguyen 2000
M/26 T-ALL CALM 2091; AF10 979 Carlson 2000
M/12 T-ALL CALM 1926; AF10 589  Carlson 2000
F/23 NHL Tcell LBL AML NR Carlson 2000
M/33 T-ALL TCRγδ AF10 424 Asnafi 2003
M/29 T-ALL TCRγδ AF10 589 Asnafi 2003
M/20 T-ALL TCRγδ AF10 883/979 Asnafi 2003
M/15 T-ALL TCRγδ AF10 589 Asnafi 2003
F/11 T-ALL TCRγδ AF10 589 Asnafi 2003
M/7 T-ALL TCRγδ NR Asnafi 2003
M/6 T-ALL TCRγδ AF10 589 Asnafi 2003
M/3 T-ALL TCRγδ AF10 424 Asnafi 2003
M/43 T-ALL IMγ AF10 589 Asnafi 2003
M/37 T-ALL IMγ AF10 883/979 Asnafi 2003
M/28 T-ALL IMγ AF10 883/979 Asnafi 2003
M/26 T-ALL IMγ AF10 424 Asnafi 2003
M/25 T-ALL IMγ AF10 883/979 Asnafi 2003
F/25 T-ALL IMδ AF10 883/979 Asnafi 2003
M/24 T-ALL IMγ AF10 883/979 Asnafi 2003
M/23 T-ALL IMγ AF10 424 Asnafi 2003
F/20 T-ALL IMγ AF10 883/979 Asnafi 2003
M/14 T-ALL IMδ AF10 883/979 Asnafi 2003
F/12 T-ALL IMδ AF10 883/979 Asnafi 2003
F/12 T-ALL IMγ AF10 883/979 Asnafi 2003
F/78 B-ALL AF10 883/979 Asnafi 2003
M/18 AUL AF10 883/979 Asnafi 2003
M/18 AUL AF10 883/979 Asnafi 2003
F/29 AUL AF10 589 Asnafi 2003
M/39 AUL CALM 2091; AF10 424 Asnafi 2003
M/13 T-ALL CALM 2091; AF10 424 La Starza 2003
F/38 T-ALL CALM 2091; AF10 589 La Starza 2003




Patient Diagnosis CALM-AF10 Breakpoint(s) References
U937 Histiocytic Lymphoma CALM 2091; AF10 423 Dreyling 1996
M/19 AML-M1 CALM 1926; AF10 883,                         
CALM 2091; AF10 883
Bohlander 2000
M/47 AML-M0 CALM 1926; AF10 883 Bohlander 2000
F/21 AML-M1 CALM 1926; AF10 589,                         
CALM 2091; AF10 589
Bohlander 2000
4 AML-M0 CALM 2091; AF10 589 Kumon 1999
M/12 AMoL NR Kobayashi 1997
F/30 Granulocytic sarcoma NR Kobayashi 1997
M/6 AML-M7 CALM 1926; AF10 424 Jones 2001
F/10 Acute eosinophilic leukemia NR Salmon-Nguyen 2000
M/16 AML-M4 CALM 1926; AF10 424 Nakamura 2003
M/20 AML-M4 NR Abdou 2002
F/44 AML-M0 CALM 2091; AF10 424 Carlson 2000
F/28 AML-M1 CALM 2091; AF10 883 Carlson 2000
M/41 AML-M5 CALM 2091; AF10 979 Carlson 2000
F/4 AML-M7 CALM 2091; AF10 423 Abdelhaleem 2007
M/2 AML-M7 CALM 2091; AF10 796 Abdelhaleem 2007
M/25 AML-M1 AF10 883/979 Asnafi 2003
F/16 AML-M1 AF10 424 Asnafi 2003
M/22 AML-M0 CALM 2091; AF10 883 Asnafi 2003
F/33 AML-M2 CALM 1926; AF10 883 Asnafi 2003
F/36 AML-M1 CALM 2091; AF10 978 Asnafi 2003
M/19 AML-M1 CALM 2091; AF10 424 Deshpande 2006
M/47 AML-M1 CALM 2091;  AF10 424 Deshpande 2006
F/12 AML-M1 CALM 2091; AF10 424 Deshpande 2006
F/19 AML CALM 2091; AF10 1048 Deshpande 2006
F/4 AML-M5a NR Deshpande 2006
F/12 AML-M1 CALM 2091; AF10 424 La Starza 2003
M/36 AML-M2 NR La Starza 2003
M/27 AML-M0 CALM 2091; AF10 424 La Starza 2003
M/47 AML-M1 CALM 2091; AF10 424 La Starza 2003
M/19 AML-M1 NR La Starza 2003
Table 1.1  Characteristics of patients with the t(10:11) CALM-AF10 translocation (Cont.)
Abbreviations:  AML, acute myeloid leukemia; Amol, acute monocytic leukemia; AUL, acute undifferentiated 
leukemia; LBL lymphoblastic lymphoma; NHL, non-Hodgkin’s lymphoma; NR, not reported; T-cell ALL, T-cell 
acute lymphoblastic leukemia.  
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Mouse Models of CALM-AF10 Leukemia 
Animal models have provided tractable systems with which to study a wide range of 
human diseases, including the recurrent chromosomal translocations involved in 
hematologic malignancies (Rabbitts 2001). Given the shared physiology between 
mice and humans, the mouse has become a standard animal model used to study 
pathophysiology and explore novel therapeutic approaches.  Chromosomal 
translocations have been studied in mouse models using a variety of techniques 
including retroviral transduction and bone marrow transplantation as well as gene-
targeting and transgenic approaches (Rabbitts 2001; Bernardi, Grisendi et al. 2002; 
Forster, Pannell et al. 2005).  Recently, two groups have published reports that used 
mice to study CALM-AF10 leukemia; findings from each of these reports are 
summarized in Table 1.2. 
 
The first study used a vector based RNA interference system to “knock down” 
CALM-AF10 expression in the U937 cell line, which expresses a CALM-AF10 fusion 
protein.  The “knock-down” clones proliferated less rapidly in vitro, and showed a 
modest survival benefit following xeno-transplantation  into NOD/SCID mice 
(median survival 27 vs. 19.5 days post transplant) (Okada, Jiang et al. 2006).   
 
A second study used retroviral transduction and bone marrow transplantation to 
generate acute leukemia in mice (Deshpande, Cusan et al. 2006).  Recipient mice 
transplanted with bone marrow cells that expressed a CALM-AF10 fusion gene 
developed disease a median of 110 days following transplantation.  Mice with 
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leukemia were anemic and had circulating blasts.  Parenchymal infiltration by 
leukemic myeloid cells was noted in a variety of organs and these cells were positive 
for the myeloid markers myeloperoxidase and chloracetate esterase.  Further analysis 
of leukemic cells from these mice demonstrated that myeloid cells positive for Mac1 
and Gr1 were also positive for the lymphoid marker B220 and had clonal 
immunoglobulin DH-JH rearrangements, consistent with the observation of clonal 
IGH gene rearrangements in patients with CALM-AF10 fusions, and suggesting that 
the target cell for malignant transformation was multi-potential.   Interestingly, these 
authors went on to show that AML could be propagated from a leukemic cell with 
lymphoid features, as Mac1+ myeloid leukemia could be established by serial 
transplantation of Mac1+/B220+ or Mac1-/B220+ leukemia cells (Deshpande, Cusan 





























Xenograft of siRNA 
clones
NOD/SCID AML 19.5 d (16-23d) control                                
27d (22-33d) siRNA 
clones
CD45 Spleen, Kidney, 
Pancreas
not applicable nd Okada, 2006
Retroviral infection 
and bone marrow 
transplantation
C57Bl/6xC3H AML 110 d (46-366d) Mac1++, Gr1++, 
B220+/-, MPO++
Bone Marrow, 
Spleen, Liver, Lung, 
Kidney, Brain, 
Intestine
Igh yes Deshpande, 2006
Table 1.2  Summary of CALM-AF10  Mouse Models
Abbreviations:  AML, acute myeloid leukemia; d, day; FVB, Friend virus B-type; nd, not done; NOD/SCID, non-obese diabetic/severe combined immunodeficiency.
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Putative targets of the CALM-AF10 fusion gene 
Understanding the flow of genetic information that occurs between the chromosomal 
translocation and the protein product that results as a consequence of these mutations 
is critical to the identification of therapeutic targets and development of effective 
therapies (Rabbitts and Stocks 2003).  In many events these fusion proteins are either 
transcription factors that regulate hematopoietic cell differentiation or tyrosine 
kinases that control cellular proliferation (Aplan 2006). Gene expression profiling of 
patients with AML has identified several putative targets including members of the 
Polycomb group (PcG), HOX, and MEIS1 genes (Grubach, Juhl-Christensen et al. 
2008).  Furthermore, additional experiments have shown that HOXA cluster genes, 
including HOXA5, HOXA9, and HOXA10 are upregulated in the leukemic cells of 
patients with CALM-AF10 fusions (Dik, Brahim et al. 2005).  In this same study 
BMI1, a PcG member that is located in close proximity to AF10 on chromosome 10 
was also aberrantly expressed (Dik, Brahim et al. 2005).  This finding suggests that 
genes that are juxtaposed to fusion genes and differentially expressed may contribute 
to a growth advantage of malignant clones.   In addition, U937 cells (which express a 
CALM-AF10 fusion) transduced with an siRNA directed to the CALM-AF10 fusion 
showed a modest decrease in HOXA5, HOXA7, HOXA9, and HOXA10 expression 
(Okada, Jiang et al. 2006).  This same study suggested that CALM-AF10 upregulates 
HOXA genes, particularly HOXA5.  In this study, it was shown that hDOT1L 
contributes to CALM-AF10 leukemia by preventing the nuclear export of CALM-




Mammalian HOX genes are members of the evolutionarily conserved homeodomain 
family of genes that are structurally organized into four discreet clusters (A, B, C, and 
D), located on four different chromosomes in mammals, that encode for transcription 
factors (Garcia-Fernandez 2005; Pearson, Lemons et al. 2005).  In addition to their 
well-studied role as executive regulators of anterior-posterior body pattern 
organization during early embryonic development, HOX genes play a fundamental 
regulatory role in hematopoietic system organization and development (van 
Oostveen, Bijl et al. 1999).  Of the distinct clusters, A, B, and C, but not D are 
thought to be important for normal hematopoiesis (Abramovich and Humphries 
2005).  Gene ablation studies have shown specifically that Hoxa9, Hoxc8, and Hoxb6 
are necessary for hematopoietic cells to progress though development (Abramovich 
and Humphries 2005).  In addition to their role in normal development, HOX genes 
also play roles in cell cycle control, cell adhesion, and cell death.  Given the central 
role of HOX genes in normal development, it is not surprising that HOX genes have 
been implicated in a number of neoplastic and non-neoplastic disease processes 
(Grier, Thompson et al. 2005).   
 
Several lines of evidence, based on clinical observations as well as data from 
experimental animal models, suggest that HOX genes are involved in leukemic 
transformation.  First, global gene expression profiling has identified HOX genes as 
being consistently overexpressed in AML (Armstrong, Golub et al. 2003; Mullighan, 
Kennedy et al. 2007).   Chromosomal translocations lead to fusions of NUP98 with 
HOXA9, HOXA11, HOXA13, HOXC11, HOXC13, HOXD11, and HOXD13 in 
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patients with myelodysplastic syndrome (MDS) or AML (Lam and Aplan 2001).  
Chromosomal translocations also lead to ectopic expression of HOXA cluster genes 
by juxtaposition of TCRA regulatory elements with HOXA coding sequences in some 
patients with T-cell ALL (Soulier, Clappier et al. 2005; Speleman, Cauwelier et al. 
2005).   In addition to these translocations which directly lead to overexpression of 
HOX genes, a number of recent studies have demonstrated that chromosome 
translocations which result in MLL fusions lead to unscheduled expression of HOX 
genes in both AML and T-cell ALL patients (Hess 2004).   
 
Direct experimental evidence supporting a role for Hox gene dysregulation in 
myeloid leukemia comes from several mouse models.  Transplantation of bone 
marrow cells that overexpressed Hoxa5, Hoxa9, or Hoxa10 consistently led to 
myeloid expansion, and, in collaboration with the Hox cofactor Meis1, AML 
(Abramovich and Humphries 2005; Grier, Thompson et al. 2005).  Transplantation of 
bone marrow cells that overexpressed Nup98-Hox fusions led to abnormal myeloid 
differentiation and AML, again in collaboration with Meis1 (Kroon, Thorsteinsdottir 
et al. 2001; Pineault, Buske et al. 2003; Pineault, Abramovich et al. 2004).  Lastly, 
transgenic mice that expressed a NUP98-HOXD13 fusion showed upregulation of 
Hoxa7, Hoxa9, and Hoxa10, and developed a myelodysplastic syndrome (MDS) that 
progressed to acute leukemia in about half of the mice (Lin, Slape et al. 2005). 
Finally, a number of Hox genes and Hox co-factors, including Hoxa7, Hoxa9, Meis1 
and Pbx1 are among the most common upregulated genes in murine leukemias that 
 27 
 
result from retroviral insertional mutagenesis (Nakamura T, Largaespada DA et al. 
1996).     
 
In summary, HOXA cluster genes are associated with normal hematopoietic 
development and are upregulated in patients with leukemia.  The CALM-AF10 gene is 
associated with increased expression of HOXA genes and inhibition of CALM-AF10 
results in a modest decrease in HOXA expression in vitro.  These findings suggest that 
the CALM-AF10 fusion gene may be involved in the aberrant upregulation of HOXA 
genes that result in impaired hematopoietic cell differentiation.  Therefore, the HOXA 
genes in particular may be important therapeutic targets in patients with CALM-AF10 
leukemias. 
 
Thesis goals and outline 
CALM-AF10 fusions result from a rare but recurring t(10;11) chromosomal 
translocation seen in both adult and pediatric patients with AML or ALL, and are 
often associated with a poor prognosis.  In the context of a current working model for 
AML, in which complementary mutations that lead to either impaired differentiation 
or increased proliferation collaborate to produce a fully leukemic clone, (Gilliland 
and Tallman 2002) it seems likely that the CALM-AF10 fusion functions to impair 
differentiation based on its influence on HOXA cluster gene expression.  The 
corollary of this hypothesis is that CALM-AF10 leukemias should acquire 
spontaneous mutations leading to increased proliferation.  In this study, it is the 
hypothesized that mice which express an aberrant fusion protein associated with acute 
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leukemia will develop acute leukemia, demonstrating that the fusion protein is indeed 
leukemogenic.  To accomplish this, the following three specific aims are proposed: 
• Characterize leukemia in a transgenic mouse that expresses CALM-AF10 
• Identify (through insertional mutagenesis) genes which collaborate with 
CALM-AF10 to induce leukemia 
• Identify differentially expressed genes in CALM-AF10 hematopoietic 
precursor cells 
 
A discussion will be provided in chapter 2 that focuses on the development of a 
transgenic mouse model that expresses a fusion CALM-AF10 cDNA.  These 
transgenic mice develop a myeloid leukemia with lymphoid features after a long 
latency period and incomplete penetrance.    In addition to these findings, the CALM-
AF10 transgenic mice have impaired T-cell differentiation.  
 
Chapter 3, will focus on acceleration of leukemia in CALM-AF10 transgenic mice 
infected with MOL4070LTR virus.  The identification of potential collaborating 
genes using retroviral insertional mutagenesis, anchored PCR, and sequence analysis 
will also be reported.  A description of the clinical and pathological findings 
identified in both CALM-AF10 transgenic mice and FVB wild-type mice infected 
with the MOL4070LTR virus will be provided.  Two potential collaborating genes 
and/or pathways that were identified through Southern blot analysis and RQ-RTPCR 




Chapter 4 will demonstrate that Hoxa cluster genes are upregulated, as determined by 
RQ-RTPCR analysis in CALM-AF10 transgenic mice as well as in tumors from these 
mice.  There will also be a report on differentially expressed genes using microarray 
analysis that are upregulated in the bone marrow from clinically healthy CALM-AF10 
transgenic mice. Here it was confirmed that Hoxa9 and Meis1 are important genes in 
CALM-AF10 mice.  In addition to these genes, an additional gene was also identified 
as being was up-regulated, desmoplakin.  Not only was there an up-regulation in abd 
b Hox genes, but there was also a concomitant down regulation of immunoglobulin 
genes as well.  
 
In chapter 5, an overall discussion and conclusion will be presented that will offer 
insight regarding the utility of this mouse model and the direction of future 
experiments.   
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Chapter 2: Characterization of the transgenic mouse for t(10;11) 





Because cancer develops in the context of an intact organism, with the influence of 
nearby cells and tissues, genetically engineered animal models have become a 
standard model for demonstrating that a lesion associated with any form of 
malignancy causes the malignancy (Bernardi, Grisendi et al. 2002).  Moreover, 
generation of genetically engineered mouse models allows one to study the process of 
malignant transformation over time in vivo.    
 
Until now, mouse models for the t(10;11) chromosomal translocation have only 
included xenograft and retroviral transduction systems.  This chapter will describe the 
characterization of a transgenic model for CALM-AF10.  It will also be shown that the 
fusion gene leads to impaired hematopoietic differentiation in clinically healthy mice. 





Materials and Methods 
Generation of Transgenic Mice 
A CALM-AF10 fusion cDNA fragment was amplified from the U937 cell line using 
RT-PCR, and fragments of CALM and AF10 derived from EST clones were ligated to 
the 5’ and 3’ portion of the fusion cDNA.  Although several different CALM-AF10 
fusion cDNAs have been described (Asnafi, Radford-Weiss et al. 2003), the 
predominant fusion cDNA that was detected in the U937 cell line joined CALM 
nucleotide 2230 (Genbank reference NM_007166.2) to AF10 nucleotide 241 
(Genbank reference NM_001009569.1).  Next, the fusion cDNA 5’ and 3’ was 
extended by ligating portions of CALM and AF10 cDNAs to the CALM-AF10 PCR 
product, and introduced a human beta-globin 5’ untranslated region to aid in the 
translation of the CALM-AF10 fusion mRNA.  The entire coding sequence of the 
CALM-AF10 cDNA was 4881 nucleotides encoding a 1627 aa protein (see Appendix 
I for nucleotide sequence). The resultant cDNA was cloned into the SfiI and NotI sites 
of the HS21/45-vav vector to orchestrate expression specifically in the hematopoietic 
tissue compartment (Adams, Harris et al. 1999).  In order to delete all plasmid 
backbone sequences, the CALM-AF10 insert was then shuttled into the pSV40zeo 
(Invitrogen, Carlsbad, CA) vector by using a partial HindIII digest.  The resultant 
plasmid, pSVZvavCA was digested with PmeI to remove all plasmid sequences.  The 
CALM-AF10 expression cassette was purified over a sucrose gradient, and FVB/N 
zygotes were microinjected with the construct at the NCI transgenic animal facility 
(NCI-Frederick, Frederick MD).  Transgenic mice that had incorporated the construct 




The transgenic lines were maintained by breeding to wild-type FVB/N mice.  
Offspring of the founders were genotyped using polymerase chain reaction (PCR) 
amplification of the CALM-AF10 fusion gene from tail biopsy at weaning (2 months 
of life).  Briefly, approximately 6 mm of the distal tail was removed by sharp 
dissection and placed into an Eppendorf tube labeled with the mouse identification 
that corresponded to mouse ear tag, snap frozen in dry ice and stored at -80°C until 
the time of genotyping.  To extract genomic DNA used for genotyping, 2 mm of 
frozen tail was sterilely cut and placed into an Eppendorf tube containing 300 µl of 
250 µM NaOH and heated to 95°C for 60 min.  Following heating, 25µl of 1M Tris 
Buffer, pH 7.5 (Quality Biologicals, Gaithersburg, MD) was added to each sample, 
vortexed and centrifuged in a table-top centrifuge at full speed for 6 minutes and 
stored at 4°C until time for PCR analysis.  The genotype of each sample was 
determined by PCR assay using 1 µl of supernatant from each boiled DNA sample in 
a mixture of 17 µl of PCR Supermix High Fidelity (A 22 U/ml DNA polymerase 
mixture in 66 mM Tris-SO4 (pH 9.1 at 25°C), 19.8 mM (NH4)2SO4, 2.2 mM 
MgSO4, 220 µM dGTP, 220 µM dATP, 220 µM dTTP, 220 µM dCTP and 
stabilizers) (Invitrogen), and 10 µM of each of the following primers: 
5’TGTTCCTGTAATGACGCAACCAACC3’ and 
5’CTCTGGAATATACAGGGCACAAACA3’.  Samples were then processed in a 
PTC-200 Peltier Thermal Cycler (MJ Research, Watertown, MA) at a thermal cycling 
profile of  94°C for 3 min; 34 cycles of 94°C for 30 seconds, 62°C for 30 seconds, 
72°C for one min; followed by a terminal extension of 72°C for 10 min.  Quality 
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control of the DNA samples was determined by PCR analysis for SCID gene using 
the following primers 5’GGAAGAGTTTTGAGCAGACAATG3’ and 
5’CATCACAAGTTATAACAGCTGGG3’.  Samples were processed in a PTC-200 
Peltier Thermal Cycler (MJ Research, Watertown, MA) at a thermal cycling profile of 
94°C for 3 min; 29 cycles of 94°C for 60 seconds, 54°C for 60 seconds, 72°C for one 
minute; followed by a terminal extension of 72°C for 5 min. See Appendix II for an 
example of genotype results.   
Expression of the CALM-AF10 transgene 
RNA extraction from tissue 
Expression of the CALM-AF10 transgene was determined by Northern blot analysis 
and RT-PCR.  Total RNA was isolated from thymus, spleen, bone marrow, liver and 
kidney of mice using Trizol (Invitrogen) reagents and protocols.  To extract the RNA, 
frozen tissue was cut using a razor blade and placed into a 1.5 ml Eppendorf tube that 
contained 200 µl of Trizol.  The tissue was ground using an electric tissue grinder, 
and 800 µl of additional Trizol was added to the tube.  After a five minute incubation 
at room temperature, 200 µl of chloroform (Mallinkrockdt Baker, Paris KY) was 
added to each sample and vortexed vigorously for 15 seconds, followed by a 2-3 min 
incubation at room temperature.  Samples were placed into a table top centrifuge and 
spun at 12000 x g for 15 min at 4ºC.  The organic supernatant layer was removed and 
transferred to a clean Eppendorf tube and 500 µl of isopropanol (Mallinkrockdt 
Baker) was added, gently mixed and incubated on ice for 10 min.  Next, samples were 
spun at 12000 x g for 10 min at 4ºC.  The supernatant was decanted and 1 ml of 75 
per cent ethanol (Warner-Graham Company, Cockeysville, MD) was added and 
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samples were then spun at 7500 x g for 5 min at 4ºC.  The supernatant was decanted 
and samples were air-dried for 5-10 min and resuspended in 60 µl of deionized water 
and stored at -80ºC until future use.      
 
Northern blot analysis 
Total RNA (10µg) was size-fractionated on an agarose/formaldehyde gel, transferred 
to a nitrocellulose membrane (Schliecher & Schuell, Dassel, Germany) over night 
(O/N) using 20X Salt Sodium Citrate (3.0 M NaCl, 0.3 M Sodium Citrate, pH 7.0; 
SSC) buffer (Roche Diagnostics, Indianappolis IN). The next day the membrane was 
removed, crosslinked with 1200 µ joules x100 UV light in a UV Stratalinker 1800 
(Stratagene, La Jolla, CA) and hybridized with a 32P-labeled-human CALM fragment 
(0.5 kb HindIII-EcoRI fragment; nucleotides 1588-2121 of NM_007166.2) as 
described below.  
 
The nitrocellulose membrane was prehybridized with  20 ml  of NC  Hybridization 
Solution (100 ml 20X SCC (Roche), 1.75 ml of 1M Tris HCl, ph 7.5, 10 mg Herring 
sperm DNA (Invitrogen), 200 ml Formamide (Sigma), 8 ml-50X Denhardt’s solultion 
(a solution of ficoll, bovine serum albumin, polyvinylpyrrolidone, and a high 
concentration of non-specific DNA to prevent non-specific binding of DNA) and 84.5 
ml deionized H20 added to 100 ml of 50% Dextran Sulfate (Ichemicon International, 
Temecula, CA) in a glass hybridization bottle for two to four hours at 42ºC in a 
rotating hybridization oven.  To generate the radiolabled probe, 50 ng of DNA 
fragment was resuspended in a total volume of 45 µl deionized H20 (diH20), boiled 
for 3 min in a water bath, followed by 3 min on wet ice.  Next, the DNA fragment 
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was mixed with Ready-To-Go™ DNA Labeled Beads (dCTP) (Amersham, 
Bioscience, Little Chalfont Buckinghamshire, England) and labeled with 5 µl of 32P-
dCTP (10µCi/mL) at 37°C for 30 min.  The labeled probe (total volume 50 µl) was 
purified over a Performa DTR Gel Filtration Cartridge (EdgeBio, Gaithersburg, MD) 
and diluted in 500 µl of diH20.  Two hundred and fifty µl of the diluted probe was 
added to 1.0 mg of Herring Sperm (Invitrogen).  Next, the probe was denatured by 
adding 50 µl of 10 mM NaOH for 1 min, and neutralized by adding, 140 µl of 1 M 
Tris pH 7.5, 1 min and 500 µl of 1M HCl for 1 min.  The total mixture was 
transferred to 20 ml of hybridization solution.  The total mixture was added to the 
prehybridized membrane for overnight incubation at 42°C.   
On the following day, the nitrocellulose membrane underwent stringency washes for 
20 min x 3 in 200 ml of 0.1x SSC/0.1% SDS (Sodium Dodecyl Sulfate, Quality 
Biological, Inc.) at 52°C.  After the last wash, the membrane was removed, wrapped 
in clear plastic wrap and placed in an intensifying screen-containing film cassette 
with BioMax XAR film (Kodak, Rochester, NY) and stored overnight at -80°C. The 
film was removed from the cassette and exposed using an RP-X-OMAT Processor, 
Model M6B (Kodak) auto processor. 
 
RT-PCR 
RT-PCR amplification of the CALM-AF10 mRNA was performed by first DNA-ase 
treating 10 µg of RNA with 2U/µl rDNase, and 0.1 vol 10X DNase I buffer (Ambion, 
Austin, TX) in a total volume of 50 µl.  The samples were incubated for 20-30 min at 
37ºC.  To inactivate the DNase, 0.1 vol DNase Inactivation Reagent was added to 
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each sample, vortexed and incubated at room temperature for 2 min.  Each sample 
was centrifuged at 10,000 x g for 1. 5 min at room temperature and the supernatant 
was transferred to a new new tube.  One microgram of total DNase-treated RNA was 
mixed with SuperscriptII reverse transcriptase (RT) and random hexamer primers 
(Invitrogen) in a volume of 20 µL.    One to two microliters of the reverse 
transcription reaction was used to amplify the CALM-AF10 fusion with 23 µl of PCR 
Supermix High Fidelity (Invitrogen) (previously described),  and 1 µl each of 10 µM 
of primers 5’TGTTCCTGTAATGACGCAACCAACC3’ and 
5’CTCTGGAATATACAGGGCACAAACA 3’ and a thermal cycling profile of 94°C 
for 3 min; 34 cycles of 94°C for 30 seconds, 62°C for 30 seconds, 72°C for one min; 
followed by a terminal extension of 72°C for 10 min.  To ensure quality control of the 
cDNA, one to two microliters of the reverse transcription reaction was also used to 
amplify the housekeeping gene β-actin using  1 µl each of 10 µM mouse primers 
5’TGTTCCTGTAATGACGCAACCAACC3’ and  
5’CTCTGGAATATACAGGGCACAAACA3’ (for mouse tissues) or the human 
primers   5’AGGCCGGCTTCGCGGGCGAC3’ and 
5’CTCGGGAGCCACACGCAGCTC3’                                (for the human cell line 
U937) and a thermal cycling profile of 94°C for 3 min; 34 cycles of 94°C for 30 
seconds, 62°C for 30 seconds, 72°C for one min; followed by a terminal extension of 
72°C for 10 min.  PCR products were size fractionated by agarose gel electrophoresis 




To verify that the CALM-AF10 transgene was indeed expressed in γδ T-cells, purified 
γδ T-cells were extracted from total CALM-AF10 transgenic spleen using a TCR γδ+ 
T-cells isolation kit specific for mouse (Miltenyi Biotec, Auburn CA).  First, 
splenocytes were physically extracted from the spleen and collected into PBS, pH 7.2, 
with 0.5% BSA.  Following single cell suspension, cells were passed through a 30 µm 
nylon mesh to remove cell clumps and stromal elements.  Next cells were centrifuged 
at 300xg for 10 min, the supernatant was removed, and cells were resuspended in 450 
µl of buffer per 108 total cells.  Fifty microliters of Non-T Cell Depletion Cocktail 
(Cocktail of Microbeads conjugated to monoclonal antibodies against mouse CD45R, 
mouse CD11b), and a biotin-conjugated monoclonal antibody against mouse TCR γ/δ 
cells, Miltenyi Biotec was added to the cells and incubated for 15 minutes at 4ºC.  
Following the incubation, the non-T cells were depleted using direct magnetic 
labeling with CD45R and CD11b Microbeads by passing the cell suspension through 
an LD magnetic column (Miltenyi Biotec), which retains the non-T cells.  Note that 
the cells were simultaneously labeled with a biotin-conjugated monoclonal antibody 
against mouse TCR γ/δ cells for downstream collection of the γ/δ+ T cells.   The 
flow-through fraction of pre-enriched T-cells was collected, centrifuged at 300xg for 
10 min, the supernatant was removed and the cells were resuspended in 450 µl of 
buffer.  In order to positively select the γ/δ+ T-cells, 50 µl of Anti-biotin Microbeads 
(Miltenyi Biotec) was added to the cell suspension, and incubated for 15 min at 4ºC.  
Following the incubation, the cells were washed by adding 10-20x labeling volume of 
buffer and centrifuged at 300xg for 10 min.  The supernatant was removed 
completely and the cells were resuspended in 500 µl of buffer.  The cell suspension 
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was applied to an MS Column (Miltenyi Biotec) and washed 3x with 500 µl of buffer.  
Once the column was empty of the final wash buffer, 1 ml of wash buffer was placed 
into the column and the TCR γ/δ+ T-cells were flushed into a clean collection tube 
using the plunger supplied with the column. RT-PCR was performed on DNase 
treated RNA extracted from the TCR γ/δ+ T-cells for the expression of CALM-AF10 
as described above.  RT-PCR products were size fractionated on an agarose gel and 
transferred to a nitrocellulose membrane (Schliecher & Schuell) and then hybridized 
with a 32P labeled CALM-AF10 probe using procedures described above. 
Evaluation of leukemic and  healthy mice 
A cohort of 38 transgenic (lines C10 and E6) and 33 wild-type littermate controls 
were housed together and observed daily for signs and symptoms of disease.  
Statistical analysis was done by chi-square with 1 df at 18 months of age.  Whole 
blood was obtained from tail veins for complete blood counts (CBC) and 
morphological evaluation in attempts to detect leukemia in clinically healthy mice.  
Mice that showed signs of disease such as ruffled fur, hunched posture, or difficulty 
in breathing were euthanized for postmortem evaluation.  Mice that were found dead 
were also dissected and tissues placed in formalin as below, unless the tissues were 
judged to be severely decomposed.  Tissue samples including the liver, kidney, 
spleen, thymus, bone marrow, lung, and heart were fixed in 10% neutral buffered 
formalin (Sigma, St. Louis, MO), paraffin embedded, sectioned at 5 µm, and stained 
with hematoxylin and eosin (HE) or anti-myeloperoxidase (MPO; DAKO), CD3 
(DAKO, Carpinteria, CA), F4/80 (Caltag, San Francisco, CA),and B220 (CD45R; 
Pharmingen, San Diego, CA).  The Bethesda proposals for classifying nonlymphoid 
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hematopoietic and lymphoid neoplasms in mice were used as guides to evaluate 
tissues from CALM-AF10 mice (Kogan, Ward et al. 2002; Morse, Anver et al. 2002).    
Single-cell suspensions were prepared from thymus, spleen, and/or bone marrow and 
incubated with fluorescein isothiocyanate (FITC), Phycoerythrin (PE) (Pharmingen, 
San Diego, CA), Allophycocyanin (APC) and Phycoerythrin-Cy5 (PE-Cy5) 
(eBioscience, San Diego, CA)  and subsequently analyzed by three-color flow 
cytometry to determine immunophenotype.  (FITC)--conjugated antibodies used were 
anti--mouse CD8, B220 and, Gr-1; (PE)--conjugated antibodies used were anti--mouse 
CD4, IgM, and Mac-1; (APC)-conjugated antibodies used were anti-mouse CD19, 
CD117, and IgM (eBioscience, San Diego, CA); and (PE-Cy5)-conjugated antibodies 
used were antimouse CD24.  To identify Lin-/Sca-1+/c-Kit+ (‘‘LSK’’) cells, mouse 
bone marrow cells were resuspended with Hank’s balanced salt solution containing 
2% FBS (HF2) at 1X107 cells/mL.  The cells were incubated with a biotin conjugated 
lineage antibody cocktail (CD5, TER119, B220, GR-1, Mac-1, Stemcell 
Technologies, Vancouver, Canada), Streptavidin conjugated to APC (Pharmingen), 
anti-cKit conjugated to FITC (Pharmingen) and anti-Sca-1 conjugated to PE 
(Pharmingen). The stained cells were resuspended with HF2 containing 1ug/mL of 
propidum iodide (Sigma).  Four-color staining was used to identify LSK cells.  




Southern blot analysis for Tcrb, Tcrd, and Igh gene rearrangements  
DNA extraction using proteinase K digestion 
A three mm cubed section was cut from either liver, spleen, or thymus that had been 
previously snap frozen and stored at -80°C and placed into a 15-ml Falcon tube which 
contained six milliliters of DNA lysis buffer (200 mM NaCl, 20 mM EDTA, 40 mM 
TrisHCl, pH 8.0, 0.5% SDS) with 80 µg of proteinase K (20 mg/ml) (Invitrogen) and 
incubated at 50°C overnight (O/N) in a waterbath. On the next day (Day 2), 10 ug of 
RNaseA was added to the lysis solution and incubated at 37ºC.  Next, three milliliters 
of saturated NaCl solution (approximately 6M) was added, shaken vigorously and 
incubated on ice for 20 minutes followed by centrifugation at 3313xg (4000 rpm) for 
20 minutes.  The supernatant (~ 7 ml) was removed and placed into a 50-ml Falcon 
tube (Becton Dickenson Labware, Franklin Lakes, NJ).  Next, ~15 ml of 100% 
ethanol (Warner-Graham Company, Cokeysville, MD) was added to the supernatant 
and allowed to incubate at room temperature in order for DNA precipitation to occur.  
The precipitated DNA was removed using a Pastuer pipette, washed twice in 70% 
ethanol and air-dried.  The DNA was resuspended in 100 µl of deionized H
2
O and 
stored at 4ºC until further use.  
 
Ten micrograms of genomic DNA from mouse liver, spleen, or thymus was digested 
with either 30 Units (U) of HindIII or SstI (for Tcrb and Tcrd gene rearrangements), 
or 30 U of EcoRI or XbaI (for Igh rearrangements), size-fractionated on a 0.8% 
agarose gels over night.  The following day the gel was denatured for one hour in 800 
ml denaturing buffer (40 ml, 10N NaOH, 240 ml 5M NaCl, and 1720 deionized H
2
0), 
neutralized for one hour in 800 ml neutralizing buffer (240 ml, 5M NaCl and 1760 ml 
 41 
 
1M Tris, pH 7.5) and transferred to nitrocellulose membranes (Schliecher & Schuell) 
O/N using 20X SSC buffer (Roche).  The next day the membrane was removed and 
crosslinked with 1200 µ joules x100 UV UV light in a UV Stratalinker 1800 
(Stratagene).  Next, the membrane was washed briefly (30 seconds) in deionized H
2
O 
and baked at 80ºC for 15 minutes and stored at room temperature (R/T) until 
hybridization.  Nitrocellulose membranes were hybridized and probes were prepared 
by random priming as described above.    The nitrocellulose membrane was 
hybridized to a 
32
P-labeled TCRB probe that detects the constant region of both Tcrb1 
and Tcrb2 gene or to a 
32
P-labeled  J δ 1 TCRD probe (Begley CG, Aplan PD et al. 
1989) that detects the Jδ1 and constant regions of Tcrd, or to a 32P-labeled  murine 
Igh probe that hybridizes to the JH3-4 region of the mouse Igh locus which was 
provided as a gift from Dr. Michael Kuehl (Lang, Stanton et al. 1982).  
Results 
Generation of mice that express a CALM-AF10 fusion gene. 
Transgenic CALM-AF10 mice were generated by pronuclear injection of FVB/N 
single cell embryos, and eight potential founders were identified by Southern blotting 
of tail DNA.  Four founders were bred and all four transmitted the transgene.  F1 
mice were euthanized to determine expression of the transgene.  As expected, the 
CALM-AF10 transgene was expressed in hematopoietic tissues (thymus, bone 
marrow, and spleen), but not in non-hematopoietic tissues (liver, kidney) (Figure. 
2.1B, C).    Complete blood counts (CBC) were obtained from clinically healthy 
offspring of  the CALM-AF10 founders aged 6-10 months; although the CALM-AF10 
transgenic mice had increased numbers of atypical lymphocytes (data not shown), 
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there were no statistical differences in, white blood cell, neutrophil, lymphocyte, 




Figure 2.1.  Expression of a CALM-AF10 transgene.  (A)  Map of the construct 
used to generate CALM-AF10 transgenic mice.  5’ and 3’ vav regulatory sequences 
are indicated.  The fusion between CALM nucleotide 2230 and AF10 nucleotide 241 
is indicated.  (B)  Northern blot of tissues from CALM-AF10 mouse (line E6) and 
wild-type littermate.  T, thymus; BM, bone marrow; Li, liver; S, spleen; K, kidney.  
The CALM-AF10 fusion transcript is shown with an arrow.  (C) RT-PCR analysis of 
tissue from CALM-AF10 line C10.  W, deionized H2O control.  Human β-actin 
primers were used as a RNA quality control for the U937 cell line; C-A, CALM-
AF10. (D) Hybridization blot of RT-PCR products from purified γδ T-cells; S, 
spleen; BM, bone marrow; T, thymus; Tu, tumor.  The template used to generate the 
cDNA from γδ T-cells was 10 ng and 2 µg from S, BM, T, and Tu. Ten microliter 
equivalents of a 20 µl reaction was loaded onto the gel.  
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  Table 2.1.  CBC from clinically healthy and leukemic CALM-AF10 mice 
Mouse Line Genotype Status WBC NE Ly Mo Hgb Plt
2953 C10 pos healthy 6.06 2.09 3.63 0.29 12.5 1243
2954 C10 pos healthy 8.82 1.85 6.32 0.58 13.7 807
2948 C10 pos healthy 6.38 1.76 4.24 0.35 10.9 1759
2950 C10 pos healthy 4.78 1.72 2.68 0.36 10.5 2078
7081 C10 pos healthy 5.06 1.46 3.34 0.24 11.4 1520
2952 C10 pos healthy 11.36 3.78 5.62 1.72 8.2 578
7058 C10 pos healthy 5.86 2.2 3.35 0.23 12.3 769
Avg ± STD 6.9 ± 2.3 2.12 ± 0.77 4.1 ± 1.3 0.54 ± .53 11.3 ± 1.8 1251 ± 562
2968 E6 pos healthy 4.16 0.96 2.89 0.3 13.4 802
7019 E6 pos healthy 6.36 1.2 4.74 0.38 10.8 1409
7095 E6 pos healthy 7.96 3.08 4.63 0.2 13.1 992
7087 E6 pos healthy 16.22 4.98 8.28 1.23 7.1 1048
7088 E6 pos healthy 2.86 0.38 2.04 0.39 8.9 761
7089 E6 pos healthy 5.5 1.62 3.6 0.22 10.9 1403
7104 E6 pos healthy 4.6 1.91 2.37 0.26 12.3 856
Avg ± STD 6.9 ± 4.5 2.02 ± 1.56 4.1 ± 2.1 0.43 ± 0.36 10.9 ± 2.3 1039 ± 270
2949 C10 neg healthy 9.86 2.89 6.28 0.47 13.4 924
2955 C10 neg healthy 7.68 2 5.11 0.35 13 867
7080 C10 neg healthy 8.82 2.8 5.67 0.29 12.9 973
7113 C10 neg healthy 5.36 1.04 4.11 0.2 13.4 831
7003 E6 neg healthy 9.04 2.04 6.32 0.65 12.6 899
7020 E6 neg healthy 7.72 1.85 5.34 0.5 12.1 965
7096 E6 neg healthy 8.28 1.59 6.23 0.41 14.1 1090
Avg ± STD 8.1 ± 1.4 2.03 ± 0.65 5.58 ± 0.81 0.41 ± 0.15 13.1 ± 0.6 936 ± 85
2952 C10 pos leukemic 11.4 3.8 5.6 1.7 8.2 578
2953 C10 pos leukemic 18.1 3.6 1.6 12.1 2.6 106
7081 C10 pos leukemic 96.7 14 4.4 51.5 4.4 555
9001 C10 pos leukemic 92.2 19.7 57.6 12.9 9.2 867
9014 C10 pos leukemic 17.5 3.3 11.3 2.6 9.6 886
9043 C10 pos leukemic 43.8 8.2 26 8.9 3 781
7026 E6 pos leukemic 2.7 0.4 1.3 0.9 2.8 871
7087 E6 pos leukemic 16.2 5 8.3 1.2 7.1 1048
7124 D3 pos leukemic 45.9 5 4.5 33.2 2.6 671
Avg ± STD 38.3 ± 34.9 7 ± 6 13.4 ± 18.2 13.9 ± 17.4 5.5 ± 3.0 707 ± 276  
WBC, white blood cell count x 103 per uL; NE, neutrophil count x 103 per uL; Ly, 
lymphocyte count x 103 per uL; Mo, monocyte count x 103 per uL; Hgb, hemoglobin 
measured in g/dL; Plt, platelet count x 103 per uL. 
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Myeloid and T-cell differentiation in clinically healthy CALM-AF10 mice. 
Given that the human disease most often associated with CALM-AF10 fusions is pre-
T LBL, it was somewhat surprising that the majority of the mice in this series had 
myeloid leukemia (although a minority of these leukemias had T-cell features such as 
CD3 staining and/or clonal Tcrb or Tcrd gene rearrangements).  Since previously 
published models of pre-T LBL have often shown evidence of perturbed thymocyte 
differentiation prior to the onset of pre-T LBL, thymocyte subsets in 8 CALM-AF10 
transgenic and 8 wild-type control littermates were studied.  Figure 2.2A shows that 4 
of 8 transgenic mice had significantly decreased numbers of double positive 
CD4+/CD8+ (hereafter DP) cells (1-36 %), coinciding with dramatically increased 
numbers of more immature CD4-/CD8- (hereafter DN) cells (27-90%).  Consistent 
with this finding, a mouse with >80 % DN cells (mouse # 9045) had Tcrb alleles that 
were exclusively in the germline configuration, in contrast to control mice with 
normal (<10%) numbers of DN cells, and transgenic mice with less marked (<30%) 
increases in DN cells, who demonstrated polyclonal Tcrb gene rearrangements 
(Figure 2.2B).  As shown in Figure 2.2, the degree of impaired thymocyte 
differentiation was quite variable, indicating that the penetrance of this phenotype 




Figure 2.2.  Aberrant thymocyte differentiation in CALM-AF10 mice.  (A)  
Scatter plot of CD4 SP, CD8 SP, DP, and DN thymocytes.  Asterisk indicates 
statistical significance.  (B)  FACS plots from transgenic CALM-AF10 mice with 
normal, dramatically increased, and moderately increased numbers of DN 
thymocytes.  (C and D)  Southern blot analysis of Tcrb gene rearrangements using 
HindIII (C) or SstI (D).  Note polyclonal “smear” indicating polyclonal Trcb gene 
rearrangements in all lanes except 9045, which has a germline Tcrb gene 
configuration.  Mice 9045, 9050, 9111, 9112, and 9113 are transgenic; 9104 and 9109 




Since the mice developed primarily myeloid leukemias, the proportion of 
Mac1+/Gr1+ cells in the bone marrow were assayed to determine if there was an 
expansion of this population in clinically healthy mice.  Although there were 
increased numbers of Mac1+/Gr1+ cells in the CALM-AF10 transgenic mice (68.7 
±12.4 ) compared to wild-type littermates (54.2±6.8), this difference did not reach 
statistical significance (Figure 2.3).  The bone marrow from clinically healthy mice 
was evaluated to determine if there was expansion of LSK cells in bone marrow.  
Although there was a trend toward decreased LSK cells in CALM-AF10 mice (0.03± 





Figure 2.3A.  Mac1+/Gr1+ cells in bone marrow from CALM-AF10 mice.  Bone 
marrow FACS with Mac1 and Gr1.  Values represent the mean ± standard deviation 




Figure 2.3B.  LSK cells in bone marrow from CALM-AF10 mice.  Values 
represent the mean ± standard error of the mean from 3 wild-type (WT) and 3 
transgenic mice (TG).  
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CALM-AF10 mice develop acute leukemia. 
A cohort of transgenic offspring from four founder lines, C10, E6, D5, and D3 were 
observed for signs of disease for 18 months.  Of these founder lines, offspring from 
C10 and E6 developed clinical signs of diseases.  These mice were euthanized when 
signs and symptoms of leukemia, such as tachypnea, lethargy, ruffled fur, hunched 
posture, or lymphadenopathy were detected.  Additionally, mice that were found dead 
in their cage were necropsied when possible, and tissues harvested for histology.  As 
shown in Figure 2.4, 83% of the E6 transgenic mice and 70% of the C10 transgenic 
mice died by 18 months of age.  At least 9 of the 18 (50%) E6 mice and 8 of the 20 
(40%) C10 mice had clear signs of leukemia; six additional mice were found dead but 
were too autolytic to analyze.  Wild type mice that died during the study showed no 
evidence of leukemia.  In addition to the E6 and C10 offspring, one potential founder 
mouse, D5, developed a myeloid leukemia, and one of six offspring of a fourth 




Figure 2.4 Survival of CALM-AF10 mice.  Transgenic mice from line C10 (20) and 
E6 (18), along with 33 wild-type littermate controls were followed for 18 months. *, 
p<1x10-08 compared to littermate controls.   
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Leukemic mice typically had hunched posture, ruffled fur, and tachypnea.  Gross 
examination revealed marked splenomegaly and hepatomegaly, with prominent 
scattered white foci.  Histologically, the splenic red pulp was effaced by an expanding 
myeloid infiltrate accompanied by follicular atrophy. Peripheral blood examination 
showed circulating blasts with a high nuclear/cytoplasmic ratio, and the bone marrow 
was replaced by cells with a similar appearance (Figure 2.5).  In addition to the 
spleen, parenchymal organs such as liver, lung, kidney and brain were infiltrated with 
malignant cells.  Involved tissues were evaluated by immunohistochemical stains 
including the myeloid marker myeloperoxidase (MPO), the B-cell marker B220, the 
T-cell marker CD3, and the monocytic marker F4/80 (Table 2.2).  CBCs, FACS, and 
antigen-receptor gene rearrangements were also analyzed on a subset of leukemic 




Figure 2.5.  Myeloid leukemia in CALM-AF10 mouse 9001.  (A) Liver stained with 
H&E (left panel), MPO (middle panel), or B220 (right panel).   Original 
magnification x 200 (inset x 1000).  (B) Peripheral blood (left panel) or bone marrow 
cytospin (right panel) stained with May-Giemsa.  Note increased numbers of blasts in 
the peripheral blood and bone marrow. Original magnification x 1000. (C)  Bone 
marrow and spleen stained with the indicated antibodies, note the Mac-1+/B220+ 




As shown in Table 2.2, all 17 of the analyzable leukemias from the E6 and C10 lines 
were MPO positive, indicating that these mice had a myeloid leukemia.  Three 
additional mice (7004, 7092 and 7061) were found dead and showed leukemic 
infiltration of parenchymal organs including the liver, kidney, and spleen, but did not 
stain positively for MPO,  B220, CD3, or F4/80, raising the possibility that these mice 
had undifferentiated leukemias. However, given the phenotype of the other leukemic 
mice, it is likely that these were also myeloid leukemias, but that the MPO antibody 
was non-reactive because the tissues were partially autolytic.   Nine of these 
analyzable leukemias were also B220+, and FACS analysis performed on a subset of 
these mice showed a population of leukemic cells that were Mac1+/B220+ (Figure 
2.5).  Eight of the MPO+ leukemias were negative for B220; a subset of these were 
analyzed by FACS and shown to be Mac1+/B220- (Figure 2.6).  Two mice (7026 and 
2953) developed myelomonocytic leukemia as evidenced by both MPO and F4/80 
immunohistochemical staining; one of these also stained positive for CD3 (Figure 
2.7).   Taken together, these findings demonstrate that expression of a CALM-AF10 
fusion gene leads to an acute leukemia, with a long latency period and incomplete 




Figure 2.6.  Myeloid leukemia in a CALM-AF10 mouse 7160.  H&E  stained liver 
(A and insert), MPO labeled liver (B and insert) and B220 labeled liver (C and 
insert).  (D) Bone marrow cytospin.  Note increased numbers of blasts in the bone 
marrow and invasion of the liver with MPO+, B220- cells.  (E and F) Bone marrow 
showing Mac1+/B220- population.  Original magnification, x400 (A, B, and C); 




Figure 2.7.  Mixed lineage leukemia in CALM-AF10 mouse 2953.  MPO labeled  
liver (A and insert), CD3 labeled liver (B and insert), B220 labeled liver (C and 
insert) and F4/80 labeled liver  (D and insert).  (E) Bone marrow cytospin.  Original 















MPO B220 CD3 F4/80
E6
2968 15 Myeloid leukemia FD Invasion of  liver, kidney  +  -  -  - nd nd nd
7001 15 Myeloid leukemia FD, splenomegaly Invasion of liver, kidney, spleen  +  -  -  - nd nd nd
7004 5 Leukemia, NOS** FD; marked autolysis Invasion of bone marrow, liver, 
kidney, spleen
 -  -  -  - nd nd nd
7019 6 Myeloid leukemia FD, Invasion of bone marrow  +  -  -  -  -  -  -
7026 18 Myelomonocytic 
leukemia
ruffled fur, splenomegaly Invasion of liver and spleen  +  -  -  +  -  -  -
7087 14 Myeloid leukemia clinically healthy* Invasion of bone marrow  +  -  -  -  -  -  -
7088 17 Myeloid leukemia ocular discharge, ruffled fur, 
splenomegaly
Invasion of liver, kidney, spleen  +  -  -  -  -  -  -
7092 14 Leukemia, NOS** FD; mildly autolytic, 
hepatosplenomegaly 
Invasion of liver, kidney, spleen  -  -  -  -  +  -  +
7095 18 Myeloid leukemia FD; splenomegaly Invasion of liver, kidney, spleen, 
lung
 +  -  -  -  +  -  +
C10
2948 18 Myeloid leukemia FD Invasion of bone marrow, liver, 
kidney, lung
 +   -  -  -  -  - nd
2952 16 Myeloid leukemia Clinically healthy*  +  +  -  -  -  -  +




Invasion of bone marrow, lung, 
liver, kidney, spleen
 +  +  +  +  +  +  +
7060 17 Myeloid Leukemia FD Invasion of bone marrow  +   -  -  - nd nd nd
7081 14 Myeloid leukemia ruffled fur, splenomegaly Invasion of liver, lung, heart, 
kidney, pancreas, meninges, 
sinuses, spleen, bone marrow
 +   -  -  -  -  -  -
7083 9 Myeloid leukemia FD Invasion of bone marrow, lung, 
kidney
 +  -  -  - nd nd nd
7160 17 Myeloid leukemia hunched, ruffled fur, 
splenomegaly
Invasion of bone marrow, liver, 
lung, kidney, spleen
 +   -  -  -  -  -  +
7161 12 Leukemia, NOS** FD, splenomegaly Invasion of liver, kidney, spleen, 
lung
 -  -  -  -  -  -  +
9001 12 Myeloid leukemia Clinically healthy*, 
splenomegaly, 
lymphadenopathy
Invasaion of bone marrow, lung, 
liver, kidney, spleen lymph nodes
 +   +   -  -  - nd  +
9014 12 Myeolid leukemia Clinically healthy*, 
splenomegaly, 
lymphadenopathy
Invasion of bone marrow, lung, 
liver, kidney, spleen, lymph 
nodes
 +   +   -  -  - nd  -
9043 17 Myeolid leukemia Lethargy, ruffled fur, hunched 
posture, splenomegaly, 
lymphadenopathy
Invasion of bone marrow,  lung, 
liver, kidney, spleen, lymph 
nodes
 +   +   -  -  - nd  +
D3
7124 16 Myeloid leukemia ruffled fur, splenomegaly, 
lymphadenopathy
Invasion of liver, kidney, spleen, 
lung, bone marrow
 +   -  -  - nd nd nd
7098 14 Leukemia, NOS FD, autolysis, splenomegaly, 
lymphadenopathy
Invasion of liver, kidney, lung, 
spleen, bone marrow
nd nd nd nd nd nd nd
D5 5 Myeloid leukemia FD Invasion of liver and kidney  +   -  -  - nd nd nd
FD = Found Dead
NOS = Not otherwise specified
nd = not done
*Mouse euthanized due to CBC that showed an increased WBC, decreased HGB, and circulating blasts
**No clonal rearrangements identified, but genomic DNA was partially degraded
***9001, 9014, and 9043 were not part of the initial cohort shown in figure 2.1
****Mouse foud dead and partially autolytic.  IHC stains were negative  
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Immunophenoptype analysis  
It was observed that over half of the leukemic mice had either MPO+/B220+ cells 
within tumor infiltrates or were Mac1+/B220+ by FACS analysis.  The possibility 
was considered that these B220+ leukemic cells might have other properties of B 
cells, or that they may be more immature bi-phenotypic cells, suggesting that the 
leukemia had arisen in a common early progenitor cell with the potential to 
differentiate along the myeloid or lymphoid lineages.  Therefore, the leukemic 
Mac1+/B220+ population was assayed for the expression of either cKit (CD117), 
CD19, CD24, or IgM.  As shown in Figure 2.8, although the leukemias were 
consistently positive for Mac1, the B220 staining was quite variable (compare #9001 
and #7160, Figure 2.8).   The Mac1+/B220+ cells were typically positive for CD24, 
negative for IgM and CD19, but showed variable expression of CD117, ranging from 
23-72% positive cells.  Of note, some of the mice (such as 9001, see Figure 2.8A) had 
a distinct B220+ population that was distinct  from the Mac1+/B220+ population 
(gate R4 in Figure 2.8A).  This “bright” B220+ population was not present in bone 
marrow from the leukemic mouse (Figure 2.8B), and these cells were positive for 
CD19 and IgM (Figure 2.8C), leading us to conclude that the Mac1-/ B220 “bright” 
population in the spleen represented contaminating normal B cells.  The B220 “dim” 
population (gate R5 in Figure 2.8A) from these same mice was negative for both IgM 


















Figure 2.8.    Immunophenotype of CALM-AF10 leukemia.  (A) Cells isolated 
from leukemic CALM-AF10 mouse spleens were labeled with the indicated 
antibodies, and 10,000 total events scored.  Gates R3, R4, and R5 are shown. Cells in 
gate R3 were scored for CD19, CD117, IgM, and CD24.  (B)  Cells isolated from 
leukemic CALM-AF10 mouse bone marrow and labeled with the indicated 
antibodies, and 10, 000 total events scored.  Note the absence of a B220 “bright” 
population compared to spleen (R4) in A. (C) Cells from R4 in A indicating that the 
B220 ”bright” population was positive for the markers IgM and CD19. (D) Cells from 
R5 in A indicating that the B220 ”dim” population was negative for the markers IgM 
and CD19. (E) Summary of five CALM-AF10 mice with AML; the cells in gate R3 
were scored for CD19, CD117, IgM, and CD24.            
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Antigen receptor gene rearrangements 
Because some of the leukemic mice stained for either the B-cell marker B220 or the 
T-cell marker CD3 in addition to myeloid markers, the possibility was considered that 
some of these cells might have additional features of T or B lymphocytes, such as 
clonal  Tcrb, Tcrd, or Igh gene rearrangements.  As shown in Figure 2.9, some of 
these leukemias had clonal T-cell and/or immunoglobulin gene rearrangements; 
indeed one mouse (2953) had clonal rearrangements of Tcrb, Tcrd, and Igh.   In all, 3 
of 15 mice analyzed had clonal Tcrb gene rearrangements, 1 of 15 had a clonal Tcrd 




Figure 2.9.   Clonal Igh and TCR gene rearrangements.  (A) Southern blot of 
HindIII digested genomic DNA hybridized to a TCRB probe.  Mouse numbers are 
indicated, a number followed by S indicates the infiltrated tissue was spleen, L 
indicates the tissue was liver.  C is germline control tissue.  Asterisk indicates 
germline bands, arrows indicate clonal rearrangments.  Size standards are in kb.  (B)  
Same as in (A), except the probe was TCRD.  (C and D)  Same as (A) except the 




To develop a mouse model for CALM-AF10 leukemia, transgenic mice were 
generated that expressed the CALM-AF10 fusion gene under control of vav regulatory 
elements.  These mice developed acute leukemia, after an extended latent period 
(median 12 months), with an incomplete penetrance (40-50%).  In addition, a 
substantial number of mice were found dead in their cages and were unable to be 
characterized as leukemic or non-leukemic.  If all of these mice were leukemic, then 
the penetrance of the disease would rise to 70-83 %, depending on the founder line, 
over the 18-month study period.   
 
The acute leukemias that developed in CALM-AF10 transgenic mice were 
predominantly myeloid leukemias.  Unexpectedly, half of these myeloid leukemias 
stained positive for B220.  Although B220 is often regarded as a pan-B cell marker, 
B220 expression has also been detected on NK, dendritic, and myeloid progenitors 
(Rolink, ten Boekel et al. 1996; Balciunaite, Ceredig et al. 2005).  The Mac1+/B220+ 
leukemic cells were negative for more specific B-cell markers, such as CD19 and 
IgM, but were positive for CD24 and heterogeneous for CD117 expression.  Igh gene 
rearrangements were studied as an additional marker of B-cell differentiation; over 
half of the mice analyzed had clonal Igh rearrangements.  Interestingly, the B220 
staining did not correlate well with clonal Igh rearrangements, for instance, mouse # 
7160 was negative for B220 and had clonal Igh gene rearrangements, and mouse 
#9014 was positive for B220 and did not have clonal Igh gene rearrangements.  In 
addition, two mice had a myelomonocytic leukemia, one of which stained weakly 
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positive for CD3 and had both Tcrb and Tcrd rearrangements as well as an Igh 
rearrangement, and one mouse (#7160) had a myeloid leukemia with both Tcrb and 
Igh rearrangements.    
 
Although CALM-AF10 fusions have been identified in patients with myeloid, 
monocytic, and megakaryocytic leukemia (Dreyling, Schrader et al. 1998; Kumon, 
Kobayashi et al. 1999; Bohlander, Muschinsky et al. 2000; Carlson, Vignon et al. 
2000; Jones, Chaplin et al. 2001), it was somewhat surprising that the mice in this 
study developed myeloid leukemia, since CALM-AF10 leukemia in humans is 
primarily γ/δ pre-T LBL.  The observation that over half (8/15) of the leukemias 
assayed had clonal Tcr or Igh gene rearrangements, and over half (9/17) stained 
positively for B220 suggests that the transformed cell, at least in some cases, was 
derived from a progenitor capable of lymphoid as well as myeloid differentiation.  
This finding is consistent with reports that clonal TCRD and/or IGH gene 
rearrangements are often detected in patients with CALM-AF10 fusion and myeloid  
leukemia (Asnafi, Radford-Weiss et al. 2003; Deshpande, Cusan et al. 2006).  
Alternatively, the difference in leukemia phenotype may be due to use of the pan-
hematopoietic vav regulatory elements to direct CALM-AF10 expression.  In humans, 
it is possible that CALM-AF10 translocations occurs only rarely in myeloid 
progenitors, and more commonly in lymphoid progenitors.  However, in CALM-AF10 
mice, the vav transgene cassette directs expression to all hematopoietic cells (Adams, 
Harris et al. 1999; Ogilvy, Metcalf et al. 1999), including those in the myeloid 
compartment, allowing the CALM-AF10 fusion an opportunity to exert its oncogenic 
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potential in myeloid cells.   Finally, it is possible that a cis effect present in CALM-
AF10 pre-T LBL patients is missing in these transgenic mice, where the CALM-AF10 
construct has integrated randomly.   
 
CALM-AF10 mice were studied to determine if signs of impending leukemic 
transformation could be identified, however, CBCs from CALM-AF10 mice were not 
significantly different than those of their wild-type littermates (Table 2.1). However, 
careful analysis of CBC data revealed clues of an emerging leukemia.  This is evident 
in the case of mouse 2952 and 7087 (Table 2.1) that had a high white blood cell 
count, a high monocyte count and a low hemoglobin value.  Although these mice 
were clinically healthy, the CBC values suggest bone marrow failure as a result of 
infiltrating or expanding leukemic blasts cells.  Abnormalities of thymocyte 
differentiation were detected, as half (4/8) of the CALM-AF10 mice had reduced 
numbers of DP thymocytes and increased numbers of more immature DN 
thymocytes.  This impaired differentiation was reinforced by the observation that the 
mouse with the most dramatic increase in DN cells had not rearranged Tcrb. Since 
most of the CALM-AF10 mice developed myeloid leukemia, it was reasoned that 
clinically healthy mice might have an increase in the proportion of Mac1+/Gr1+ cells 
in the bone marrow.  However, although there was an increased proportion of 
Mac1+/Gr1+ cell in the bone marrow of the CALM-AF10 mice compared to wild-




Deshpande and colleagues reported the use of retroviral transduction and 
transplantation of primary bone marrow cells to show that expression of CALM-AF10 
in mouse bone marrow cells led to myeloid leukemia (Deshpande, Cusan et al. 2006).  
They noted that the myeloid leukemia cells were invariably B220+, with clonal Igh 
gene rearrangements, whereas in our study, only half of the myeloid leukemias were 
B220+, and only half had clonal Igh gene rearrangements. Similar to our findings, 
they found that the Mac1+/B220+ cells lacked specific B-cell markers such as CD19 
and IgM.  In contrast, the Mac1+/B220+ cells in their study lacked  CD117 
expression, whereas a variable (as high as 70%) percentage of Mac1+/B220+ 
leukemic cells from CALM-AF10 transgenic mice expressed CD117.   Intriguingly, 
they noted that transplantation of Mac1-/B220+ leukemic cells led to myeloid 
leukemia in recipient mice, and that the leukemic stem cell was likely to be a Mac1-
/B220+ cell.  In the current study, two distinct populations of Mac1-/B220+ cells 
were noted in some of the CALM-AF10 leukemic mice (see Figure 2.9).  The “bright” 
Mac1-/B220+ population (Fig. 2.8A, box R4) likely reflected contaminating normal 
B-cells, as these cells were positive for CD19 and IgM, and were only seen in 
leukemic spleen but not leukemic bone marrow, whereas the “dim” Mac1-/B220+ 
cells (Fig. 2.8A, box R5) were negative for CD19 and IgM, and may represent part of 
the leukemic clone, similar to the B220+ cells transplanted by Deshpande and 
colleagues (Deshpande, Cusan et al. 2006).  Given the absence of other B lineage 
markers on the “dim” B220 population, along with reports of B220 expression on 
progenitor cells (20, 21), it is important to consider the possibility that the “dim” 
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B220 expression detected in these leukemic samples does not indicate B-lineage 
commitment.  
 
In this chapter, it has been demonstrated that CALM-AF10 expression is strongly 
leukemogenic.  An emerging paradigm in leukemia biology predicts that most, if not 
all leukemic cells must undergo at least two collaborative events to produce a fully 
transformed cell.  One of these events leads to impaired differentiation, and the 
second event results in increased proliferation and/or decreased apoptosis.  The long 
latency period and incomplete penetrance of the leukemic phenotype supports the 
hypothesis that at least one additional event is required to fully transform these cells.  
The impaired differentiation that was observed in the thymus, along with previous 
reports that HOX gene overexpression is associated with impaired blood cell 
differentiation (Abramovich and Humphries 2005), is consistent with a model in 
which overexpression of the CALM-AF10 gene impairs differentiation of 
hematopoietic cells.   It seems likely that secondary, as yet undefined events which 
lead to increased proliferation and/or decreased apoptosis collaborate with the 
impaired differentiation caused by CALM-AF10 expression and result in a completely 




Chapter 3: Cloning and identification of potential collaborating 




The rare but recurring chromosomal translocation [t(10;11)(p13;q21)] results in a 
CALM-AF10 fusion that occurs in patients with both acute lymphoblastic leukemia 
(ALL) and acute myeloid leukemia (AML) (Asnafi, Radford-Weiss et al. 2003). It 
was shown in chapter two that CALM-AF10 transgenic mice develop AML with 
lymphoid features.  In this model, mice develop leukemia after a long latency period 
(median 12 months) with incomplete penetrance (40-50%).  These findings suggest 
that additional genetic events are needed to complement the CALM-AF10 transgene 
and complete the process of leukemic transformation.  Identification of these genetic 
events as potential collaborating events with CALM-AF10 could support an emerging 
paradigm, which predicts that most, if not all leukemic cells, must undergo at least 
two collaborative events to produce a fully transformed cell (Kelly and Gilliland 
2002). As a consequence of these cumulative genetic and epigenetic events, the 
affected cell has a clonal advantage of progressing to a fully malignant cell.   
 
Recent development of genetic screens to detect mutations seen in cancer have 
proven to be a useful tool for identifying important cancer associated genes and/or 
their associated pathways, as well as therapeutic targets.  Retroviral insertional 
mutagenesis (RIM) is a large-scale, whole-genome screening technique used to 
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identify genes, many of which have been associated with a variety of human diseases 
including hematopoietic malignancies (Li, Shen et al. 1999; Suzuki, Shen et al. 2002; 
Castilla, Perrat et al. 2004).  
 
To better understand this method, it is important to first review the retrovirus life 
cycle and its mechanisms that lead to celluar transformation (Wolff 2006; Slape 
2008).  In order for retrovirus infection to occur, the virus must first recognize and 
attach to the host cell membrane receptor that binds to viral specific receptors. 
Following attachment and entry, viral RNA undergoes reverse transcription into DNA 
using viral reverse transcriptase encoded by the viral gene pol.  Next, the newly 
formed linear viral DNA provirus integrates into the host’s genomic DNA through the 
use of integrase also encoded by the pol gene.  After stable integration of the proviral 
DNA, production of new viral RNA begins through the use of host transcriptional and 
mRNA processing machinery.  Finally, after RNA processing, new virions are 
released from the host cell through a process known as “budding”.  Following 
infection of the host cell, the retrovirus integrates into the genome and transforms 
cells through several different  mechanisms (Dudley 2003; Wolff 2006; Slape 2008).   
First, the provirus can integrate into an endogenous promotor that results in 
replacement of the host’s promotor with that of the viral promotor in the 3’ UTR.  
This mechanism commonly occurs in the c-myc locus. Secondly, activation of nearby 
genes occurs when the provirus inserts near a host gene and exerts its influence over a 
long distance using proviral enchancer elements.  A third mechanism of proviral 
activation occurs when the provirus inserts in either an exon or intron of a host gene.  
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This mechanism results in a truncated protein that gives rise to posttranscriptional 
dysregulation.  Finally, the provirus can insert within a tumor suppressor gene and 
result in  gene inactivation or truncation.  Transformation of the cell leads to a growth 
advantage and clonal expansion which results in tumor formation.  Integration of the 
provirus into the host’s DNA serves as a tag by which nearby genes can be identified 
through ligation-mediated PCR (Li, Shen et al. 1999; Mikkers, Allen et al. 2002).  
Identification of these candidate disease genes provides insightful clues into their role 
in cancer.  
  
One example of RIM involved the cloning of integrations from wild type mice.  
Recombinant inbred BXH2 mice are known to develop spontaneous retrovirally 
induced myeloid leukemia (Bedigian, Johnson et al. 1984) and the AKXD inbred 
mouse is susceptible to lymphoma development (Mucenski, Taylor et al. 1988; 
Gilbert, Neumann et al. 1993).  The cloning of these retroviral integration sites from 
mouse tumor DNA led to the discovery of important disease genes, namely Evi1 and 
Meis1 (Mucenski, Taylor et al. 1988).  In addition, Nf1, which is associated with the 
human disease Neurofibromatosis, type 1 and its associated myeloid disease, Juvenile 
myelomonocytic leukemia (JMML) (Korf 2000), was also identified using RIM 
(Buchberg, Bedigian et al. 1990; Cho, Shaughnessy et al. 1995).  In a larger study, Li 
and colleagues used RIM in BXH2 and AKXD recombinant inbred mice to induce 
myeloid, B-cell or T-cell leukemia (Li, Shen et al. 1999).  This was followed by large 




As shown above, RIM is a powerful tool by which to identify disease associated 
genes.  This tool has broader application when combined with “sensitized” or 
genetically engineered mice to interrogate collaborating genes and/or their associated 
pathways.  The first study to use RIM to identify collaborating genes in sensitized 
mice was conducted in Cbfb-MYH11 knock-in chimeric mice infected with the 
4070LTR retrovirus (Castilla, Perrat et al. 2004).  In that particular study, 54 
candidate genes and 4 CIS were identified; these included Plag1, and Plagl2, in 
addition to Runx2, Myb, H2T24, and D6Mm5e. Additional studies since then 
identified PRUNX1 and RUNX3 in a mouse model for CML/AML as a collaborating 
gene with BCR-ABL (Miething, Grundler et al. 2007).  Hoxa genes have been 
identified as target genes in an E2a-PBX1 mouse model for B-cell leukemia (Bijl, 
Sauvageau et al. 2005).  Lymphoma was induced using M-MuLV in p27-null mice, 
and as a consequence Myc was identified as a target as well (Hwang, Martins et al. 
2002).  In another study that involved NUP98HOXA9, retroviral insertional 
mutagenesis was used to identify a large set of cofactors including the transcription 
regulator, Meis1 (Iwasaki, Kuwata et al. 2005).  Finally, a more recent study using 
MOL4070LTR-infected NUP98HOXD13 transgenic mice identified candidate genes 
that included Meis1, Mn1, Gata2, and miR29a and b respectively (Slape, Hartung et 
al. 2007). 
 
In this chapter demonstrates that retroviral insertional mutagensis can be used in 
CALM-AF10 transgenic mice to accelerate the onset of acute leukemia and that genes 
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can be identified that potentially collaborate with the CALM-AF10 fusion gene in the 
leukemic transformation process.   
Materials and Methods 
Retroviral Infection 
The MOL4070LTR retrovirus was propagated at NCI-Frederick using a previously 
published protocol (Wolff, Koller et al. 2003). In order to propagate the 
MOL4070LTR retrovirus, 105 NIH3T3 cells chronically infected with virus were co 
cultured with an equal number of uninfected NIH3T3 cells in a 100-mm dish. The 
cells were propagated for 4 days in medium, which was replaced with fresh medium, 
and on day 5, the virus-containing medium was harvested, and titer was determined 
by the XC assay (Rowe, Pugh et al. 1970).  A total of 76 two day-old mouse pups of 
undetermined genotype were inoculated intravenously into the tail vein with 4 x 104 
infectious particles in 0.05 mL of culture medium.   
 
Two months after infection the genotype was determined on the mice as previously 
described.  In all, there were 45 CALM-AF10 transgenic mice and 31 FVB wild-type 
mice.  The mice were housed at NCI-Frederick and evaluated daily under the ACUC 
Guidelines for the Care and Use of Animals.   
 
Evaluation of leukemic mice 
Mice were observed daily for signs and symptoms of leukemia, which included 
ruffled fur, lethargy, labored breathing, lymphadenopathy, or abdominal swelling. 
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Mice that showed these signs of disease were humanely euthanized (as previously 
described) for postmortem evaluation.  Mice that were found dead were also dissected 
and tissues placed in formalin as described below, unless tissues were severely 
autolytic.  Whole blood was collected in EDTA for CBC analysis.  Bone marrow cells 
were viably harvested by flushing a dissected femur with Dulbellco’s medium with 
2% Fetal calf serum (Invitrogen), hereafter referred to as HF2.  Blood smears and 
cytospin preparations of bone marrow cells were stained with May-Grunwald-Giemsa 
and evaluated microscopically.  Sections of tissue including liver, spleen, kidney, 
lymph nodes, thymus, and sternum were fixed in 10% neutral buffered formalin 
(Sigma), paraffin embedded, sectioned at 5µm, and stained with H&E or incubated 
with antiperoxidase (MPO; DAKO), CD3 (DAKO), F4/80 (Caltag), and B220 
(CD45R; PharMingen).  The Bethesda proposals for classifying nonlymphoid 
hematopoietic and lymphoid neoplasms in mice were used as guides to evaluate 
tissues from CALM-AF10 mice (Kogan, Ward et al. 2002; Morse, Anver et al. 2002). 
Single-cell suspensions derived from spleen and/or bone marrow were incubated with 
FITC-conjugated antimouse CD8, B220, and Gr1; phycoerythrin-conjugated 
antimouse CD4 and Mac1 (PharMingen).  The stained cells were resuspended in HF2 
containing 1 µg/mL propidium iodide (Sigma) and analyzed by three-color flow 
cytometry to determine immunophenotype. 
 
Ligation mediated PCR 
One microgram of genomic DNA extracted from infiltrated spleens was digested with 
MseI (10 units) (New England Biolabs, Ipswich, MA)  or NlaIII (10 units) (New 
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England Biolabs) in a total reaction volume of 40 µl for 6 hr at 37°C followed by heat 
inactivation at 70°C for 10 min.  Digested fragments of DNA were ligated to linkers 
constructed by annealing the oligonucleotides 5'-
GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC-3' and 5'-Phos-
TAGTCCCTTAAGCGGAG-C3spacer-3' for MseI-digested DNA and 5'-
GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG-3' and 5'-Phos-
GTCCCTTAAGCGGAG-C3spacer-3' for NlaIII-digested DNA  (Integrated DNA 
Technologies) in a  20 µl volume using 2000 units T4 DNA ligase (New England 
Biolabs) and 10mM ATP  at 4°C overnight.  The ligation was heat inactivated at 
70°C for 10 minutes followed by a second digestion with EcoRV (20 units) (New 
England Biolabs) for one hr and heat inactivated at 70°C for 10 min.  Primary PCR 
was performed using 2 µl of DNA template, 10 µmol/L deoxynucleotide 
triphosphate, 0.4 µmol/L of primer complementary to the linkers        (5’-
GTAATACGACTCACTATAGGGCTCCG-3’ and the LTR of the MOL4070LTR 
retroviral sequence 5’-GCTAGCTTGCCAAACCTACAGGTGG-3’),  
and 2.5 units of Taq enzyme (Invitrogen). Following a 1:50 dilution of the primary 
PCR product a secondary PCR was performed using nested primer sets for the 
MOL4070LTR retroviral sequence, 5’-CCAAACCTACAGGTGGGGTCTTTC-3’, 
and complementary to the linkers, 5’-AGGGCTCCGCTTAAGGGAC-3’.  Both the 
primary and secondary PCR reactions were performed on a PTC-200 Petltier Thermal 
Cycler (MJ Research, Watertown, MA) at the following conditions: a denaturing step 
at 94˚C for 2 minutes followed by 25 cycles of amplification (each cycle included 
94˚C for 15s, 60˚C for 30s annealing, and extension at 72°C for 60s) and a final 
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extension at 72°C for 5 min.    PCR products were purified through PCR columns 
(Quiagen), ligated into pGEM-T Easy (Promega), and transformed into DH5α E. coli 
cells (Invitrogen).  Plasmid DNA was isolated from a total of 12-18 ampicillin-
resistant colonies using a QIAprep Spin Miniprep Kit (Qiagen) and digested with 
EcoRI.  Plasmids that were determined to contain unique insertions were sequenced 
using an SP6 primer with BigDye Terminator reagents and analyzed on a 3730 DNA 
Analyzer (Applied Biosystems) by Retrogen (Retrogen, Inc, San Diego, CA). 
Sequences were compared to the genomic build of February 2006 (National Center 
for Biotechnology Information Build 34) using the UCSC genome browser 
(http://genome.ucsc.edu/).  
 
Southern blot analysis for virus integrations or Igh, Nf1, and Zeb2 gene 
rearrangements. 
Genomic DNA from either transgenic or wild-type mouse spleens was isolated as 
previously described and digested with either EcoRI (10 units) (Ivitrogen) (for virus 
integrations or Igh gene rearrangements), XbaI (10 units) (Invitrogen) (for Igh gene 
rearrangements), StuI (10 units) (Invitrogen) (for Zeb2 gene rearrangements), BamHI 
(10 units) (Invitrogen) or HindIII (10 units) (Invitrogen) (Nf1 gene rearrangements) 
size fractionated on either 0.65% or 0.8% agarose gels and transferred to nylon 
membranes (Schliecher & Schuell) as previously described.  The nylon membrane 
was prehybridized using ULTRAhyb (Ambion) and hybridized to either 
MOL4070LTR envelope, murine Igh, murine Zeb2, or murine Nf1 probes.  The 
MOL4070LTR probe provided as provided as a gift by Dr. Chris Slape (Slape, 
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Hartung et al. 2007).  The murine Igh probe was provided as a gift by Dr. Michael 
Kuehl.   
 
The 803 bp Zeb2 probe was generated using primers 
5’TGAGCATCATTAAGCAGTGAGCAG3’ and 
5’AGTTGACTGTAGGTGGACTTGGTG3’. A second 613 bp Zeb2 probe was 
generated using primers 5’AAGCGTTTGCGGAGACTTCAAGG3’ and 
5’AAAGAAAGCCTGCCACCAAAGAGC3’.   The 527 bp Nf1 probe was generated 
using primers 5’TTCAAGGCCTTGAAAACGTTAAGC3’ and 
5CTATATGTTCAGCCAGCTTCCCAGG3’.  The following thermocycling 
conditions were used to generate the Zeb2 and Nf1 probes:  94°C for 3 min; 34 cycles 
of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for one min; followed by a 
terminal extension of 72°C for 10 min.  All probes were 32P-labeled by random 
priming as described in Chapter 2.  
 
Real Time PCR 
Total RNA (1 µg) from spleen and bone marrow was reverse transcribed using 1-µg 
total RNA with SuperscriptII reverse transcriptase and random hexamer primers 
(Invitrogen) in a volume of 20 µL. Real-time RT-PCR was performed on a 7500 Fast 
Real-time TaqMan PCR system (Applied Biosystems, Fosters City CA) using 
aliquots of 1 of first-strand cDNA as templates for mouse Zeb2b, and k-Ras, with 
Applied Biosystems primer and probe sets. The expression of the 18S ribosomal RNA 
was used as an endogenous control. All reactions were done in triplicate with 20 µl 
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PCR reactions using the Applied Biosystems default thermalcycling conditions (an 
activation step at  95˚C for 20 sec followed by 40 cycles of amplification at 95˚C for 
0.03 sec,  followed by an annealing and extension step at 60˚C for 30 sec). The –
∆∆CT
 mean and SE were calculated for each sample. Values for the transcript of 
interest were normalized to the 18S rRNA value and compared with the expression in 
wild-type bone marrow.  
 
 Real-time RT-PCR was performed for mouse Nf1, with specific primers 
5’TTCAAGGCCTTGAAAACGTTAAGC3’ and 
5’CTATATGTTCAGCCAGCTTCCCAGG3’ that spanned exons 36 and 37 of Nf1. 
SYBER Green was used as a detector and the expression of actin was used as an 
endogenous control. All reactions were done in triplicate with 20 µl PCR reactions 
using the Applied Biosystems default thermalcycling conditions (an activation step at  
50˚C for 1 min then 95ºC for 10 min followed by 40 cycles of amplification at 95˚C 
for 0.15 sec,  followed by an annealing and extension step at 60˚C for 1 min).  The –
∆∆CT
 mean and SE were calculated for each sample. Values for the transcript of 
interest were normalized to the actin value and compared with the expression in wild-
type bone marrow. 
Reverse transcription-PCR 
In order to determine if there was an Mn1-retrovirus fusion in mice with an Mn1 
retrovirus integration, first-strand cDNA templates were generated as previously 
described.  A forward Mn1 primer (5’TACCTTCAACCCCTGACAGCTATGG-3’) 
and a reverse Moloney pol primer (5’CTCCCGATCTCCATTGGTTACCTC3’) were 
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used to amplify the fusion product.  The thermocycling conditions were as follows:  a 
denaturing step at  94˚C for 3 min followed by 35 cycles of amplification (each cycle 
included 94˚C for 30 s,  60˚C for 30 s annealing, and extension at 72°C for 90s) and a 
final extension at 72°C for 5 min.    PCR products were evaluated using agarorse gel 
electrophoresis.  
 
An EST is located 250 kb 5’ of Zeb2 and is ~75 kb from the region that contains most 
of the viral integrations detected by PCR (see map).  In order to evaluate whether or 
not this was expressed in samples that contained Zeb2 insertions, RT-PCR (as 
previously described) was performed using the following primer pairs (5’GCA GCC 
GGC GCT CAC CTT CC3’ and 5’AAT GTT GTA AGA AAT GTG CC3’;   5’CTC 
ACC TTC CCT TAA ATC C3’ and 5’AAT CGT TGT GGA CAA ATT AAG C3’)  
The thermocycling conditions were as follows:  a denaturing step at  94˚C for 3 
minutes followed by 35 cycles of amplification (each cycle included 94˚C for 30 s,  
60˚C for 30 s annealing, and extension at 72°C for 90s) and a final extension at 72°C 
for 5 min. 
 
Results 
MOL4070LTR infection accelerates acute leukemia in CALM-AF10 transgenic mice 
In the previous chapter it was observed that CALM-AF10 transgenic mice developed 
leukemia after a long latency period with incomplete penetrance.  In order to 
accelerate the leukemia mice were infected with MOL4070LTR retrovirus.  The 
MOL4070LTR is a recombinant retrovirus derived from the Moloney murine 
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leukemia virus (Mo-MuLV) and the 4070A virus.  The majority of the U3 region of 
the long terminal repeat region from Mo-MuLV has been replaced with those from 
the 4070A virus.  This NB tropic retrovirus is reported to cause myeloid leukemia in 
approximately half of the mice infected, in contrast to Mo-MuLV, which is associated 
with a predominately lymphoid phenotype in newborn mice. A previous study 
showed that infection of wild-type FVB mice with MOL4070LTR retrovirus results 
in leukemia after a mean latency of 31.7 weeks (Wolff, Koller et al. 2003).  In this 
current study, 45 CALM-AF10 and 31 wild type littermate control mice were infected 
on day two of life and monitored them for signs of leukemic diseases.  Complete 
blood counts were obtained from a subset of 24 CALM-AF10 mice at the time they 
developed disease; results are shown in table 3.1.  Acute leukemia developed more 
rapidly in CALM-AF10 infected mice than in either the FVB wild type mice infected 
with retrovirus (P < 0.004) or CALM-AF10 mice not infected with retrovirus (P < 
0.037); Figure 3.1  The mean latency of disease onset in CALM-AF10 infected mice 
was 5.5 months.  Transgenic and wild-type mice that developed leukemia were 
reported as pale, tachypneic, listless, hunched, and often had distended abdomens.   
Gross examination of the internal organs of these mice revealed marked 
splenomegaly, lymphadenopathy, hepatomegaly, pale kidneys, and invariably, 
enlarged thymuses.  In three cases, mice were reported as being found dead (FD) in 




Figure 3.1.  MOL4070LTR infection accelerates leukemic transformation in 
CALM-AF10 mice.  Survival of MOL4070LTR-infected CALM-AF10 mice (■ 
n=58), MOL4070LTR-infected wild-type (○ n=30), and noninfected CALM-AF10 




























Table 3.1. Summary of Clinical and Immunphenotypic Findings in Retroviral-Infected CALM-AF10  Mice with Leukemia
CBC IHC
†
Flow Cytometry Gene Insertion


















M/B Igh Zeb2 Nf1
2* 4 Biclonal FD, splenomegaly, 
enlarged thymus, 
mottled liver
np np np Invasion of thymus, 
spleen, bone marrow, 
liver, kidney
 -  -  +  -  - np np np np np np np
17 6 B-ALL Labored breathing, 
pale, dist abd, 
splenomegaly, 
mottled liver
> 200* 7 465 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 28.52 66.99 6.98 81.57 y y y





159.04 10.2 450 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 1.23 9.16 2.42 9.48 y y n
23 4.5 B-ALL Splenomegaly, 
lymphadenopathy
44.78 10.1 1589 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 4.26 24.26 5.69 25.88 y y y
25 6 B-ALL Pale, dist abd, 
splenomegaly, 
lymphadenopathy
182.78 11.9 456 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - np np np np y y n




38.22 6.6 216 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 7.13 51.66 4.25 35.14 y y y




5.06 6 228 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 22.79 29.11 16.67 26.65 y n n
14 5 B-ALL Pale, dist abd, 
splenomegaly, 
lymphadenopathy
6.5 14.2 126 Invasion of spleen, bone 
marrow, liver
 -  +  -  -  - 22.22 15.58 11.35 15.88 y n n




> 200 6.98 95 Invasion of spleen, bone 
marrow, liver, kidney






Table 1. Summary of Clinical and Immunphenotypic Findings in Retroviral-Infected CALM-AF10  Mice with Leukemia (Cont.)
CBC IHC
†
Flow Cytometry Gene Insertion














M/B Igh Zeb2 Nf1
42 5 Biclonal Splenomegaly, 
lymphadenpathy, 
enlarged thymus
125.86 8.9 540 Invasion of thymus, 
spleen, bone marrow, 
liver, kidney
 -  -  +  -  - 16.24 12.34 14.17 20.21 y n y
80 4 Biphen. hind limb paralysis, 
splenomegaly
23.36 7 600 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  +  - 57.85 4.98 27.53 14.96 y y n




36.48 5.4 288 Invasion  of spleen, bone 
marrow, liver, kidney
 +/-  +/-  -  -  - 44.78 22.4 25.31 16.69 n n n





44.78 11.3 1235 Invasion of spleen, bone 
marrow, liver, kidney
 -  -  +  -  - 44.9 44.95 35.65 40.66 n n n
13 5 ANLL Pale, dist abd, 
splenomgegaly, 
lymphadenopathy,
87.46 5 966 Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - 84.62 3.74 49.06 1.99 n n y






21.38 1.8 184 Invasion of spleen, bone 
marrow, liver, kidney
 +/-  +/-  -  -  - 82.61 10.44 9.58 10.57 n n n




16.72 5.4 429 Invasion of spleen, bone 
marrow, liver
 -  -  -  -  - 59 14 n n n




126.46 7.3 332 Invasion of thymus, 
spleen, bone marrow, 
liver, kidney
 +  -  -  -  - 72.59 2.22 48.46 6.98 n n y
35 5 ANLL Splenomegaly, 
lymphadenopathy
12.02 5.82 979 Invasion of spleen, bone 
marrow, liver, kidney






Table 3.1. Summary of Clinical and Immunphenotypic Findings in Retroviral-Infected CALM-AF10  Mice with Leukemia (Cont.)
CBC IHC
†
Flow Cytometry Gene Insertion














M/B Igh Zeb2 Nf1





16.78 8.2 395 Invasion of spleen, liver,  
kidney
 +  -  -  +  - 46.12 19.95 13.76 20.95 n y y




np np np Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - np np np np y y n
28 3 ANLL Pale, labored 
breathing, dist abd, 
splenomegaly, 
hepatomegaly
97.78 4.6 757 Invasion of spleen, liver  -  -  -  -  - np np np np n n n
32* 3 B-ALL FD Mild to moderate 
splenomegaly
np np np Invasion of liver  -  +  -  -  - np np np np np np np




73.66 5.2 800 Invasion of spleen, bone 
marrow, liver
 -  +  -  -  - 31.86 22.34 1.02 np n n n




164.58 6.5 616 Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - 15.23 43.56 3.57 15.47 n n n




114.64 5.2 674 Invasion of spleen, bone 
marrow, liver, kidney
 -  -  -  -  - 9.07 36.31 0.07 np n n n





105.32 5.2 771 Invasion of spleen, liver, 
kidney
 +  -  -  -  - np np np np n n n






Table 3.1. Summary of Clinical and Immunphenotypic Findings in Retroviral-Infected CALM-AF10  Mice with Leukemia (Cont.)
CBC IHC
†
Flow Cytometry Gene Insertion














M/B Igh Zeb2 Nf1
52* 4 NL FD dried blood, 
saliva around muzzle
np np np autolytic  -  -  -  -  - np np np np n n n 






np np np Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - np np np np y y n 




np np np Invasion of spleen, bone 
marrow, liver, kidney
 -  +  -  -  - np np np np y y y
47 5 ANLL Pale, labored 
breathing, dist abd
np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np n n n
102 4 ANLL Pale, labored 
breathing, dist abd
np np np Invasion of spleen, bone 
marrow, liver
 -  -  -  -  - np np np np n n n
18 6 Biclonal Pale, splenomegaly, 
lymphadenopathy
np np np Invasion of spleen, bone 
marrow, liver
 -  -  +  -  - np np np np y n n
76 5 ANLL Pale, labored 
breathing, dist abd
np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np n y n




np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np y y n
9 7 Biphen. Pale, labored 
breathing
np np np Invasion of spleen, bone 
marrow, liver
 -  -  +  -  - np np np np y n n
72 5 Biphen. Ruffled fur, pale, 
labored breathing
np np np Invasion of spleen, bone 
marrow, liver
 -  -  +  -  - np np np np y n n
20 6 ANLL Pale, dist abd np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np y n n
66 5 T-ALL Pale, labored 
breathing, dist abd
np np np Invasion of spleen, bone 
marrow, liver
 -  -  -  -  + np np np np y n n
70 6 Biphen Splenomegaly, 
lymphadenopathy
np np np Invasion of spleen, bone 
marrow, liver







Table 3.1. Summary of Clinical and Immunphenotypic Findings in Retroviral-Infected CALM-AF10  Mice with Leukemia (Cont.)
CBC IHC
†
Flow Cytometry Gene Insertion














M/B Igh Zeb2 Nf1
51 4 Biphen Pale, dist abd, 
labored breathing
np np np Invasion of spleen, bone 
marrow, liver
 -  -  +  -  - np np np np y y n




np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np n n y




np np np Invasion of spleen, bone 
marrow, liver
 +  -  -  -  - np np np np n n y
69 4 ANLL Pale, labored 
breathing
np np np Invasion of spleen, bone 
marrow, liver
 +/-  +/-  -  -  - np np np np y n n 
67 5 ANLL Pale, labored 
breathing, dist abd
np np np Invasion of spleen, bone 
marrow, liver, kidney
 +  -  -  -  - np np np np y n n 
CBC, complete blood count; IHC, immunohistochemistry; WBC, white blood cell; NT, neutrophils; LM, lymphocytes; MO, monocytes
BM, bone marrow; Sp, spleen; B-ALL, B-cell acute lymphoid leukemia;  ANLL, acute non-lymphoid leukemia; Hgb, hemoglobin; Plt, platlets; MPO, myeloperoxidase
M/G, Mac1/Gr1 double positive; M/B, Mac1/B220 double positive; Igh , Immunoglobulin heavy chain; y, yes; n, no; np, not performed
FD, Found dead
†IHC results based on degree of antibody labeling blasts in infiltrated liver, kidney, speen, and bone marrow







CALM-AF10 develop B-ALL and ANLL 
As shown in Table 3.1 mice developed either acute lymphoid (B-cell or T-cell), 
nonlymphoid (Myeloid), or biphenotypic (Myeloid and B-cell) leukemia as 
determined by histologic and immunophenotypic analysis.  Of the three mice that 
were found dead in their cages, only one mouse did not develop leukemia (mouse 52).  
Histologically the splenic red pulp was expanded and effaced by a leukemic infiltrate 
with simultaneous loss of the white pulp.  There was marked perivascular 
accumulation and sinusoidal expansion by leukemic cells in the liver and kidney.  
Bone marrow elements were effaced by the expansive leukemic infiltrate.   Peripheral 
blood examination revealed circulating lymphoid or myeloid blasts that often had 
large nuclear to cytoplasmic rations and open chromatin.  Immunohistochemistry for 
the markers MPO, CD45 (B220), CD3, and F4/80 was also performed.  The markers 
Mac1, Gr1, and B220 were used for flow cytometry. The Bethesda proposals 
described above were used as guides to classify the leukemias.  In addition to the 
classification scheme used in the Bethesda proposal, biclonal and biphenotypic 
diagnoses were also applied to a subset of the leukemias.  In this study, mice 
developed leukemias that represented a broader spectrum of phenotypes with respect 
to myeloid disease compared to mice that developed leukemia in Chapter 2.  The 
predominant phenotype seen in mice in Chapter 2 was either AML or AML with B-
lymphoid features.  That is contrast to mice in this study that were infected with 
MOL4070LTR retrovirus that developed both well differentiated AML and poorly 
differentiated AML (these tumors did not label for the surface antigens MPO, F4/80,  
B220, and CD3).  Because of this spectrum of myeloid disease, the term acute non-
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lymphoid leukemia (ANLL) was used rather than AML.  A subset of mice also 
developed AML with features of myeloid and/or B-lymphoid disease.  These 
leukemias may represent either biphenotypic or biclonal leukemias.  Biclonal 
leukemias represent two distinct clones with cell populations that express distinct 
surface antigens that are not expressed on cells from the other clone.  This is in 
contrast to biphenotypic leukemias that are thought to arise in a multipotent 
progenitor cell capable of differentiating simultaneously into both myeloid and 
lymphoid lineages (Matutes, Morilla et al. 1997).  The most common outcome are 
blasts cells that coexpress myeloid and B-cell surface antigens (Matutes, Morilla et al. 
1997).   
 
In this study, there was a large percentage of ANLL (45%) (Figure 3.2 and 3.3) and 
B-ALL (29%) (Figure 3.2 and 3.4) and biphenotypic (13%) or biclonal leukemias 
(9%) (Figure 3.2 and 3.5 and 3.6), and much smaller percentage of T-ALL (2%) 
(Figure 3.2 and 3.7) compared to the leukemias that developed in wild type mice. 
Figure 3.8 depicts the morphology of acute lymphoid leukemia in a CALM-AF10 
mouse infected with MOL4070LTR.  This is in contrast to an acute nonlymphoid 
(myeloid) leukemia shown in Figures 3.9 and 3.10. These mice were evaluated for 
Igh gene rearrangements and 23 of 43 mice had Igh rearrangements as shown in 
Figure 3.11.  Taken together, these findings demonstrated that CALM-AF10 mice 
infected with retrovirus developed a broader spectrum of leukemias with respect to 
immunophenotype than did CALM-AF10 mice not infected with retrovirus that 





Figure 3.2. Distribution of leukemia by phenotype in CALM-AF10 (A) and FVB 
wild-type control mice (B) infected with MOL4070LTR retrovirus. Note the 
predominance of B-cell and myeloid (ANLL) tumors, as well as the biphenotypic 
tumors, in the CALM-AF10 mice compared to the wild-type control mice.  *NOS is 
not otherwise specified.  This represents mouse 71 that developed leukemia; however 




Figure 3.3.  Acute myeloid leukemia in CALM-AF10 mouse 13 infected with 
MOL4070LTR.  H&E stained liver (A and insert), MPO labeled liver (B and insert) 
and B220 labeled liver (C and insert).  Note the invasion of liver with MPO+, B220- 





Figure 3.4.  Acute lymphoid leukemia (B-ALL) in CALM-AF10 mouse 17 infected 
with MOL4070LTR.  H&E stained liver (A and insert), B220 labeled liver (B and 
insert) and MPO labeled liver (C and insert). Note the invasion of liver with B220+, 





Figure 3.5.  Acute myeloid leukemia (Biphenotypic) in CALM-AF10 mouse 80 
infected with MOL4070LTR.  H&E stained liver (A and insert), F4/80 labeled liver 
(B and insert), B220 labeled liver, (C and insert), and MPO labeled liver (D and 





Figure 3.6.  Acute myeloid leukemia (Biclonal in CALM-AF10 mouse 42 infected 
with MOL4070LTR.  H&E stained liver (A and insert), MPO labeled liver, (B and 
insert), B220 labeled liver (C and insert).  Note the mutually exclusive areas of 
immunoreactivity in the perivascular infiltrates.  Original magnification, x200 (A, B, 





Figure 3.7.  Acute lymphoid leukemia (T-ALL) in CALM-AF10 mouse 66 infected 
with MOL4070LTR.  H&E stained liver (A and insert), CD3 labeled liver (B and 
insert), B220 labeled liver, (C and insert), and MPO labeled liver (D and insert). 





Figure 3.8.  Acute lymphoid leukemia in CALM-AF10 mouse 17 infected with 
MOL4070LTR.  H&E stained liver (A and insert), spleen (B and insert), bone 
marrow (C and insert).  Note the perivascular accumulation of lymphoblasts in the 
liver and the marked expansion by lymphoblasts in spleen and bone marrow.  





Figure 3.9.  Acute myeloid leukemia in CALM-AF10 mouse 13 infected with 
MOL4070LTR.  H&E stained liver (A and insert), spleen (B and insert), bone 
marrow (C and insert).  Note the perivascular accumulation of myeloblasts in the 
liver and the marked expansion by blasts in spleen and bone marrow.  Original 





Figure 3.10.  Acute myeloid leukemia in CALM-AF10 mouse 80 infected with 
MOL4070LTR.  H&E stained liver (A and insert), spleen (B and insert), bone 
marrow cytospin (C and insert).  Note the perivascular accumulation of myeloblasts 
in the liver and infiltration into hepatic sinusoids, and the marked expansion by blasts 






Figure 3.11.  Clonal Igh gene rearrangements.  Southern blot of EcoRI digested 
genomic DNA from spleen hybridized to an IgH probe.  Mouse numbers are 
indicated.  C is germline control tissue. Asterisk denotes germ-line band. Size 





Tumors are either clonal or oligoclonal. 
Leukemic samples from the infected CALM-AF10 mice were evaluated using 
Southern blot analysis to determine the clonality of tumors (Figure 3.11). There were 
between one and ten integrations per tumors suggesting the tumors were clonal to 
oligoclonal. These findings in our study suggest a number of possibilities.  First, a 
single dominant band (such as mouse #5 in Figure 3.12) suggests that the tumor 
developed from a single integration event and is therefore clonal.  In the case of 
mouse 9 (Figure 3.12), there are five unique bands, all of equal intensity suggesting 
that the tumor was comprised of one major clone with five insertions.  Mouse 13 
developed a tumor that contains two prominent bands and two-three bands that are 
less intense; this tumor is likely oligoclonal, comprised of a major clone (represented 
by the two intense bands) and a minor clone (represented by the three fainter bands).    
There were between one and ten integrations in WT mice.  Interestingly, one CALM-
AF10 mouse and three WT mice did not have detectable integrations suggesting that 
these mice did not get infected with the retrovirus; there was no evidence of leukemia 




Figure 3.12.  Retroviral integration analysis.  Southern blot analysis of EcoRI-
digested genomic DNA from spleens of transgenic mice infected with MOL4070LTR 
hybridized to probe that targets the env viral genome.  Mouse identifications are 
indicated; C, germ-line control tissue; Size standards are given in kilobases.  Note the 




Identification of unique retrovirus insertions 
Ligation-mediated PCR was attempted on all 42 mice.  A total of 255 unique 
insertions were identified in 39 mice (See Appendix V).  Seventeen common 
insertion sites (CIS); defined as an insertions within 100 kb of a nearby gene and 
occurring in two or more mice were identified; Table 3.2.  Nonrecurrent integrations 
were also identified that are of interest due to the function of nearby genes or because 
they were previously identified in other mutagenesis screens.  
 
Inbred strains of mice are known to harbor proviral DNA derived from retroviral 
infections.  Because of this biological phenomenon, the possibility was considered 
that the primers used in the linker-mediated PCR assay were not specific to the 
MOL4070LTR and therefore could amplify non-MOL4070LTR provirus.  As shown 
in Figure 3.13, the primers used in the PCR assay were indeed specific for 






Figure 3.13.  PCR to validate LTR primer specificity. PCR showing that primers 
used to amplify the LTR of MOL4070LTR retrovirus were specific.  1 is FVB wild-
type mouse spleen, 2 is FVB wild-type mouse spleen, 3 is CALM-AF10 mouse with 
tumor, 4 is CALM-AF10 mouse with tumor, 5 is CALM-AF10 mouse infected with 
MOL4070LTR, 6 is CALM-AF10 mouse infected with MOL4070LTR.  Note bands 
in lanes 5 and 6 are from a mouse infected with MOL4070LTR.  
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5, 17,  21, 27, 36, 98 2 13
Mn1 6 25, 38, 39, 46, 67, 80 5 8
Evi1 5 6, 14, 29, 31, 36 3 7
Nf1 4 (7)  17, 23, 36, 98 11 28
Ift57 3 14, 36, 69 16 0
Mllt3 3 14, 47, 69 4 0Chchd7 / 
Plag1 2 21, 42 4 8
Mpl 2 10, 80 4 0
Prkcz 2 17, 31 4 0
Foxp1 2 35, 88 6 0
Kras 2 20, 27 6 7
AK212323 2 25, 23 7 0Copb1 / 
Rras2 2 21, 39 7 32
Phb 2 69, 96 11 0
Erg 2 6, 69 16 3
Vav1 2 15, 74 17 0
Gata1 2 14, 47 X 0
a
Common integration sites determined by ligation-mediated PCR and sequence analysis
c
Numbers in parenthesis represent number of additional mice with an integrations as identified by 
Southern blot analysis 
Table 3.2.  Common integration sites in CALM-AF10  mice infected with MOL4070LTR retrovirus
a
b




Zeb2 (Zfhxx1b or Sip1) is a potential collaborating gene with CALM-AF10 
Zeb2 was identified by PCR in six mice.  This gene has been reported 13 times in the 
RTCGD.  Five of the Zeb2 integrations determined by PCR occurred within a 12 kb 
cluster 164 kb 5’ of Zeb2; the sixth integration was 106 kb 5’ of Zeb2.  All six 
integrations were determined to be in the reverse orientation of Zeb2 transcription; 
Figure 3.14.  Southern blot analysis was performed using a probe that targeted a 9.5 
kb region within the clustered region on all 45 CALM-AF10 mice to screen for Zeb2 
rearrangements.  Four out of six mice that had a Zeb2 insertion by PCR (17, 21, 23, 
31, 36, and 98) also had a gene rearrangement as determined by Southern blot 
analysis (17, 23, 31, and 98); mouse 21 and 36 were not confirmed by Southern blot 
analysis because their integration event was outside the range of the Southern blot 
probe. Five additional mice (5, 27, 51, 70, and 80) were also detected with a gene 
rearrangement for Zeb2.  Since the germ-line and rearranged bands were of 
approximate equal intensity, it is likely that the Zeb2 insertion represented a major 
clone in each tumor, except mouse 98; Figure 3.15.   There was a second cluster of 
viral integrations from the RTCGD associated with the first exon of Zeb2, it was 
hypothesized that there might also be additional integrations in the CALM-AF10 mice 
not previously identified by the initial Southern blot analysis.  A second Southern blot 
analysis was performed using a probe that covered a 16.7 kb region of the first exon 
of Zeb2 and identified two additional mice (25 and 26) with gene rearrangements; 




An EST was also observed 200kb from Zeb2 and ~75 kb from the cluster of 
integrations located 160kb from Zeb2.  It was hypothesized that because the viral 
integrations were in close proximity to the EST, they could be altering the expression 
of the EST. The expression of the EST was assayed using RTPCR and determined 
that its expression was negative. Next, we assayed the expression of Zeb2 was 
assayed in leukemic spleens by real time PCR and showed that tumors as a 3-10 fold 
higher level of Zeb2 expression than did wild-type bone marrow (Figure 3.16) All of 
the mice with Zeb2 insertions developed either B-cell or biphenotypic leukemia 
except for mouse 36; all of the mice in this sub cohort had an Igh gene rearrangement 




Figure 3.14.  Gene map of Zeb2 viral insertion events.  Viral insertions identified 
by PCR in CALM-AF10 mice are indicated by black arrows.  Insertions events 
reported in the RTCGD are indicated by red arrows. The vertical red arrows represent 
insertion events for which the integration orientation was not reported in the RTCGD.   
Black circles indicate insertion events identified by Southern blot analysis.  Probes 







Figure 3.15.  Zeb2 gene rearrangements.  Southern blot of StuI-digested genomic 
DNA extracted from leukemia-infiltrated spleen and hybridized with Zeb2 probe A 
(upper blot) or Zeb2 probe B (lower blot). Mouse numbers are indicated; C is germ-
line control tissue.  Asterisks, germ-line bands.  Size standards are given in kilobases.  
Note the equal intensity of germline and rearranged bands indicating that the 













Figure 3.16. Zeb2 expression in CALM-AF10 mice infected with MOL4070LTR.  
RNA transcript analysis by real time RT-PCR of leukemia –infiltrated spleen  from 
transgenic mice with Zeb2 retrovirus insertions (mice 5, 17, 21, 23, 27, 36, and 98), in 
mice without a known  Zeb2 insertion (28, 38, and 46), and in addition to wild-type 




Figure 3.17. Expression of EST associated with Zeb2.  RT-PCR analysis of 
leukemic spleen from CALM-AF10 mice infected with MOL4070LTR that had viral 
integrations associated with Zeb2.  Numbers represent individual mouse IDs, C is 
deionized  H20 control.  Primer pairs are shown above the brackets.  Mouse β-actin 
primers were used as RNA quality control for each sample shown in lower panel 
which represents 25 cycles of DNA replication. 
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Nf1 is a potential collaborating gene with CALM-AF10 
Retroviral integrations were identified within intron 36 of the tumor suppressor gene 
Nf1 in four mice by ligation-mediated PCR (17, 23, 36, and 98); Figure 3.18.  The 
retroviral integrations determined by PCR were confirmed by Southern blot analysis 
Additional integrations were identified by Southern blot analysis in an additional 
seven mice (13, 26, 31, 40, 42, 44, and 96).  Of note, there was loss of the germ line 
allele in mice 17 and 23.  Next, the tumors from these mice were evaluated using real 
time RTPCR and showed that there was a decreased expression in samples 17, 23, 26, 







Figure 3.18.  Nf1 integration analysis. Nf1 gene rearrangements (upper panel).  
Southern blot of BamHI-digested genomic DNA extracted from leukemia-infiltrated 
spleen and hybridized with an Nf1 probe (see map)  Mouse numbers are indicated; C 
is germ-line control tissue.  Asterisks, germ-line bands.  Two germ-line bands are 
seen as the probe is split by a BamH1 site.  Size standards are given in kilobases.  
Note the loss of germ-line allele in # 17 and 23.  Gene map of Nf1 viral insertion 
events (lower panel).  Viral insertions identified by PCR in CALM-AF10 mice are 
indicated by black arrows.  The red arrows indicate the position of primers used in the 
real time PCR gene expression assay.  The red box represents the probe used for the 
Southern blot assay. 
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Figure 3.19.  Nf1 expression in CALM-AF10 mice infected with MOL4070LTR.  
RNA transcript analysis by real time RT-PCR of leukemia–infiltrated spleen from 
transgenic mice with Nf1 retrovirus insertions (mice 17, 23, 26, 98, 13, 31, 36, 40, 42, 
and 96); in mice without a known Nf1 insertion (28, 38, and 46); and in wild-type 













5 7 B-ALL yes Zeb2
21 5 B-ALL yes Zeb2
27 4 B-ALL yes Zeb2
80 4 Biphenotypic yes Zeb2
51 4 Biphenotypic yes Zeb2
25 6 B-ALL yes Zeb2
17 6 B-ALL yes Zeb2, Nf1
36 5 ANLL no Zeb2, Nf1
23 4 B-ALL yes Zeb2, Nf1
98 4 B-ALL yes Zeb2, Nf1
26 5 B-ALL yes Zeb2, Nf1
31 5 ANLL no Nf1
13 5 ANLL no Nf1
40 6 ANLL no Nf1
42 6 Biphenotypic yes Nf1
44 6 ANLL no Nf1






Mn1 forms a fusion transcript with MOL4070LTR 
Mn1 was identified in six mice (25, 38, 39, 46, and 80). Three insertions were 
identified in the same intron of Mn1, all in the forward direction.  MN1-TEL fusions 
have been identified in a subset of human leukemias.  The three insertions that were 
detected occurred in the same breakpoint region as MN1TEL fusions, and in the same 
intron and orientation of integrations identified in NUP98HOXD13 mice infected 
with MOL4070LTR (Slape, Hartung et al. 2007).  RT-PCR analysis revealed an Mn1-
retroviral fusion transcript in all three mice with the intronic insertion.  Sequence 
analysis showed that the Mn1 exon contained a cryptic splice acceptor that spliced to 
the viral pol gene which resulted in an in-frame Mn1-pol fusion; Figure 3.22.  This 
fusion transcript encodes a protein that fuses the Mn1 N-terminus to the final 115 
amino acid residues of the integrase peptide which is encoded by the viral pol gene 






Figure 3.20  RT-PCR analysis of CALM-AF10 mice with Mn1 integrations.  
Samples 38, 39, and 46, all had integrations that occurred within the first intron; 
samples 25 and 80 had integrations that occurred in the opposite orientation as Mn1 
transcription and occurred after outside of 3’ of intron one; PC is a positive control 
sample.  Samples 38, 39, and 49 were sequenced and shown to form an Mn1-viral 
fusion as indicated. 
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Kras is a CIS in CALM-AF10 mice and has a point mutation 
Kras was identified as a CIS in two mice (20 and 27).  Point mutations have 
previously been reported in KRAS from patients with AML, among other 
malignancies (Reuter, Morgan et al. 2000; Bacher, Kern et al. 2005; Renneville, 
Roumier et al. 2008).  In one of the samples with a Kras retroviral integration (27) 
there was a single point mutation that resulted in a glycine to aspartic acid amino acid 
change (Figure 3.21A).  Next, the gene expression of Kras was assayed in the tumors 
from these mice and found that the expression was 3.5-27 fold higher in mice with 
Kras integrations when compared to wild-type bone marrow (Figure 3.21B).  Of note, 





Figure 3.21.  Analysis of Kras as a CIS.  A.  Chromatogram of DNA sequence 
analysis from mouse 27.  Note the GGC>GAC point mutation that resulted in a 
glycine to aspartic acid amino acid change.  B.  RNA transcript analysis by real time 
RT-PCR of leukemia-infiltrated spleen from CALM-AF10 mice (20 and 27), 
clinically healthy transgenic bone marrow (TG BM); transgenic spleen (TG SP); 
wild-type spleen (WT SP); and wild-type bone marrow (WT BM). 
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Meis1 was not identified as a CIS in CALM-AF10 mice 
Meis1 is one of the genes most commonly identified by RIM, but was identified only 
once by PCR analysis in this study, therefore 43 tumor samples were screened using 
Southern blot analysis.  However, additional insertion events for Meis1 were not 
identified.     
Discussion 
In Chapter 2, a CALM-AF10 fusion cDNA resulted in impaired thymocyte 
differentiation and AML when expressed in mice.  The CALM-AF10 mice develop 
leukemia after a long latency period and incomplete penetrance, which suggest the 
need for complementary events.  A current concept in leukemic biology suggest that 
one mutation event results in impaired differentiation and a complementary 
mutation(s) increases cellular proliferation and/or decreased apoptosis (Kelly and 
Gilliland 2002).  Retroviral insertional mutagenesis was used to identify candidate 
genes that complement a CALM-AF10 fusion during the leukemogenic 
transformation.  
 
A cohort of newborn CALM-AF10 mice infected with MOL4070LTR developed 
acute leukemia after a median of 4.5 months.  This is an acceleration of disease 
compared to wild type mice infected with retrovirus (median latency 10.5 months) or 
CALM-AF10 mice not infected with retrovirus (median latency 13 months).  These 
findings support our hypothesis that the retrovirus collaborates with CALM-AF10 to 
accelerate leukemia in mice.  Ligation-mediated PCR and sequence analysis was used 
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to identify a total of 17 CIS (two insertions that occur within 100 kb) (Hwang, 
Martins et al. 2002).  Of these CIS, many had been reported in other retroviral 
mutagenesis studies as either proto-oncogenes or tumor suppressor genes.  In some 
cases (Mllt3, Ift57, Mpl, Foxp1, Phb, Vav, and Gata1) the insertions have not been 
identified as CIS in retroviral mutagenesis screens.  
 
To verify the retroviral insertions identified by PCR, Southern blot analysis and RQ-
RTPCR were performed on a subset of CIS.  A strong correlation was observed 
between certain CISs and immunophenotype.  Gene expression analysis also 
correlated with immunophenotype again supporting the role of the CIS in that 
particular leukemia.  
 
Zeb2 (Sip1 or Zfhx1b) located on chromosome 2q22 encodes for Smad interacting 
protein 1, a member of the TGF-β family of cytokines.  Much of what is known about 
this gene comes from studies in patients with Mowat-Wilson Syndrome (Mowat, 
Wilson et al. 2003).  These patients have marked developmental disorders as a result 
of various mutations that occur in cells of neural crest origin (Dastot-Le Moal, Wilson 
et al. 2007).  Zeb2 also plays a role in epithelial to mesenchymal transition that is seen 
in certain types of cancers such as breast cancer and renal cell carcinoma 
(Krishnamachary, Zagzag et al. 2006; Lombaerts, van Wezel et al. 2006; Beltran, 
Puig et al. 2008; Gregory, Bert et al. 2008; Korpal, Lee et al. 2008). Previous 
retroviral mutagenesis screens in mice have identified this gene 13 times (RTCGD) in 
mouse models of leukemia supporting a role in leukemogenesis.  Finally, Zeb2 was 
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identified as being overexpressed by gene expression array analysis in pediatric AML 
patients with MLL gene rearrangements (Aoi Jo 2007).    Here Zeb2 was identified by 
either PCR or Southern blot in 12 mice and showed that the majority of the tumors 
with Zeb2 integrations were also clonal.  When the tumor samples were assayed for 
expression of Zeb2 it was not surprising, given the findings on Southern blot analysis 
that the tumors also had high levels of the Zeb2 transcript.  It was observed that a 
large percentage of mice with Zeb2 insertions also developed B-cell or biphenotypic 
leukemia and that all of the mice except for mouse 36 had an Igh gene rearrangement.  
It should be noted that the integration site for mouse 36 was outside of the region 
assayed by either of the Southern blot probes.  Therefore, it is possible that the 
leukemic clone containing a Zeb2 insertion from mouse 36 represented a minor clone, 
providing a potential explanation for the lack of a B-cell phenotype in this mouse.  
These findings suggest that Zeb2 collaborates with CALM-AF10 to promote B-cell 
leukemia.  Tumor samples from seven of the mice with a known Zeb2 insertion event 
were assayed for gene expression.  There was a 3 to 10 fold increase in Zeb2-
associated tumors when compared to Zeb2 expression in wild-type bone marrow.  
 
Neurofibromatosis type 1 (NF1) is an autosomal disorder in humans which results in 
the development of peripheral nerve sheath tumors, neurofibromas (Korf 2000). 
Children with NF1 are at increased risk for developing malignant myeloid disease 
that includes AML, monosomy 7 syndrome, and juvenile myelomonocytic leukemia 
(JMML).  Pediatric patients with NF1 share a variety of common clinical and 
molecular characteristics, including sex, early onset, marked hepatomegaly and 
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splenomegaly, leukocytosis and Nf1 loss of heterozygosity in myeloid progenitor 
cells.  The prognosis is poor (O'Marcaigh and Shannon 1997; Tefferi and Gilliland 
2007).    
 
NF1 plays a crucial role in hematopoiesis, especially in myeloid cell development.  
Neurofibromatosis, type1, encodes a 327 kD protein known as neurofibromin.  
Neurofibromin serves as a GTPase-activating protein that accelerates Ras-GTP 
hydrolysis, converting Ras-GTP to its inactive form Ras-GDP (Braun and Shannon 
2008). In health, granulocyte-macrophage colony stimulating factor, a growth 
promoting transmembrane signal induces p21ras activation by enhancing the levels of 
Ras-GTP (active) as opposed to Ras-GDP (inactive).  The active Ras-GTP, in turn 
activates a series of downstream kinases that promote cellular proliferation.  To 
further highlight the role of NF1 in hematopoiesis, studies have shown that a loss or 
deficiency in Nf1 results in a hypersensitivity to granulocyte-macrophage colony 
stimulating factor resulting in aberrant hematopoietic cell growth and/or the 
development of chronic myeloid leukemia (Bollag, Clapp et al. 1996; Largaespada, 
Brannan et al. 1996).     
 
Several lines of evidence from studies in mice further emphasize the role of Nf1 in 
hematopoiesis and leukemia. Gene targeting strategies have been used to disrupt Nf1 
in the mouse.  In one study, Nf1+/- heterozygous mice developed a myeloproliferative 
disease, in year two of life, which was associated with LOH in myeloid cells(Jacks, 
Shih et al. 1994).  This particular model recapitulates the findings seen in JMML.  In 
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a second model, Nf1-/- mice died in utero at E12.5-E13.5 from cardiopulmonary 
development disorders.  The fetal liver is a rich source of hematopoietic cells.  These 
cells were harvested from the Nf1-/- embryos on day 13.5 and used to reconstitute 
trilineage hematopoiesis in recipient mice.  Following a short incubation period, the 
mice developed a myeloproliferative syndrome similar to that seen in patients with 
JMML (Largaespada, Brannan et al. 1996).  Finally, the analysis of retroviral 
integration sites in BXH2 mice that developed spontaneous leukemias identified Evi-
2 as a candidate gene.  Further analysis revealed that this gene was located in a large 
intron of Nf1, suggesting a role of Nf1 in leukemia. 
 
In this present study, Nf1 was identified as a CIS in 11 mice by either ligation-
mediated PCR or Southern blot analysis. This gene has been reported 28 times in the 
RTCGD.  All four insertion events identified by PCR occurred in the same orientation 
within the Evi2b gene located within intron 36 of Nf1. In two mice (17 and 23) that 
had Nf1 integrations, the loss of the germ line band on the Southern blot analysis 
suggests a reduction to homozygosity.  The expression of Nf1 was assayed in mice 
that evidence for Nf1 insertions.  In two samples (17 and 23), expression was 
decreased compared to wild-type bone marrow.  The remaining samples had gene 
expression levels higher than that of wild-type bone marrow.  Of note, the mice with 
the lowest levels of gene expression also developed B-ALL.  We did not anticipate 
the high level of Nf1 expression in tumor samples with an Nf1 gene rearrangement.  It 
is possible that an alternate splice variant is produced as a consequence of viral 
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integration into Nf1, and provides a mechanism by which Nf1 can be overexpressed in 
myeloid cells (Largaespada, Shaughnessy et al. 1995).  
 
Mn1 was identified six times as an insertion event by PCR.  MN1 was first cloned 
from a patient with meningioma(Lekanne Deprez, Riegman et al. 1995) and is a 
transcriptional coactivator  that cooperates with retinoic acid to mediate transcription 
(van Wely, Molijn et al. 2003).  MN1 is implicated in leukmogenic transformation 
through two possible mechanisms.   MN1 forms a fusion transcript with TEL, a 
member of the ETS transcription factors and  known oncogene in AML (Buijs, Sherr 
et al. 1995), 1995).  It is likely that the MN1-TEL fusion produces an aberrant 
transcription factor that contains the ETS DNA binding-domain derived from TEL 
(Buijs, Sherr et al. 1995). In another study, 142 patients with AML with normal 
cytogentics were analyzed for the expression of MN1.  Patients with high levels of 
MN1 had a poor response to induction therapy, a higher relapse rate, and a shorter 
relapse free period as well as decreased overall survival (Heuser, Beutel et al. 2006). 
In a recent retrovirus mutagenesis screen, MN1 was reported eight times in 
NUP98HOXD13 mice that were infected with MOL4070LTR.  This finding suggests 
that Mn1 collaborates with the NUP98HOXD13 transgene to cause leukemia in mice.   
 
The fact that Mn1 was identified six times in CALM-AF10 mice supports the role of 
Mn1 as an oncogene in AML.   Furthermore, three mice in this study had viral 
insertions in the first intron of Mn1 that formed fusion transcripts with the viral gene, 
integrase.  This finding highlights the previous observation of MN1-TEL fusions.  A 
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previous study in mice showed that the MN1-TEL fusion collaborates with HOXA9 to 
induce a myeloid malignancy.  Slape and colleagues hypothesized that the Mn1-
integrase fusions could collaborate with the NUP98HOXD13 transgene in a way 
similar to MN1-TEL fusions to induce myeloid leukemia (Slape, Hartung et al. 2007).  
Intriguingly chapter 4 showed (Caudell, Zhang et al. 2007) that Hoxa9 is up-regulated 
in CALM-AF10 induced myeloid leukemias.  Taken together these findings suggest a 
collaborative role between CALM-AF10 and Mn1 in leukemia.  
 
Kras is one of three 21 kD protein members of the Ras family that binds quanine 
nucleotides and plays a central role in cell proliferation, survival, and differentiation 
(Ellis and Clark 2000; Adjei 2001).  Activating mutations in Kras result in the 
constitutive activation of cell proliferation signals (Adjei 2001).   Mutations involving 
Kras have been reported in five per cent of patients with AML, and when combined 
with mutations that involve Nras, can be seen in as many as 20% of all AMLs 
(Renneville, Roumier et al. 2008). Studies in mouse models have shown that the 
oncogenic form of Kras results in a myeloproliferative disease but not AML; this 
finding suggests that additional mutations are needed for mice to develop leukemia.  
Here Kras was identified as a CIS in two mice; Kras has been reported 7 times in the 
RTCGD.  These findings prompted us to screen the samples for the presence of point 
mutations.  Because point mutations occur at such a high rate in humans with 
leukemia, it was not surprising that a point mutation was identified in at least one of 
the mice (mouse 27).  The expression of Kras was assayed and found that the 
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expression was higher than in wild-type bone marrow.  Of note, sample 27 which had 
the highest gene expression was the same mouse with the point mutation.   
 
Meis1 is a transcription factor that collaborates with HOX genes in leukemia 
(Moskow, Bullrich et al. 1995; Nakamura T, Largaespada DA et al. 1996; Kroon, 
Krosl et al. 1998; Thorsteinsdottir, Kroon et al. 2001; Pineault, Buske et al. 2003).   
Meis1 has previously been identified as a CIS through a retroviral mutagenesis 
screens in mice (Iwasaki, Kuwata et al. 2005).   In fact, in a recent study, Meis1 was 
identified in 14 NUP98HOXD13 transgenic mice that were infected with the 
MOL4070LTR(Slape, Hartung et al. 2007). In Chapter 4 it is shown that Meis1 is up-
regulated in CALM-AF10 mice with leukemia along with Hoxa9 in bone marrow 
from clinically healthy CALM-AF10 mice and in mice with AML.   Meis1 was 
identified only once in a tumor sample by PCR in our study.  Because Meis1 is 
overexpressed in CALM-AF10 sensitized mice it is an unlikely target by the retrovirus 
during infection and integration, and is not surprising that we identified it only once 
as an insertion event.  
 
Recently, a similar study was published that used retroviral mutagenesis in 
NUP98HOXD13 sensitized mice to screen for collaborating genes (Slape, Hartung et 
al. 2007).   In that study, they found that many of the leukemias contained more than 
one CIS suggesting that multiple retroviral integrations complement the transgene.  In 
retroviral-infected CALM-AF10 mice, there was evidence by Southern-blot analysis 
that a single insertion was sufficient to complement CALM-AF10 in a subset of the 
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mice.  Other leukemias that developed in the CALM-AF10 mice were indeed 
oligoclonal; some of these leukemias had a single intense integration with additional 
less intense bands, or multiple equally intense bands.  This suggests that these tumors 
were composed of major and minor clones, or multiple dominant clones.  Several 
insertions were also identified that occurred only once that are of interest either 
because of their known role in cancer biology or have been previously reported in the 
RTCGD.  These single insertion events may have occurred due to the CALM-AF10 
transgene effect or the type of retrovirus used to accelerate the leukemia.  
Furthermore, although these events were detected, they represented “passenger 
mutations” i.e., events that occurred within hematopoietic cells but did not offer a 
selective advantage to the cell and thus leukemic transformation.  
 
In Chapter 2 it was shown that CALM-AF10 mice developed acute leukemia after a 
long latency and incomplete penetrance.  These findings suggest that additional 
mutations were needed to complement the transgene. In this study, we used retroviral 
insertional mutagenesis to identify complementary genetic events that might 
collaborate with CALM-AF10 during leukemic transformation.  We identified several 
CIS that potentially collaborate with CALM-AF10.  Of these CIS, Zeb2 and Nf1 are 
interesting and warrant further investigation into their role as collaborating genes with 
CALM-AF10.  Overexpression of Zeb2 in a retroviral-based bone marrow 
transduction and transplantion system would be one mechanism by which to study 
Zeb2 collaboration with CALM-AF10.  The role of Nf1 in CALM-AF10 leukemias 
could be studied by crossing CALM-AF10 mice to Nf1+/- mice with the expectation 
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that mice would develop leukemia at an accelerated rate.    Retroviral infection was 
shown here to accelerate the onset of acute leukemia, and genes were identified that 
potentially collaborate with the CALM-AF10 fusion gene in the leukemic 
transformation process.  This transgenic murine model serves as a model system for 
studying leukemogenesis similar to that observed in humans with leukemia. 
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Chapter 4: Evaluation of differentially expressed genes in 




This chapter will focus on experiments designed to gain insight into the consequence 
of CALM-AF10 fusion transcript expression on potential gene targets in the CALM-
AF10 transgenic mouse model.  In order to identify theses genes, two different 
approaches were taken to address this question, a candidate gene approach as well as 
a whole genome screen. A recently published study using gene expression profiling 
showed that human CALM-AF10+ T-ALLs are characterized by overexpression of 
HOXA, MEIS1, and BMI1 oncogenes. Therefore, gene expression of these and other 
Hox genes were assayed in CALM-AF10 positive leukemic cells compared to wild-
type hematopoietic progenitors using real time RT-PCR.  The second approach used 
to address this question involved gene expression profiles of bone marrow from 
CALM-AF10 mice compared to the expression profiles of wild-type mouse bone 
marrow by microarray analysis.  
Materials and methods 
Real Time RT-PCR assay for Hoxa5, Hoxa7, Hoxa9 Hoxa10, Hoxa11, Hoxa13, 
Hoxb4, Hoxd13,and Meis1. 
Total RNA (1ug) from transgenic or wild-type spleen, bone marrow, and thymus, as 
well as spleen infiltrated by leukemic cells was reverse transcribed as described in 
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chapter two.   Real time RT-PCR was performed on a 7500 Fast Real Time Taqman 
PCR system (Applied Biosystem) using aliquots of first strand cDNA as templates for 
mouse Hoxa5, Hoxa7, Hoxa9, Hoxa10, Hoxa11, Hoxa13, Hoxb4, Hoxd13, and Meis1 
with Applied Biosystems primer and probe sets.  All reactions were done in triplicate 
with 20 µl PCR reactions using the Applied Biosystems default thermalcycling 
conditions  (an activation step at  95˚C for 20 sec followed by 40 cycles of 
amplification at 95˚C for 0.03 sec,  followed by an annealing and extension step at 
60˚C for 30 sec). The expression of the 18S ribosomal RNA was used as an 
endogenous control.  All reactions were performed in triplicate, and the –∆∆CT mean 
and standard error were calculated for each sample.  Values for the transcript of 
interest were normalized to the 18S rRNA value and compared to the expression in 
wild-type bone marrow. 
RT-PCR 
RT-PCR analysis was performed for the expression of Bmi1 in tumors as well as 
transgenic and wild-type liver as previously described.  The PCR was performed as 
previously descried using with the following primers 
5’CCCAGTGCTAACCACCAATCTTCC3’ and 
5’GGAAGCAAACTGGACGACAGTCAC3’ with the following thermocycling 
conditions 94°C for 3 min; 34 cycles of 94°C for 30 seconds, 62°C for 30 seconds, 




Bone marrow, spleen, and thymus was harvested from three wild-type and three 
CALM-AF10 mice and placed in either Hanks Balanced Salt Solution with 2% FCS or 
snap frozen and stored at -80°C. Whole blood was collected for CBC analysis. 
Single-cell suspensions prepared from thymus and bone marrow were incubated with 
fluorescein isothiocyanate (FITC)--conjugated anti--mouse CD8, B220, Gr-1, 
phycoerythrin (PE)--conjugated anti--mouse CD4, IgM, Mac-1 (Pharmingen) and 




Total RNA was isolated from bone marrow samples by Trizol (Invitrogen) as 
described in Chapter 2, and three micrograms of total RNA was sent to the 
Laboratory of Molecular Technology (LMT), NCI-Frederick, Frederick, MD. To 
perform the Affymetrix microarray, 50 ng of total RNA was used for microarray 
hybridization following the Affymetrix protocol for 2-cycle cDNA synthesis 
(http://www.affymetrix.com/products/reagents/specific/cdna2.affx and 
http://www.affymetrix.com/support/technical/manual/expression_manual.affx). First, 
Poly-A RNA controls, designed to provide exogenous controls that evaluate the total 
labeling process of the eukaryotic target, were prepared using the Poly-A RNA 
Control Kit (Affymetrix).  These controls were mixed with the T7-Oligo(dT) Primer 
and added to the total RNA sample for the first cycle, first strand and second strand 
cDNA synthesis using the Affymetrix 2-cycle cDNA synthesis kit. Next, the first 
cycle in vitro transcription (IVT) reaction was performed overnight using a 
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MEGAscript T7 kit (Ambion). Afterwards, the first cycle RNA clean-up step was 
performed using a cRNA clean-up column.  Next, the second cycle of first and second 
strand cDNA synthesis was performed using the Affymetrix 2-cycle cDNA synthesis 
kit.   The second cycle cDNA clean-up was performed the following day using a 
column followed by an overnight IVT reaction that produced biotin-labeled cRNA.  
Next, biotin-labeled cRNA was fragmented followed by a final cleaned up step.  This 
was followed by overnight hybridization of the fragmented cRNA, using the 
Affymetrix GeneChip Eukaryotic Hybridization Control Kit, to the mouse gene chip 
array (430 2.0 GeneChip® Array; Affymetrix, Santa Clara, CA).  Finally, the arrays 
were washed and loaded into the Affymetrix GeneChip System scanner 3000 
(Hewlett-Packard, Santa Clara, CA).  Data files (.CEL, .DAT, .CDF and .CHP) were 
copied to a cd and returned for analysis.  The fluorescence of the hybridized chips 
was analyzed using BRB array tools software, version 3.6.0.  A comparison analysis 
based on CALM-AF10 fusion was performed after normalization using standard 
settings of BRB array tool (experiment/baseline ratio higher or lower than 2) 
Results 
Hoxa cluster genes are up-regulated in CALM-AF10 mice 
We assayed Hoxa5, Hoxa7, Hoxa9, Hoxa10, Hoxa11, Hoxa13, Hoxb4, Hoxd13, and 
Meis1 expression by real time RT-PCR in leukemias from CALM-AF10 mice to 
determine if the up-regulation of these genes was seen in this mouse model as well as 
in the human leukemias.   As shown in Figure. 4.1, Hoxa5, Hoxa7, Hoxa9, Hoxa10,  
and Meis1 were all up-regulated in hematopoietic tissue (bone marrow, spleen, 
thymus) from clinically healthy CALM-AF10 mice.  Myeloid leukemias from CALM-
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AF10 mice also showed up-regulation of Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1, 
indicating that up-regulation of these genes occurs in myeloid as well as T-cell 
tumors associated with CALM-AF10 expression.  Hoxb4 was modestly decreased  in 
clinically healthy transgenic bone marrow, as well as in one of four leukemia 
samples.   Expression of Hoxa11, Hoxa13, and Hoxd13 was undetectable in all tissues 
and tumor samples after 35 cycles of amplification in contrast to the threshold of 
detection for the 18S ribosomal control at 18 cycles of amplification.  In contrast to 
the upregulation of Hoxa cluster genes described above, conventional RT-PCR 
demonstrated that Bmi1 was highly expressed in hematopoietic tissue and leukemias 




Figure 4.1.  Hoxa cluster and Meis1 expression in CALM-AF10 mice.   RNA 
transcript analysis by real time RT-PCR of bone marrow (BM), spleen (Sp), and 
thymus (Th) from clinically healthy wild type (WT) and transgenic (TG) mice in 
addition to mice 7088, 7180, 7160, and 9014 (samples 1,2,3,4) with AML. 
Expression of Hoxa5, Hoxa7, Hoxa9, Hoxa10, Hoxa11, Hoxa13, Hoxb4, Hoxd13, 
and Meis1 was normalized to 18S rRNA expression and shown as mean fold change 





Figure 4.2.  RT-PCR analysis of Bmi1 expression.  RT-PCR analysis of tumors (Tu 
1,2,3,4, and 5) from CALM-AF10 mice and Liver (L); Spleen, (S); Bone marrow (B); 
and Thymus (Th) from CALM-AF10 transgenic (T) and wild-type (W) mouse, upper 




Genes upregulated in CALM-AF10 bone marrow 
In order to gain insight into the consequences of CALM-AF10 gene expression on 
downstream gene targets we performed gene expression arrays on bone marrow 
samples from three CALM-AF10 clinically healthy mice and three wild-type control 
mice.  Analysis of the microarray set at a 2-fold change in expression identified 80 
genes.  Five genes were significantly (P<0.05) increased in CALM-AF10 bone 
marrow compared to wild type controls. These genes included Hoxa9, Meis1, Dsp 
(twice), Xlr4b, BB053468.  Of these five genes, Hoxa9 and Meis1 are the two genes 
most significantly associated with CALM-AF10 expression (Table 4.1).   
Genes downregulated in CALM-AF10 bone marrow 
Microarray analysis showed that six genes that belonged to the immunoglobulin 
family (Ighg, Igh-6, Igl-V1, Igh, Igkv14-111, and Igk-V28) were significantly 
(P<0.05) down-regulated in CALM-AF10 bone marrow samples compared to wild-
type controls. The genes within this cluster that showed the most significant degree of 
downreguation were those that belong to the immunogbulin family.   Specifically, 
Igh-6, which encodes for IgM was detected on four distinct probe sets and showed a 






Figure 4.3 Heat map.  This heat map depicts a 2-fold change between differentially 
expressed genes in CALM-AF10 clinically healthy mouse bone marrow compared to 
wild-type controls.  Samples are indicated at the top, gene abbreviations are indicated 
at the right.  The heat map was generated using BRB array tools v3.6.0.
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Table 4.1 Genes differentially upregulated in CALM-AF10  transgenic mouse bone marrow
Gene symbol Description
 Biological or 
Molecular Function
Mean of log 
intensities for T
Mean of log 
intensities for W Fold Diff Probe set
Hoxa9 homeo box A9 transcription factor 6.81655 4.05052 6.80 1455626_at
Meis1 myeloid ecotropic viral integration 
site 1
transcription factor 6.01177 4.05436 3.88 1450992_a_at
Dsp desmoplakin intercellular adhesion 5.34648 3.64366 3.26 1435493_at
Dsp desmoplakin intercellular adhesion 5.24705 3.64951 3.03 1435494_s_at
Prg2 proteoglycan 2, bone marrow immune response 9.74908 8.15596 3.02 1422873_at
BG070088 Unknown unknown 4.32633 2.77767 2.93 1445773_at
Xlr4b X-linked lymphocyte-regulated 4B lymphocyte regulation 8.63156 7.12867 2.83 1449347_a_at
OTTMUSG00000000971 predicted gene, 
OTTMUSG00000000971
unknown 7.92819 6.46624 2.75 1436530_at
Ms4a4c membrane-spanning 4-domains, 
subfamily A, member 4C
signal transduction 7.90808 6.48779 2.68 1450291_s_at
Vcan versican cell adhesion, heart 
development
4.09383 2.7888 2.47 1427256_at
BB053468 Unknown unknown 3.46935 2.2425 2.34 1440431_at
Ms4a6d membrane-spanning 4-domains, 
subfamily A, member 6D
signal transduction 6.84554 5.68744 2.23 1419599_s_at
Fn1 fibronectin 1 ECM-receptor 
interaction, focal 
9.17377 8.0605 2.16 1426642_at
Ms4a6d membrane-spanning 4-domains, 
subfamily A, member 6D
signal transduction 5.05986 3.94961 2.16 1419598_at
Ms4a4c membrane-spanning 4-domains, 
subfamily A, member 4C
signal transduction 7.06742 5.95976 2.15 1420671_x_at
Stfa3 stefin A3 endopeptidase/ cysteine 
protease inhibitor 
activity
6.63602 5.53681 2.14 1419709_at
Ms4a6b membrane-spanning 4-domains, 
subfamily A, member 6B
signal transduction 4.72428 3.63995 2.12 1439956_at
Ccl9 chemokine (C-C motif) ligand 9 chemotaxis, immune 
response, signal 
transduction
8.77605 7.73974 2.05 1417936_at
Lrrk1 leucine-rich repeat kinase 1 nuclease, ATP, ion 
binding
5.09694 4.06928 2.04 1451985_at





Figure 4.4.  Scatter plot of differentially up-regulated genes from CALM-AF10 
bone marrow.  The red dots below the linear regression line depict genes from Table 
4.1 that were up-regulated in CALM-AF10 transgenic mouse bone marrow compared 























    
Table 4.2 Genes differentially downregulated in CALM-AF10  transgenic mouse bone marrow
Gene symbol Description
 Biological or Molecular 
Function
Mean of log 
intensities for T
Mean of log 
intensities for W Fold Diff Probe set
Mfhas1 malignant fibrous histiocytoma 
amplified sequence 1
small GTPase mediated signal 
transduction 5.37112 6.37516 0.50 1436897_at
4930430F08Rik RIKEN cDNA 4930430F08 gene unknown 4.60125 5.63136 0.49 1453468_at
March3 membrane-associated ring finger 
(C3HC4) 3
ubiquitin cycle, endocytosis
5.56403 6.63243 0.48 1441643_at
Wnk1 WNK lysine deficient protein 
kinase 1
unknown
8.28331 9.36445 0.47 1436746_at
LOC672450 V(kappa) gene product unknown 6.85216 7.9587 0.46 1451965_at
Ppp2r5e protein phosphatase 2, regulatory 
subunit B (B56), epsilon isoform
signal transduction
3.74209 4.85734 0.46 1452788_at
Smc1a structural maintenance of 
chromosomes 1A
cell cycle checkpoint, DNA 
repair, chrom. segregation 5.29126 6.43449 0.45 1417831_at
Gm1499 Gene model 1499, (NCBI) unknown 4.30106 5.45504 0.45 1426201_at
Igk-V28 /// 
LOC213481
immunoglobulin kappa chain 
variable 28 (V28) /// 
immunoglobulin kappa light chain 
17-1A
antigen binding
4.75719 5.97045 0.43 1451962_at
Ddx6 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6
unknown
3.79017 5.06666 0.41 1424598_at
Malat1 Metastasis associated lung 
adenocarcinoma transcript 1 (non-
coding RNA)
unknown
5.0933 6.46321 0.39 1418189_s_at
Ighg Immunoglobulin heavy chain 
(gamma polypeptide)
antigen binding
10.23961 11.63655 0.38 1424631_a_at
Cr1 Ig kappa chain complement cascade 7.32921 8.7828 0.37 1460423_x_at
Igh-6 Immunoglobulin heavy chain 6 
(heavy chain of IgM)
ADCC, Type I, II hyper- 
sensitivity, antigen processing
10.05111 11.50638 0.36 1425247_a_at
Igkv14-111 Immunoglobulin kappa chain 
variable 14-111
unknown
5.82124 7.29228 0.36 1451951_at
Igh-6 Immunoglobulin heavy chain 6 
(heavy chain of IgM)
ADCC, Type I, II hyper- 
sensitivity, antigen processing
9.17671 10.66721 0.36 1427756_x_at
Igh /// Ighg immunoglobulin heavy chain 
complex /// Immunoglobulin 
heavy chain (gamma polypeptide)
antigen binding
10.69404 12.2014 0.35 1451632_a_at
Igh-6 Immunoglobulin heavy chain 6 
(heavy chain of IgM)
ADCC, Type I, II hyper- 
sensitivity, antigen processing
9.34102 10.9124 0.34 1425324_x_at
Igh-6 Immunoglobulin heavy chain 6 
(heavy chain of IgM)
ADCC, Type I, II hyper- 
sensitivity, antigen processing
7.74318 9.31974 0.34 1427870_x_at
Igl-V1 immunoglobulin lambda chain, 
variable 1
humoral immune response, 
antigen binding 5.75049 7.33528 0.33 1430523_s_at
Malat1 Metastasis associated lung 
adenocarcinoma transcript 1 (non-
coding RNA)
unknown
7.12584 8.71402 0.33 1418188_a_at
Igh-6 immunoglobulin heavy chain 6 
(heavy chain of IgM)
ADCC, Type I, II hyper- 
sensitivity, antigen processing
10.58038 12.31376 0.30 1427351_s_at
Ighg Immunoglobulin heavy chain 
(gamma polypeptide)
antigen binding
8.07328 9.89093 0.28 1426174_s_at
LOC100046552 similar to Unknown (protein for 
MGC:103328)
unknown
7.53875 9.96831 0.19 1427837_at
LOC100046973 similar to [Human Ig rearranged 
gamma chain mRNA, V-J-C 
region and complete cds.], gene 
product
unknown
5.24322 8.46545 0.11 1425871_a_at





Figure 4.5.  Scatter plot of differentially down-regulated genes from CALM-
AF10 bone marrow.  The black dots below the linear regression line depict genes 
from Table 4.2 that were down-regulated in CALM-AF10 transgenic mouse bone 




















Patients with CALM-AF10 fusion are known to have differentially expressed genes 
that are thought to be targets as a consequence of CALM-AF10 expression.  These 
genes include HOXA, MEIS1, and BMI1 oncogenes (Dik, Brahim et al. 2005).  In 
order to gain insight the role of CALM-AF10 on potential target genes, RT-PCR and 
whole genome arrays were used to identify differentially expressed genes in bone 
marrow of CALM-AF10 transgenic mice.  In this study, Hoxa and Meis1, but not 
Bmi1 were differentially expressed in CALM-AF10 mouse bone marrow.  Several 
other genes known to be involved in B-cell development were also identified as being 
differentially expressed in CALM-AF10 mice.  These findings mimic those that have 
been reported in CALM-AF10 patients with leukemia.  
 
Several lines of evidence developed over the past several years have demonstrated the 
importance of HOX gene dysregulation during leukemic transformation.  First, HOX 
genes are located downstream of MLL; their unscheduled expression has been 
observed in leukemias associated with MLL fusions(Ferrando and Look 2003).  
Second, multiple HOX genes have been identified as either fusion partners with 
NUP98 or TCRA regulatory elements in chromosomal translocations associated with 
acute leukemia (Calvo, Sykes et al. 2002; Ferrando and Look 2003; Slape and Aplan 
2004).  Third, gene expression profile studies have shown that up-regulation of 
several HOX genes, especially HOXA7 and HOXA9, occurs in both acute lymphoid 
and myeloid leukemia (Golub, Slonim et al. 1999; Abramovich and Humphries 2005; 
Soulier, Clappier et al. 2005).   Fourth, Hox genes, again including Hoxa7 and Hoxa9, 
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have been found to be up-regulated by retroviral insertion in mice with retroviral-
induced myeloid leukemia (Nakamura, Largaespada et al. 1996).  Finally, a number 
of investigators have reported that over-expression of HOX genes or NUP98-HOX 
fusion genes leads to acute myeloid malignancies in mice (Kroon, Thorsteinsdottir et 
al. 2001; Pineault, Buske et al. 2003; Pineault, Abramovich et al. 2004; Abramovich 
and Humphries 2005; Lin, Slape et al. 2005).  Of note, recent reports demonstrated 
over-expression of HOXA5, HOXA9, and HOXA10 in pre-T LBL patients who had 
CALM-AF10 translocations (Dik, Brahim et al. 2005; Soulier, Clappier et al. 2005; 
Bergeron, Clappier et al. 2006).   
 
In this study, expression of a CALM-AF10 fusion gene lead to upregulation of Hoxa5, 
Hoxa9, and Hoxa10 in hematopoietic tissues from clinically healthy and leukemic 
CALM-AF10 transgenic mice.  In contrast to previous studies that used retroviral 
transduction and transplantation to over-express HOXA9 or HOXA10 in mouse bone 
marrow, evidence for myeloproliferation was not detected in CALM-AF10 transgenic 
mice (Thorsteinsdottir, Sauvageau et al. 1997; Kroon, Krosl et al. 1998; Calvo, Sykes 
et al. 2000; Buske, Feuring-Buske et al. 2001; Thorsteinsdottir, Kroon et al. 2001)  
This difference may be due to the relative levels of Hox gene expression, or to 
activation of multiple Hox genes by the CALM-AF10 transgene, or to the technique 
employed to express CALM-AF10 in hematopoietic cells (retroviral transduction and 
transplantation vs. transgenesis).  Given the documented leukemogenicity associated 
with up-regulation of HOX genes, particularly those of the abd-b group (paralogs 9-
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13) (Abramovich and Humphries 2005), it seems likely that the CALM-AF10 
transgene exerts its leukemic effect, at least in part, through HOX gene activation. 
 
Previous studies have shown that BMI1 is upregulated in patients with CALM-AF10 
pre T-ALL (Dik, Brahim et al. 2005).  Presumably, in this case the upreguation of 
BMI1 occurs through a cis effect as the AF10 gene is located near BMI1 on 
chromosome 10.  It was hypothesized that this effect was absent in the transgenic 
mice and that the CALM-AF10 mice would not up-regulate Bmi1.  The results 
reported here demonstrate that expression of a CALM-AF10 fusion gene does not 
result in overexpression of Bmi1 as it is was shown to be differentially expressed in 
both hematopoietic and nonhematopoietic tissues.  
 
There was great interest in elucidating the role that Hoxa9 might have on B-cell 
development.  In one study, overexpression of Hoxa9 in bone marrow resulted in 
enhanced granulopoiesis as well as a  partial block in  B-cell lymphopoiesis at the pre-
B-cell stage (Thorsteinsdottir, Mamo et al. 2002).  In this study, Hoxa9 was 
overexpressed in transgenic bone marrow with a concomitant decrease in Igh6, which 
encodes for IgM.  Furthermore, we showed here that mice, which developed AML, 
had overexpression of Hoxa9 in tumors, and that there was evidence of Igh 
rearrangement by Southern blot analysis (chapter 2 and 3).  Taken together, it is 
reasonable to suggest that an overexpression of Hoxa9 impairs B-cell differentiation 
in CALM-AF10 mice.  It would also be reasonable to expect that these mice might 
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also be deficient in IgM.  In this case, the mice would have impaired immunoglobulin 
class switching from IgM to IgG and thus have a deficient humoral immune system.  
 
Gene expression analysis revealed that Desmoplakin (Dsp) was overexpressed in 
bone marrow from CALM-AF10 mice.  This is intriguing because Dsp encodes for 
desmoplakin, an intermediate filament found in tissues subject to mechanical stress 
(Sonnenberg and Liem 2007).  Diseases such as pemphigus, an autoimmune skin 
disease that results in vesicle formation, as well as arrhythmogenic ventricular 
cardiomyopathy have been associated with mutations that involve desmoplakin (Lai 
Cheong, Wessagowit et al. 2005).  Desmoplakin has also been studied in the context 
of cancer, particularly hepatocellular carcinoma, an epithelial cancer; however, there 
are no known reports citing a direct role of desmoplakin in leukemia (Cao, Chang et 
al. 2007).  
In Chapters 2 and 3, CALM-AF10 mice that developed leukemia also had a striking 
perivascular accumulation of neoplastic cells in peripheral tissues.  The observation 
that desmoplakin is overexpressed in transgenic bone marrow, and that it is a known 
cell adhesion protein, warrants further investigation into its potential mechanistic role 









Gross chromosomal rearrangements are molecular lesions observed in patients with 
hematological malignancies.  A chromosomal translocation is the product of a 
reciprocal event whereby two chromosomes undergo double strand breaks and 
exchange their DNA as a consequence of misrepair. Evaluation of these genetic 
aberrations has proven to be a rich source of information regarding mechanisms of 
leukemogenesis, prognostic classifications, and therapeutic target identification.  
Understanding these events through mouse models would help identify and target 
molecular markers that would improve quality of life for patients.   
 
The t(10;11) translocation was first identified in the U937 cell line derived from a 
patient with histiocytic lymphoma (Sundstrom and Nilsson 1976), and later was 
shown to result in a fusion gene product known as CALM-AF10 (Kobayashi, Thirman 
et al. 1995; Shipley, Williams et al. 1995).  This fusion has been observed in both 
adult and pediatric patients with a wide variety of hematological malignancies 
including AML, ALL, and histiocytic lymphoma (Caudell and Aplan 2008).  A subset 
of patients with gamma/delta T-ALL have also been observed with the t(10;11) 
translocation; of the diverse phenotypes, this is the most striking association between 
phenotype and the t(10;11) chromosomal translocation (Asnafi, Radford-Weiss et al. 
2003).  This broad spectrum of phenotypes suggests that the original cell type 
affected by the translocation is an hematopoietic stem cell or early progenitor cell; 
however, the exact cell of origin remains unknown.  At the inception of this work, 
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little was known about the mechanism of action of the CALM-AF10, fusion, and no 
biological models existed in which to study this genetic lesion.  This generated a need 
for a mouse model in which to show that the CALM-AF10 fusion was indeed 
leukemogenic, interrogate genes and their respective pathways associated with the 
biology of CALM-AF10, and identify potential therapeutic targets.  
 
In order to express CALM-AF10 in mice, we cloned a CALM-AF10 fusion cDNA 
from the U937 cell line into a Vav vector, in order to achieve expression across the 
entire hematopoietic cellular compartment, and derived transgenic mice on an FVB 
background.  In this model mice developed AML with lymphoid features including 
immunoglobulin gene rearrangements, and the B-cell surface marker B220.  These 
findings suggested that the target cell was an early progenitor cell.  Interestingly, the 
mice did not develop T-cell tumors; however, they did show evidence of clonal TCR-
beta gene rearrangements in myeloid tumors, as well as a reduction in CD4/8 double 
positive cells in the thymus.   
 
We also showed by gene expression analysis, using RQ-RTPCR, that Hoxa cluster 
genes and Meis1 were upregulated in tumors from transgenic mice with AML as well 
as in spleen, bone marrow and thymus of clinically healthy transgenic mice.  Using a 
whole-genome survey, we showed that two of the three most differentially 
upregulated genes (from a set of 80 genes) were Hoxa9 and Meis1.  These findings 
mimic previous results from studies that involved mouse models and patients with 
MLL and NUP98 fusions, as well as some T-ALL-associated translocations.  In those 
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studies, the fusion genes mediated their action, in part, through HOX genes, especially 
HOXA9.  These findings in our mouse model warrant further biochemical studies 
such as chromatin immunoprecipitation (ChIP) assays to show how directly or 
indirectly CALM-AF10 and Hoxa genes interact to transduce hematopoietic cell 
differentiation.  
 
The current paradigm in leukemic biology is that Class I mutations (e.g. RAS, FLIT3, 
or cKIT mutations) lead to uncontrolled proliferation or impaired apoptosis and that 
Class II mutations target transcription factors, e.g. HOXA clusters, and result in 
impaired differentiation (Kelly and Gilliland 2002).  The mice in our initial study 
developed leukemia after a long latency period (median 13 months) with incomplete 
penetrance.  This suggested that additional mutations, namely those that would result 
in uncontrolled proliferation were likely needed as complementary events, which 
would collaborate with the CALM-AF10 transgene in leukemia development.  
 
To test our hypothesis that complementary events were needed to collaborate with the 
CALM-AF10 transgene to produce leukemia, we infected two-day old CALM-AF10 
transgenic and wild-type control mice with MOL4070LTR retrovirus in order to 
accelerate the leukemia and identify collaborating genes.  In this latter study, 
transgenic mice that were infected with retrovirus developed leukemia more quickly 
than retrovirus-infected wild-type mice or CALM-AF10 mice not infected with 
retrovirus.  The CALM-AF10 retrovirus-infected mice developed leukemia that was 
predominately B-cell ALL or ANLL.  This was in contrast to the wild-type retrovirus-
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infected mice that, in addition to B-cell ALL and ANLL, also developed T-cell ALL.  
The B-cell ALL finding was also strikingly different than the noninfected CALM-
AF10 mice that developed AML with lymphoid features.  These findings suggest that 
the retrovirus collaborates with the CALM-AF10 transgene and targets a progenitor 
cell of B-cell origin, in at least a subset of the leukemias.  
 
The second aim of this study was to identify collaborating genes and their pathways, 
which complement the CALM-AF10 transgene.   We used ligation-mediated PCR and 
sequence analysis to identify ~255 unique retroviral insertion sites.  Seventeen 
common integrations were identified; of these, we focused on two genes in particular, 
Zeb2 and Nf1. 
 
ZEB2 (also known as SIP1 or ZFHX1B) is a transcription factor associated with 
TGFβ that is involved in neurogenesis and Mowat-Wilson syndrome, a neurological 
developmental disorder (Mowat, Wilson et al. 2003).  Zeb2 has been identified by 
retroviral insertional mutagenesis in previous mouse models for T-cell, B-cell, and 
myeloid leukemia, in addition to AML pediatric patients with MLL-associated 
leukemias.  In our study we observed that retroviral-infected CALM-AF10 mice that 
had an identifiable insertion near Zeb2, either by PCR or Southern blot analysis also 
developed B-cell ALL suggesting an association between Zeb2 and B-cell ALL.  
Although the insertions are 160 kb 5’ of Zeb2, it is possible that retroviral enhancer 
elements lead to dysregulation of Zeb2 and uncontrolled proliferation through some, 
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as yet, unidentified mechanism.  Taken together, these findings strongly suggest that 
Zeb2 collaborates with CALM-AF10 to produce leukemia in mice.   
 
Nf1, a tumor suppressor gene that plays a critical role in the RAS signaling pathway 
of myeloid cells, is associated with myeloid leukemia.  In this present study, Nf1 was 
identified as a potential collaborating gene with CALM-AF10.  A subset of tumors 
with Nf1 retroviral integration events had evidence of LOH; B-ALL tumors with Nf1 
retroviral integrations also had decreased Nf1 gene expression.  
 
In this two-part study a transgenic mouse model for the t(10;11) translocation was 
developed that recapitulates the disease observed in patients with leukemia.  In 
addition to confirming the oncogenicity of the CALM-AF10 fusion, it was shown that 
this mouse model produces a myeloid leukemia with lymphoid features.  
Furthermore, it was shown that the transgenic mice have impaired differentiation, 
which is possibly mediated through overexpresion of Hoxa and Meis1.  Through the 
use of retroviral insertional mutagenesis genes and pathways were identified that 
potentially complement the CALM-AF10 fusion.  Because of these findings, this 
model lends itself as a useful model for studying early hematopoietic progenitor or 
stem cells as a target of the t(10;11) translocation.   
 
The potential candidate genes that we identified are of interest either because of their 
established role in leukemia, or because they were previously identified through 
whole genome screens.  These findings warrant further investigation into their 
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collaborative role with the CALM-AF10 fusion.  A first approach would be to express 
the genes of interest, e.g. Zeb2 in retroviral vectors and conduct retroviral bone 
marrow transduction and transplantation studies.  Similar experiments could also be 
performed for some of the other CIS such as Mpl, Foxp1, or Plag1.  Nf1 is interesting 
because of its role as a tumor suppressor gene.  Two approaches could be taken to 
better understand the role of this gene in the CALM-AF10 mouse model.  First, 
decreasing the expression of Nf1 in CALM-AF10 transgenic bone marrow using RNA 
interference (RNAi) would allow for the study of gene dosage effect on myeloid cells.  
A second approach would be to cross Nf1+/- mice with CALM-AF10 transgenic mice 
with the anticipation that offspring would develop leukemia at a faster rate than either 
of the individual genotypes.  
 
Class I mutations are frequently associated with point mutations in genes associated 
with myeloid leukemia such as RAS, FLT3, or cKIT.  We believe, based on our 
studies that the CALM-AF10 transgene is a Class II event and probably blocks 
differentiation in hematopoietic precursor cells. A candidate gene approach that 
interrogates these specific Class I events would be useful in our mouse model system 
to potentially identify secondary events that could collaborate with the CALM-AF10 
transgene.   
 
The CALM-AF10 transgenic mouse model has applications for preclinical research.  
There is evidence of impaired humoral and cell-mediated immunity.  First, clinically 
healthy CALM-AF10 mice have impaired thymocyte differentiation.  A follow-up 
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experiment would be to challenge these mice with infectious agents and monitor their 
cellular immune response to infection.  Secondly, because there was evidence of Igh 
gene rearrangements, and a decrease in IgH-6 gene expression by microarray 
analysis, this model could also be useful for humoral immunity studies.  It is feasible 
to speculate that these mice have decreased serum IgM and IgG given the findings in 
both clinically healthy and tumor-bearing mice. 
 
Of note, a recurring lesion in both non-retroviral, as well as retroviral-infected mice, 
was the perivascular infiltration in peripheral tissue including liver, kidney, and lung.  
Little work has been done to address the molecular features of these unique lesions.  
Interrogation of this lesion could shed new insight into mechanisms that influence 
neoplastic cell trafficking into peripheral tissues, as well as the interactions between 
neoplastic cells and blood vessels.    
 
In this study evidence is offered to support our hypothesis that the CALM-AF10 
transgene leads to acute leukemia in mice.  This model has many useful features 
including hematopoietic progenitor and stem cells biology, impaired differention.  
This model can also be used to study the complex gene interactions associated with 
CALM-AF10 leukemias.  Finally, this mouse model can has potential for identifying 












 1 ggcccgtacg gccttctgac acaactgtgt tcactagcaa cctcaaacag acaccatgat  
       61 catgtccggc cagagcctga cggaccgaat cactgccgcc cagcacagtg tcaccggctc  
      121 tgccgtatcc aagacagtat gcaaggccac gacccacgag atcatggggc ccaagaaaaa  
      181 gcacctggac tacttaattc agtgcacaaa tgagatgaat gtgaacatcc cacagttggc  
      241 agacagttta tttgaaagaa ctactaatag tagttgggtg gtggtcttca aatctctcat  
      301 tacaactcat catttgatgg tgtatggaaa tgagcgtttt attcagtatt tggcttcaag  
      361 aaacacgttg tttaacttaa gcaatttttt ggataaaagt ggattgcaag gatatgacat  
      421 gtctacattt attaggcggt atagtagata tttaaatgag aaagcagttt catacagaca  
      481 agttgcattt gatttcacaa aagtgaagag aggggctgat ggagttatga gaacaatgaa  
      541 cacagaaaaa ctcctaaaaa ctgtaccaat tattcagaat cagatggatg cacttcttga  
      601 ttttaatgtt aatagcaatg aacttacaaa tggggtaata aatgctgcct tcatgctcct  
      661 gttcaaagat gccattagac tgtttgcagc atacaatgaa ggaattatta atttgttgga  
      721 aaaatatttt gatatgaaaa agaaccaatg caaagaaggt cttgacatct ataagaagtt  
      781 cctaactagg atgacaagaa tctcagagtt cctcaaagtt gcagagcaag ttggaattga  
      841 cagaggtgat ataccagacc tttcacaggc ccctagcagt cttcttgatg ctttggaaca  
      901 acatttagct tccttggaag gaaagaaaat caaagattct acagctgcaa gcagggcaac  
      961 tacactttcc aatgcagtgt cttccctggc aagcactggt ctatctctga ccaaagtgga  
     1021 tgaaagggaa aagcaggcag cattagagga agaacaggca cgtttgaaag ctttaaagga  
     1081 acagcgccta aaagaacttg caaagaaacc tcatacctct ttaacaactg cagcctctcc  
     1141 tgtatccacc tcagcaggag ggataatgac tgcaccagcc attgacatat tttctacccc  
     1201 tagttcttct aacagcacat caaagctgcc caatgatctg cttgatttgc agcagccaac  
     1261 ttttcaccca tctgtacatc ctatgtcaac tgcttctcag gtagcaagta catggggaga  
     1321 tcctttctct gctactgtag atgctgttga tgatgccatt ccaagcttaa atcctttcct  
     1381 cacaaaaagt agtggtgatg ttcacctttc catttcttca gatgtatcta cttttactac  
     1441 taggacacct actcatgaaa tgtttgttgg attcactcct tctccagttg cacagccaca  
     1501 cccttcagct ggccttaatg ttgactttga atctgtgttt ggaaataaat ctacaaatgt  
     1561 tattgtagat tctgggggct ttgatgaact aggtggactt ctcaaaccaa cagtggcctc  
     1621 tcagaaccag aaccttcctg ttgccaaact cccacctagc aagttagtat ctgatgactt  
     1681 ggattcatct ttagccaacc ttgtgggcaa tcttggcatc ggaaatggaa ccactaagaa  
     1741 tgatgtaaat tggagtcaac caggtgaaaa gaagttaact gggggatcta actggcaacc  
     1801 aaaggttgca ccaacaaccg cttggaatgc tgcaacaatg gcaccccctg taatggccta  
     1861 tcctgctact acaccaacag gcatgatagg atatggaatt cctccacaaa tgggaagtgt  
     1921 tcctgtaatg acgcaaccaa ccttaatata cagccagcct gtcatgagac ctccaaaccc  
     1981 ctttggccct gtatcaggag cacagagatg tgaactttgt ccccataagg atggagcttt  
     2041 aaaaagaaca gataatgggg gttgggccca tgtggtttgt gccctgtata ttccagaggt  
     2101 acaatttgcc aatgtttcca caatggaacc aattgtttta cagtctgttc cgcatgatcg  
     2161 ttataataag acttgctaca tttgtgatga acaaggaaga gaaagcaaag cagccactgg  
     2221 tgcttgcatg acatgtaata aacatggatg tcgacaggct ttccatgtaa catgcgctca  
     2281 gtttgccgga ctgctttgtg aagaagaagg taatggtgcc gataatgtcc aatactgtgg  
     2341 ctactgtaaa taccatttta gtaagctgaa aaagagcaaa cggggatcta ataggtcata  
     2401 tgatcaaagt ttaagtgatt cttcctctca ctctcaggat aaacatcatg agaaagagaa  
     2461 aaaaaaatat aaagagaagg acaaacacaa acagaaacac aagaagcagc cagaaccatc  
     2521 acctgcattg gttccatcct tgactgttac tacagaaaaa acttatacaa gcactagcaa  
     2581 caactctata tctggatcat tgaagcgctt ggaagatact actgcacgat ttacaaatgc  
     2641 aaatttccag gaagtctctg cacacacctc tagtggaaaa gatgtttcag agactagagg  
     2701 gtcagagggc aaagggaaga aatcttcagc tcacagctca ggtcaaaggg gaagaaagcc  
     2761 tggtggtgga agaaatccag gaacaactgt gtcagcagct agcccttttc ctcaaggcag  
     2821 tttttcagga actccaggca gtgtaaagtc atcttctgga agttcagtgc agtctcccca  
     2881 ggatttcctg agctttacag actcagatct gcgtaatgac agttactctc actcccaaca  
     2941 gtcatcagca accaaagatg tacataaagg agagtctgga agccaggaag ggggggtaaa  
     3001 tagttttagt accttaattg gcctcccttc aacctcagct gttacttcac agcctaaaag  
     3061 ctttgaaaat tcacctggag atttgggtaa ttccagcctt cctacagcag gatataagcg  
     3121 ggctcaaact tctggcatag aagaagaaac tgtaaaggaa aagaaaagga aaggaaataa  
     3181 acaaagtaag catgggcctg gcagacccaa aggaaacaaa aatcaagaga atgtttctca  
     3241 tctctcagtt tcttctgctt caccaacatc atctgtagca tcagctgcag gaagcataac  
     3301 aagctctagt ctgcagaaat ctcctacatt gctcaggaat ggaagtttac agagcctcag  
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     3361 tgttggctca tctccagttg gttcagaaat ttccatgcag tatcggcatg atggagcttg  
     3421 cccaacaact agtatttata acagcaatga tgtagcagta tcgtttccaa atgtagtatc  
     3481 tggctcggga tctagtactc ctgtctccag ctctcactta cctcagcagt cttctgggca  
     3541 tttgcaacaa gtaggagcgc tctctccctc agctgtgtca tctgcagccc ctgctgttgc  
     3601 tacaactcag gcaaatactc tatctggatc ttctctcagt caggcaccat ctcatatgta  
     3661 tggcaataga tcaaattcat caatggcagc tcttatagct cagtctgaaa acaatcaaac  
     3721 agatcaagat cttggagaca atagccgcaa cctagttggc agaggaagct caccccgagg  
     3781 aagtctctcg ccacgatccc ctgtaagcag cttacagatt cgctatgatc aaccaggcaa  
     3841 cagcagtttg gaaaatctgc ctccagtagc agccagcata gaacagcttt tggagaggca  
     3901 gtggagtgaa ggacagcaat ttttactaga acagggtact cctagtgaca ttttaggaat  
     3961 gctgaagtca ttacaccaac ttcaagttga aaaccgaaga ttagaggaac aaattaaaaa  
     4021 cttgactgcc aaaaaggaac ggcttcagtt attgaatgca cagctttcag tgccttttcc  
     4081 aacaataaca gcaaatccta gtccgtctca tcaaatacac acattttcag cacagactgc  
     4141 tcctactact gattccttga acagcagtaa gagccctcat ataggaaaca gctttttacc  
     4201 tgataattct cttcctgtat taaatcagga cttaacctcc agtggacaaa gtaccagcag  
     4261 ctcatcagct ctttctaccc cacctcctgc tgggcagagt ccggctcaac aaggctcagg  
     4321 agtgagtgga gttcagcagg tcaatggcgt gacagtgggg gcactagcta gtggaatgca  
     4381 gcctgtaact tccaccattc ctgccgtgtc tgcagtgggt ggaataattg gagctttgcc  
     4441 aggtaaccaa ctggcaatta atggcattgt aggagcttta aatggggtta tgcagactcc  
     4501 tgtcacaatg tcccagaacc ctacccctct cacccacaca accgtaccac ctaatgcaac  
     4561 acatccaatg ccagctacac tgactaacag tgcctcagga ctaggattac tttctgacca  
     4621 gcaacgacaa atacttattc atcaacagca gtttcagcag ttgttaaatt ctcaacagct  
     4681 cacaccagaa caacatcaag cctttttgta tcagttaatg caacatcacc accagcagca  
     4741 ccaccaacct gaacttcagc agctgcagat ccctggacca acacaaatac ccataaacaa  
     4801 ccttcttgca ggtacacagg cacccccact tcacacagct accaccaacc catttctcac  
     4861 catccatgga gataatgcaa gtcagaaagt agcaagactt agtgataaaa ctgggcctgt  
     4921 agctcaagag aaaagttgac acctgagaaa catctagaaa ttgcctatcc tgctgttcta  
     4981 gcacttcatc tggctgcctt tgcagtcctt ttactacagc tatgaagaaa cgcaacaaga  
     5041 aactcaatgc acaacaaagg attaattgct gcaaggacat tcttgtaagg ctttgattag  
     5101 ttttcttgtt gctttgttgc actgaaatgg aattcccatg cccctacccc ttaccccagt  
     5161 tttttgaaca tggaaagaaa atttaataac tttttaaagt gacataattt acatgcaata  
     5221 tgtttatcaa ctcaagaatt taatatagtt ggtacacaac tagttttgtt tataaattgg  
     5281 agatgcaaat agcaaaacta aatacttgct ccatttacaa actacttgat tttattgtac  
     5341 aagttgaaat atgctctttt gtttgggtta cagtatgctt gctctaagtc aaattccaag  
     5401 gaactaattt cttctcctgg agttgcattg attcagtatt acaaatatat agcacatcac  
     5461 ctgggacttg gcaatctttg ttaaaaaaaa atttcctttc taatgggatt tggccaattt  
     5521 tggtaatgaa gttaggatgg taatgtctgc atctgctaaa ggtaattttc ttttgagaat  
     5581 tgctttcttt agtgttaaga cctactcata ttttgaagaa atcttgagtt aagtgagttc  
     5641 tgaggctgct gggggaacca gatcaattca aagctaaata cttctttcag aaaggggcca  
     5701 ctgtggaaag tgctggtggg gtttgccctt gatcaagtgc ctccattgtg ctgcaagggc  
     5761 tgtagacagc agggtgggac agtcagtcct ccgagcagca ggaatcatcc cgtcacctgc  
     5821 agccttccca tgcttccgcc tttattcaga actttctgtg ccactgtaga tagctcaggc  
     5881 aaaactatta cctgggtatt tatccactaa tgagtcacaa gaaaaggagt ggatttggta  
     5941 agaatagaga tttgttttat ttaaaccact tcccattact gaccattaaa agctcaccac  
     6001 tagagttcct gaaacaggtg aaacctgtat gacagccctt ccactttggg gagccacgct  
     6061 tttgatgtga cagtaccgca gagtgattcc cccactgagg atgtcatcat caaactcttc  
     6121 tttggtgtgt gaattattag tggaaaagac ccagctgtaa ttagacctcc actgtgtact  
     6181 tagctggaag aacatgttaa ttctgcaata tgtttcttgg ttaaacattg cacagttctt  
     6241 acctcatttc tgtaaataaa gttttgtgaa tctgttttgt attgtgacaa attcataaga  
     6301 taacattgat attttgattt gtaatatttc taattggtag atttaattga aaagtaaaat  
     6361 taatttattt ttatatgttc aggggaattt taaagtcaaa tcttttgtag ataatttaaa  
     6421 aaatcagtgt ggtttatttt acttatttaa cccactggtt gttattctgt aacagtttgt  
     6481 ataaatggta aattttgaat gtgttgttat tttacctaga tgtaaaattc cacatgtatt  
     6541 aaaatgtaca aaatgttttg ttaataaaat ttaataatgt ttataaaaaa aaaaaaaaaa  
     6601 aaaaaaaaaa aagggcggcc gctctagagt atccctcgag gggcccaagc ttacgcgat 
 
Legend:  Nucleotides 1-12 are plasmid backbone, 13-58 are human beta-globin, 






Genotyping of CALM-AF10 mice.  This is a representative PCR result from 
genotyping of CALM-AF10 offspring.  Note, lanes 1-7 and 11 represent CALM-AF10 
positive mice; lanes 8, 9, and 10 represent mice negative for the transgene; lane 12 is 












Appendix V  
Retroviral Integration Sites
Chromosome Location Mouse ID Gene Phenotype
1 12,378,313 39 no gene determined B-ALL
1 39,150,002 9 Npas2 Biphen
1 39,552,852 21 Creg2 B-ALL
1 54,722,952 17 Ankrd44 B-ALL
1 64,542,390 30 2310038H17Rik ANLL
1 71,906,799 9 AK016843 Biphen
1 88,534,415 15 4930429A22Rik ANLL
1 107,808,316 47 AA959805 ANLL
1 108,478,223 6 BC12 ANLL
1 166,654,770 31 Dpt ANLL
1 175,717,510 13 Ifi204 ANLL
1 194,900,850 6 Traf3ip3 ANLL
2 4,431,225 10 Frmd4a Biphen
2 6,625,143 76 Cugbp2 ANLL
2 21,149,073 72 Thnsl1 Biphen
2 22,623,996 29 AK079736 Biphen
2 25,288,474 29 Ptgds Biphen
2 28,349,450 9 Ralgds Biphen
2 28,428,791 88 Gfilb ANLL
2 30,356,804 66 Cstad T-ALL
2 31,936,904 14 Ppapdc3 B-ALL
2 33,692,356 98 2610528K11Rik B-ALL
2 45,041,528 36 Zfhx1b ANLL
2 45,093,140 21 Zfhx1b B-ALL
2 45,099,048 27 Zfhx1b B-ALL
2 45,101,941 5 Zfhx1b B-ALL
2 45,103,868 17 Zfhx1b B-ALL
2 45,104,975 98 Zfhx1b B-ALL
2 49,669,349 30 2310010M24Rik ANLL
2 69,661,682 42 M55334 Biphen
2 73,287,719 18 Waspip Biphen
2 74,873,167 70 Mtx2 Biphen
2 91,298,699 21 Lrp4 B-ALL
2 102,799,503 80 Pdhx ANLL
2 116,801,284 67 Spred1 ANLL
2 117,095,572 66 Rasgrp1 T-ALL
2 118,347,894 25 Pak6 B-ALL
2 143,937,495 102 Snx5 ANLL
2 163,460,902 9 Ada Biphen
3 28,762,768 28 BC050866 ANLL
3 30,260,030 6 Evi1 ANLL
3 30,287,734 14 Evi1 B-ALL
3 30,296,436 29 Evi1 Biphen  
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Retroviral Integration Sites Continued
Chromosome Location Mouse ID Gene Phenotype
3 30,297,768 31 Evi1 ANLL
3 30,334,581 36 Evi1 ANLL
3 53,129,110 14 Lhfp B-ALL
3 96,283,440 23 Bola1 B-ALL
3 101,150,307 18 Igsf2 Biphen
3 103,187,870 35 NRas ANLL
3 107,979,920 21 Eps813 B-ALL
3 116,974,438 98 AK144215 B-ALL
3 127,783,021 30 T2bp ANLL
3 135,362,484 13 1500009M05Rik ANLL
3 137,374,333 88 Txn12 ANLL
4 3,880,574 21 Chchd7 B-ALL
4 3,881,017 42 Chchd7 Biphen
4 19,825,466 27 Atp6v062 B-ALL
4 37,365,340 23 AK029761 B-ALL
4 56,136,319 9 no gene determined Biphen
4 57,956,743 13 Akap2 ANLL
4 58,403,609 67 Musk ANLL
4 59,857,534 67 3110003ARik ANLL
4 87,505,624 69 Mllt3 ANLL
4 87,506,224 47 Mllt3 ANLL
4 87,507,253 14 Mllt3 B-ALL
4 94,795,845 38 AK156722 B-ALL
4 106,407,720 6 Ssbp3 ANLL
4 117,956,058 80 Mpl ANLL
4 117,956,360 10 Mpl Biphen
4 133,088,597 39 Rps6ka1 B-ALL
4 135,149,622 10 AK134078 Biphen
4 141,065,267 47 Casp9 ANLL
4 148,545,307 14 Pik3cd B-ALL
4 154,149,872 17 Prkcz B-ALL
4 154,196,007 31 Prkcz ANLL
5 20,767,008 35 A530088I07Rik ANLL
5 59,110,298 46 no gene determined ANLL
5 62,106,040 38 AK090048 B-ALL
5 64,437,560 35 BC059824 ANLL
5 97,157,449 38 DV045711 B-ALL
5 107,995,097 44 Evi5 ANLL
5 111,661,045 67 Mn1 ANLL
5 111,672,110 38 Mn1 B-ALL
5 111,673,890 46 Mn1 ANLL
5 111,675,787 39 Mn1 B-ALL
5 111,751,056 80 Mn1 ANLL
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Retroviral Integration Sites Continued
Chromosome Location Mouse ID Gene Phenotype
5 111,778,020 25 Mn1 B-ALL
5 117,424,372 102 Taok3 ANLL
5 118,757,401 42 CX763467 Biphen
5 118,776,213 25 CX763467 B-ALL
5 123,642,855 20 BC17a ANLL
5 150,869,891 5 AK034023 B-ALL
6 30,628,910 5 Tsga14 B-ALL
6 52,606,503 14 Hibadh B-ALL
6 99,240,070 35 Foxp1 ANLL
6 99,351,171 88 Foxp1 ANLL
6 101,600,686 10 AK050931 Biphen
6 122,865,978 42 Necap1 Biphen
6 136,463,497 27 Atf7ip B-ALL
6 136,894,758 46 Arhgdib ANLL
6 139,354,636 20 AK015023 ANLL
6 145,203,054 20 Kras ANLL
6 145,246,479 27 Kras B-ALL
7 3,685,107 23 Lair1 B-ALL
7 18,826,062 69 ApoC2 ANLL
7 23,135,748 46 Nalp5 ANLL
7 25,388,035 5 AK141500 B-ALL
7 28,090,560 70 Supt5h Biphen
7 30,100,048 28 BF158903 ANLL
7 45,550,595 15 Sec1 ANLL
7 45,732,883 14 Grin2d B-ALL
7 48,872,735 39 AK084063 B-ALL
7 58,601,420 72 Atp10a Biphen
7 63,696,673 36 Otud7 ANLL
7 79,776,366 30 Ap3s2 ANLL
7 80,135,456 30 Ngrn ANLL
7 80,939,544 21 Alpk3 B-ALL
7 87,006,481 14 AK169304 B-ALL
7 100,103,567 28 Pgm2l1 ANLL
7 113,962,540 39 Copb1 B-ALL
7 113,986,816 98 Copb1 B-ALL
7 127,834,231 69 Itgam ANLL
7 131,998,390 23 AK212323 B-ALL
7 132,193,327 25 AK212323 B-ALL
7 142,270,422 25 Lsp1 B-ALL
7 144,857,798 20 AK007224 ANLL
8 10,924,764 5 AK014460 B-ALL
8 10,992,091 15 Irs2 ANLL
8 11,576,209 21 Ankrd10 B-ALL
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Retroviral Integration Sites Continued
Chromosome Location Mouse ID Gene Phenotype
8 13,095,649 76 AK020930 ANLL
8 37,625,616 6 AK082764 ANLL
8 83,347,838 44 Gypa ANLL
8 87,074,472 42 CJ191375 Biphen
8 113,823,939 72 St3ga12 Biphen
8 114,707,232 27 Cfdp1 B-ALL
8 129,742,437 42 AK050164 Biphen
9 32,292,302 14 Fli1 B-ALL
9 44,161,347 10 AK014147 Biphen
9 57,201,584 80 AK038628 ANLL
9 57,351,271 96 Mpi ANLL
9 61,049,727 69 Tle3 ANLL
9 63,412,090 74 2310007F21Rik ANLL
9 86,368,231 88 Pgm3 ANLL
9 86,420,670 39 Mod1 B-ALL
9 90,040,590 30 Tbc1d2b ANLL
9 107,967,452 5 Bsn B-ALL
9 111,114,687 23 Mlh1 B-ALL
9 113,900,595 31 BC011245 ANLL
9 115,015,692 15 Osbpl10 ANLL
9 118,245,732 21 BF016740 B-ALL
9 120,872,653 96 Ctnnb1 ANLL
10 6,082,314 28 AV503505 ANLL
10 13,429,502 30 Aig1 ANLL
10 13,776,534 47 Hivep2 ANLL
10 19,049,748 25 Olig3 B-ALL
10 19,519,107 10 Slc35d3 Biphen
10 61,902,461 36 Prg1 ANLL
10 66,466,991 29 D10Ucla1 Biphen
11 8,585,738 9 Tns3 Biphen
11 18,934,224 46 Meis1 ANLL
11 22,870,377 47 Commd1 ANLL
11 24,127,662 28 AK139779 ANLL
11 27,953,124 88 Def6 ANLL
11 49,952,680 102 Rnf130/Tbc1d9b ANLL
11 51,847,171 25 Cdk13 B-ALL
11 58,030,359 38 Iigp2 B-ALL
11 69,405,390 6 Trp53 ANLL
11 70,000,905 9 Mgl1 Biphen
11 76,553,046 66 Gosr1 T-ALL
11 77,335,993 98 1300007F04Rik B-ALL
11 79,336,856 36 Nf1 ANLL
11 79,343,850 17 Nf1 B-ALL  
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Retroviral Integration Sites Continued
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11 79,344,840 98 Nf1 B-ALL
11 79,345,029 23 Nf1 B-ALL
11 94,816,159 98 Ppplr9b B-ALL
11 95,483,829 96 Phb ANLL
11 95,549,894 69 Phb ANLL
11 97,132,332 35 Mrpl45 ANLL
11 113,198,658 38 Slc39a11 B-ALL
11 114,301,628 20 C0809189 ANLL
11 121,621,466 15 AK079017 ANLL
12 7,188,662 6 Psma3 ANLL
12 21,454,732 30 Ddef2 ANLL
12 78,054,162 39 DV 659889 B-ALL
12 83,921,882 17 Rgs6 B-ALL
12 83,921,882 31 Rgs6 ANLL
12 111,887,124 20 Tnfaip2 ANLL
12 114,992,643 46 BC096667 ANLL
12 115,915,686 67 BC028249 ANLL
12 118,746,963 20 Sp4 ANLL
13 28,562,017 66 Sox4 T-ALL
13 28,612,959 21 BC025054 B-ALL
13 102,637,523 74 Pik3r1 ANLL
14 18,718,332 46 Gng2 ANLL
14 29,470,236 23 Rft1 B-ALL
14 60,395,119 15 Kpna3 ANLL
14 66,796,360 21 Dock5 B-ALL
14 68,011,066 23 Stc1 B-ALL
14 74,572,199 98 Tpt1 B-ALL
14 75,519,298 36 CK128313 ANLL
14 75,675,612 47 CK128313 ANLL
15 27,803,018 10 Trio Biphen
15 62,003,093 66 AAk090048 T-ALL
15 72,798,579 96 1810044A24Rik ANLL
15 79,487,459 18 Pgea1 Biphen
15 79,828,786 69 Pdgfb ANLL
15 90,685,460 67 Kif21a ANLL
15 100,502,653 20 Ela1 ANLL
15 101,149,578 98 6030408B16Rik B-ALL
15 101,804,832 30 Krt85 ANLL
15 102,061,235 18 Itgb7 Biphen
15 103,087,078 28 BY227355 ANLL
16 21,849,020 35 Tmem41a ANLL
16 22,034,071 28 C330012H03Rik ANLL
16 30,834,719 13 AK139695 ANLL  
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Retroviral Integration Sites Continued
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16 45,467,470 13 Slc9a10 ANLL
16 45,467,557 21 s1c9a10 B-ALL
16 48,637,202 14 Ift57 B-ALL
16 49,708,746 69 Ift57 ANLL
16 49,719,563 36 Ift57 ANLL
16 95,547,315 6 Erg ANLL
16 95,604,074 69 Erg ANLL
17 5,194,932 46 Arid1b ANLL
17 8,228,372 66 T2 T-ALL
17 26,740,523 30 BC054732 ANLL
17 29,586,014 13 Mdga1 ANLL
17 35,476,754 67 BC025573 ANLL
17 35,481,038 76 BC025573 ANLL
17 35,629,534 96 H2-T24 ANLL
17 48,550,193 69 Nfya ANLL
17 56,974,517 15 Vav1 ANLL
17 56,976,462 74 Vav1 ANLL
17 75,048,418 67 Ltbp1 ANLL
17 83,065,753 72 AW548124 Biphen
17 83,825,134 10 AK007978 Biphen
17 84,028,403 42 AK040143 Biphen
17 87,089,800 39 Mcfd2 B-ALL
17 87,253,687 21 Ttc7 B-ALL
17 354,814,421 67 BC025573 ANLL
18 61,224,277 80 Csfir ANLL
18 67,424,965 39 Impa2 B-ALL
18 78,060,362 31 Pstpip2 ANLL
19 6,349,813 102 Map4k2 ANLL
19 10,090,248 35 Rab3il1 ANLL
19 10,650,554 15 Cybasc3 ANLL
19 37,113,459 47 Cpeb3 ANLL
19 53,518,776 69 AK146072 ANLL
19 55,754,176 25 Tcf7l2 B-ALL
19 57,396,578 98 AK043887 B-ALL
X 7,121,530 14 Gata1 B-ALL
X 7,127,514 47 Gata1 ANLL
X 18,319,512 66 AK170409 T-ALL
X 47,400,164 46 Mbnl3 ANLL
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